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Abstract 
 
 
Congenital hypopituitarism can be triggered by environmental insults, such as viral 
infections, vascular or degenerative damage and exposure to alcohol and drugs. Genetic 
mutations have been identified in genes responsible for pituitary development and 
function, however, only up to 10% of patients affected by hypopituitarism have 
recognised mutations in known genes. Clinical phenotypes may arise from gene dosage 
imbalance, but routine cytogenetic and molecular techniques can be insufficiently 
sensitive to detect chromosome rearrangements that are either submicroscopic in size or 
limited to a specific genomic locus or both. 
In the present study, ten patients with a complex pathology of the pituitary gland of 
unknown aetiology were clinically pre-selected according to a criteria checklist, to 
undergo a genome-wide screening of copy number changes with high-resolution 250K 
SNP array. Genomic sequencing of three candidate genes, BARX2, OTX2 and BMP4, 
was carried out in larger cohorts of selected patients. 
Three pathogenic genomic imbalances, chromosome 6q terminal duplication, 
chromosome 11q terminal deletion, and an interstitial deletion of chromosome 22q were 
detected in two patients, and the breakpoints were defined at high resolution. A 
submicroscopic rearrangement in the chromosome region 1p36.33 was found in a 
patient presenting with the association of hypopituitarism and tetralogy of Fallot. Two 
CNVs were found at the location of the breakpoints of a cytogenetically visible 
translocation between chromosomes 11q and 22q in one patient. One region of genomic 
imbalance, identified in one patient, contained the whole length of the ENG gene. A 
novel amino acid change was identified in BARX2 in a patient with isolated 
hypopituitarism. A novel nonsense mutation was found in OTX2 in a patient with 
pathology of the pituitary gland associated wth severe eye defects. 
These findings contribute to the understanding of the genetic bases of congenital 
hypopituitarism. 
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1. INTRODUCTION 
 
 
 
 
1.1. Pituitary Gland 
 
The pituitary gland is a central regulator of growth, reproduction, metabolism and stress 
responses, and functions to relay signals from the hypothalamus to peripheral organs. It 
is situated within the sella turcica, a recess in the sphenoid bone, at the base of the brain. 
The hypothalamus is the principal neural structure regulating homeostasis in 
vertebrates, coordinating complex signals from other regions of the brain and the 
periphery. The hypothalamus releases factors that control the endocrine activity of the 
pituitary cells. [1] 
 
 
1.1.1. Anatomy and Physiology of the Pituitary Gland 
 
The pituitary gland is formed by the juxtaposition of the adenohypophysis (anterior and 
intermediate lobes) and the neurohypophysis (posterior lobe). 
The anterior pituitary consists of five different endocrine cell types secreting six 
hormones: somatotrophs that secrete growth hormone (GH), lactotrophs that secrete 
prolactin (PRL), thyrotrophs that secrete thyroid-stimulating hormone (TSH), 
gonadotrophs that secrete both gonadotrophins, follicle-stimulating hormone (FSH) and 
luteinizing hormone (LH), and corticotrophs that secrete adrenocorticotrophin (ACTH). 
[2] 
Somatotrophs are the majority of adenohypophyseal secretory cells comprising nearly 
50% of all anterior pituitary cells. Lactotrophs embryologically arise from GH-
producing cells, and constitute about 15-20% of the anterior pituitary cell population, 
although pregnancy and lactation alter the number of maternal lactotrophs. 
Corticotrophs and gonadotrophs represent 15-20% and 10-15% of anterior pituitary 
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cells, respectively. The thyrotroph is the least common cell type in the anterior pituitary, 
accounting for less than 10% of the pituitary cell population. [3, 4] 
The intermediate lobe secretes proopiomelanocortin (POMC), a precursor to 
melanocyte-stimulating hormone (MSH), and involutes in the adult. [2] 
The neurohypophysis is formed from axonal terminals, projecting from two discrete 
groups of magnocellular neurones in the hypothalamus, surrounded by modified 
astrocytes called pituicytes. The two hormones secreted by the posterior lobe of the 
pituitary gland, arginine vasopressin (AVP) and oxytocin, are synthesized in the 
paraventricular and supraoptic nuclei within the hypothalamus. [2, 5] 
The anatomical and functional relationships between the hypothalamus and the pituitary 
gland are described in Figure 1. 
 
 
Figure 1. Anatomical and functional relationship between the hypothalamus and 
the pituitary gland. The hypothalamus is positioned above the pituitary gland in the 
basal part of the forebrain. The magnocellular neurons, within the paraventricular and 
supraoptic nuclei in the hypothalamus, produce AVP and oxytocin. Their axons form 
the hypothalamo-hypophyseal tract, and the hormones are released from the posterior 
pituitary into the general circulation in response to electrical excitation. The 
adenohypophysis is anatomically distinct from the hypothalamus. However, 
parvocellular neurons of the hypothalamus secrete releasing factors that, via a system of 
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hypophyseal portal vessels, act on the endocrine cells of the anterior lobe to stimulate or 
inhibit the synthesis and secretion of GH, prolactin, TSH, ACTH, and FSH and LH. The 
infundibulum (or pituitary stalk) carries both the portal blood delivering hypothalamic 
hormones to the anterior pituitary and the neural tract from the hypothalamic nuclei to 
the posterior pituitary. It is noteworthy that the optic chiasm lies above the hypophysis 
and anterior to the pituitary stalk. Thus, any mass lesion of sufficient size in the area of 
the pituitary gland will cause visual field defects. [1, 2, 4] ACTH: adrenocorticotrophin, 
AVP: arginine vasopressin, FSH: follicle-stimulating hormone, GH: growth hormone, 
LH: luteinizing hormone, TSH: thyroid-stimulating hormone. 
 
The hormones secreted from the anterior pituitary regulate growth, puberty, 
metabolism, response to stress, reproduction, and lactation, while those from the 
posterior pituitary are required during parturition and lactation, and regulate water 
balance. [2] 
GH stimulates insulin-like growth factor 1 (IGF1) gene expression and IGF1 synthesis 
in liver and bone, amongst other tissues, acting on growth. GH also regulates the hepatic 
production of insulin-like growth factor binding protein 3 (IGFBP3), acting as a gluco-
counterregulatory hormone in metabolism. In muscle, GH increases protein synthesis, 
while in the adipocyte, GH induces lipolysis. [6, 7] PRL is the major hormone that 
simulates milk production, it inhibits LH and FSH secretion inducing lactation-related 
amenorrhea in the postpartum period. [5] ACTH binds with high affinity to the 
melanocortin 2 receptor (MC2R) in the adrenal gland and regulates steroidogenesis. [3] 
In the male, LH binds to a receptor on testicular Leydig cells and increases the synthesis 
of testosterone, [8] while FSH binds to testicular Sertoli cell and stimulates the 
production of proteins in the seminal fluid. [9] In females, LH binds to its receptor on 
ovarian theca cells and stimulates steroidogenesis; FSH stimulates ovarian follicular 
growth and facilitates generation of estrogen from thecal cells. [10] TSH binds to its 
receptor on thyrocytes, resulting in an increase in iodine transport, in the expression of 
thyroperoxidase and thyroglobulin, and ultimately in increased synthesis of thyroid 
hormones. [2, 3] 
AVP acts on the V2 receptor in the renal collecting duct and increases water 
permeability to facilitate water reabsorption, and on V1 receptor in endothelial cells to 
promote vasoconstriction. [3] Oxytocin acts through its receptor, inducing intracellular 
calcium release that, in turn, results in smooth muscle contraction in the uterine 
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myometrial cells and mammary gland myoepithelial cells to cause uterine contraction 
and milk ejection, respectively. [11] 
 
 
1.1.2. Pathology of the Pituitary Gland 
 
Hypopituitarism is defined as a deficiency of one or multiple pituitary hormones. 
Congenital hypopituitarism is a syndrome with a wide variation in severity, age at 
presentation, from the early neonatal period to later in life (e.g. with abnormal pubertal 
development), and inheritance. It may manifest as isolated deficiency of GH, ACTH or 
TSH, hypogonadotropic hypogonadism (HH) or central diabetes insipidus (DI). 
Alternatively, several pituitary hormone axes may be defective, resulting in combined 
pituitary hormone deficiency (CPHD) syndromes. The hormonal deficits can be 
associated with extra-pituitary abnormalities, notably of the eye and midline forebrain, 
such as optic nerve hypoplasia (ONH), anophthalmia/microphthalmia, agenesis of 
corpus callosum (ACC) and absence of septum pellucidum. [1, 2] 
The endocrinopathy can evolve to include other hormonal deficits, necessitating 
ongoing assessment, as these conditions are often associated with significant morbidity 
and occasional mortality. Neonates with congenital hypopituitarism may present with 
nonspecific symptoms, such as hypoglycaemia, lethargy, seizures, failure to thrive, 
cholestasis and prolonged jaundice, with or without associated developmental defects. 
Alternatively, they may be initially asymptomatic but at risk of developing pituitary 
hormone deficiencies over time. Males may present with undescended testes and a 
micropenis. Growth failure in severe growth hormone deficiency (GHD) can occur early 
in infancy, while bone maturation may be delayed for the chronological age but this is 
usually evident later in life. DI is characterised by polyuria and polydipsia. [2, 12] 
Moreover, neonates with optic nerve hypoplasia and/or midline abnormalities or 
syndromes known to be associated with hypopituitarism will need, in the first instance, 
assessment of their endocrine status, as well as long term follow-up even if the initial 
endocrine investigations are normal. Early diagnosis of hypopituitarism in the neonatal 
period is difficult due to the immaturity of the hypothalamic-pituitary axis, and the 
contraindication for some GH provocation tests at this age. More than 50% of patients 
with eye/forebrain and pituitary abnormalities have ACTH deficiency, and the resulting 
cortisol deficiency can be life threatening. Neonates with TSH deficiency may also 
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present with temperature instability. [12] 
Investigations of hypopituitarism include the use of combined pituitary function and 
provocative testing of the hypothalamo-pituitary axis. GHD may be confirmed on the 
basis of low concentrations of IGF1 and IGFBP3 in combination with a poor growth 
rate, while GH provocation tests are contraindicated in children less than one year of 
age. The diagnosis of TSH deficiency is made in the presence of a low concentration of 
free thyroxine and basal TSH, and central hypothyroidism is associated with additional 
pituitary hormone deficiencies in 78% of cases. A thyrotropin-releasing hormone (TRH) 
test may be useful for the diagnosis of prolactin deficiency. A poor response to 
gonadotropin-releasing hormone (GnRH) stimulation within the first 12-18 months of 
life is suggestive of gonadotropin deficiency, which provides a window of opportunity 
for the early detection of HH, although patients will require repeat investigations at 
puberty. In neonates, multiple random cortisol measurements may point towards the 
integrity of the hypothalamo-pituitary-adrenal axis, but requires frequent blood 
sampling, while hypoglycaemia-inducing tests are contraindicated at this age. The 
cortisol response to an exogenous ACTH test is safe, but it has a sensitivity of 80%. 
Once the circadian rhythm has been established, an 08:00 am cortisol, a 24-hour plasma 
cortisol, and a mean cortisol may represent a more sensitive tool to confirm ACTH 
deficiency. Finally, early morning paired plasma and urine osmolarities point towards 
the diagnosis of DI. [2, 12] 
Neuroimaging also plays an important role in the diagnosis and monitoring of patients 
with congenital hypopituitarism, as there is a correlation between the neuroradiological 
abnormalities and the severity and evolution of the endocrinopathy. Signs to look for at 
the magnetic resonance imaging (MRI) of the brain and pituitary include the size of the 
anterior pituitary, the presence and location of the posterior pituitary (absent or 
ectopic/undescended), the presence and morphology of the infundibulum, the presence 
and morphology of the corpus callosum and septum pellucidum, the appearance of the 
optic nerves and chiasm, as well as associated brain abnormalities. [13] The risk of 
hypopituitarism is 27.2 times greater in patients with an undescended posterior pituitary 
as compared with those with a normally positioned posterior pituitary, and midline 
forebrain defects are up to 5.2 times more prevalent in patients with CPHD as compared 
with isolated growth hormone deficiency (IGHD). [12, 13] 
The mainstay of treatment of hypopituitarism is replacement therapy with appropriate 
hormones, which entails the use of subcutaneously administered recombinant human 
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growth hormone, oral hydrocortisone, thyroxine, and intramuscular or transdermal 
testosterone or oestrogen. [14] 
 
 
1.1.3. Embryology of the Pituitary Gland 
 
In the developing human embryo, the prosencephalon consists of two secondary brain 
vesicles: the diencephalon and the telencephalon. The diencephalic lateral walls form 
three swellings that develop into the thalamus, hypothalamus and epithalamus. In 
particular, the hypothalamus arises by proliferation of neuroblasts in the intermediate 
zone of the diencephalic walls, and the nuclei develop within its structure concerned 
with homeostasis, endocrine regulation, and the activity of the pituitary gland. [15, 16] 
The embryological development of the pituitary gland is described in Figure 2. 
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Figure 2. Stages of embryological development of the pituitary gland. A) Sagittal 
section of the cranial end of a human embryo of circa 36 days of gestation, showing the 
genesis of the pituitary gland, as a compound structure of the infundibulum and the 
Rathke’s pouch, driven by morphogenetic transformations of the developing brain. B) 
Development of the adenohypophysis begins in week 4, Carnegie Stage (CS) 12a (25-
26 days post-ovulation), of embryonic growth: an ectodermal placode appears in the 
roof of the stomodeum (the primary oral cavity) and outgrows dorsally to form a 
diverticulum, called Rathke’s pouch. [17] C) At CS 13-14, the Rathke’s pouch appears 
as a thin tube anteroposteriorly flattened to the lower posterior wall of the diencephalon, 
and opens into the cavity of the pharyngeal intestine with a blind terminating upper end. 
A separating mesenchymal layer appears between its anterior wall and the lower inferior 
wall of the diencephalon. [17] The rudiment of the hypothalamic infundibulum and 
neurohypophysis forms at CS 15 (33-36 days post-ovulation), as a thickening of the 
posterior wall of the floor plate of the diencephalon. During CS 17-18 (41-46 days 
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post-ovulation), the neuroectodermal thickening grows ventrally and the infundibulum, 
flexing above the floor of the Rathke’s pouch, occupies the position characteristic of the 
neurohypophysis. Joining of the epithelial and neural rudiments of the pituitary gland 
into a single organ occurs during week 7 of embryo development. [5, 17] D) The 
epithelium of the lateral parts of the Rathke’s pouch overlaps the growing 
infundibulum, and the growth and placement of the neurohypophysis leads to 
deformation and gradual separation of the Rathke’s pouch from the roof of the 
stomodeum. [5, 17] E) The lumen of the Rathke’s pouch is reduced to a small cleft that 
demarcates the boundary between the anterior and posterior lobes of the pituitary gland 
(CS 19; 47-49 days post-ovulation). By CS 20 (50-51 days post-ovulation), all 
component parts of the hypophysis occupy positions corresponding to those of the 
definitive pituitary gland. A developing capillary bed appears around the epithelial 
rudiment, this being absent only at the point of contact of the epithelial and neural 
elements of the organ. [5, 17] F) The degeneration of the connection between the 
Rathke’s pouch and the stomodeum is complete by week 8 of embryonic development, 
and Rathke’s pouch forms a discrete sac, separated by the growing sphenoid bone. [5, 
17] RP: Rathke’s pouch. 
 
From week 5 of embryonic development, the walls of the Rathke’s pouch contain 
numerous cells in different stages of mitosis, with proliferation mostly evident at the 
luminal border. Ultrastructurally, these cells display typical epithelial features and are 
interconnected by junctional complexes. In the diencephalon opposite the wall of the 
Rathke’s pouch, numerous mitotic figures are also seen. At week 6, proliferation 
becomes more extensive in the developing adenohypophysis than in the 
neurohypophysis and adjacent mesenchyme, but mitotic cells decrease significantly 
after week 6 in the adenohypophysis, as well as in the neurohypophysis and in the 
mesenchyme. [18] From week 8 CS 21-23 (51-57 days post-ovulation), proliferation 
remains intense around the residual lumen of the Rathke’s pouch only. Epithelial cords 
invaginate from the wall of the adenohypophysis to form a gland-like primordium, the 
structural-functional units of the organ, separated by deep and branching strands of 
mesenchymal tissue. Mitotic cells become less numerous in more differentiated gland-
like structures of adenohypophysis, but they are very numerous in the mesenchyme 
penetrating the gland, prior to vascular invasion of the mesenchyme itself. A gradual 
increase in the volume of the organ is observed, and the increase in the length of the 
Rathke’s pouch, between its appearance and the moment of formation of the posterior 
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lobe of the hypophysis, is proportional to the rapid growth of the diencephalon. [17, 18] 
Using in vivo foetal MRI, Schmook et al. (2010) looked at prosencephalic development 
for anatomical landmarks before gestational week 27. The pituitary gland was 
detectable, overall, in 60% of the foetuses. The detection rate increased significantly 
with gestational age (30% between gestational week 16-21 and 77% after week 21). If 
delineable, the maximum diameter of the pituitary gland ranged from 2 to 6 mm 
[mean±Standard Deviation (SD): 3.9±0.9 mm] and increased with gestational weeks. 
Differentiation between adeno- and neurohypophysis was not reliably possible. The 
infundibulum was visible, overall, in 87% of the foetuses. [19] 
Concurrently with the growth of the embryonic pituitary gland, cytological 
differentiation into endocrine cells proceeds, along with the onset of the active 
functioning of the organ and signs of secretion. [17, 18] By week 16 the 
adenohypophysis is fully differentiated, and the hypothalamo-pituitary axis is 
established by week 20. GH, ACTH and TSH are detectable in the foetus by week 12. 
Between weeks 20 to 24, serum GH levels peak, then decline gradually to term. [20] 
 
 
1.1.4. Molecular Basis of Pituitary Development and 
Disorders 
 
Isolated growth hormone deficiency (IGHD) is the most common endocrinopathy with 
an incidence ranging from 1 in 3,500 to 1 in 10,000 births, with the majority of cases 
being idiopathic in origin. [21-23] However, familial inheritance, which can be 
dominant or recessive, accounts for between 5 and 30% of all cases, suggesting a 
genetic aetiology for the condition. [24] At the more severe end of the spectrum, septo-
optic dysplasia (SOD) is a rare congenital anomaly with a prevalence of approximately 
1 in 10,000. It is a heterogeneous disorder characterized by a clinical triad of midline 
forebrain abnormalities, ONH and hypopituitarism. Each of these components can occur 
in isolation or in combination. Although the condition is generally sporadic, familial 
cases have been described. [25-26] 
 
While the aetiology of congenital hypopituitarism remains unknown in the majority of 
cases, mutations have been found in genes encoding both transcription factors and 
signalling molecules important for the normal development of the hypothalamo-
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pituitary axis, closely related to that of the forebrain. The clinical phenotype is 
extremely variable, depending upon the expression patterns of the molecule/s implicated 
in the aetiology of hypopituitarism. [1, 2, 12-14, 27, 28] Mutations in genes involved in 
the early development of the pituitary gland and patterning of the forebrain (homeobox 
gene expressed in ES cells 1: HESX1, SRY-box 2: SOX2, GLI-Kruppel family member 
2: GLI2, SRY-box 3: SOX3, LIM homeobox gene 3: LHX3, LIM homeobox gene 4: 
LHX4 and orthodenticle, drosophila homolog of, 2: OTX2) tend to result in syndromic 
forms of congenital hypopituitarism, in association with extrapituitary defects of the 
midline forebrain structures and of the eye. [29, 30] Mutations in genes involved in the 
initial stages of pituitary cell differentiation (prophet of Pit1: PROP1 and POU domain, 
class 1, transcription Factor 1: POU1F1) often result in isolated/non-syndromic CPHD. 
[12] 
The phenotype and pattern of inheritance of disorders of the pituitary gland, associated 
with mutations in developmental genes, are compared in Table 1. 
 
Gene Loss of Function 
Phenotype in Mouse 
Phenotype in Human Inheritance in 
Human 
HESX1 Anophthalmia or 
microphthalmia, agenesis 
of corpus callosum, 
absence of septum 
pellucidum, pituitary 
dysgenesis or aplasia. 
[32, 35] 
Variable: SOD, CPHD, 
IGHD with EPP. Anterior 
pituitary hypoplastic or 
absent. Posterior pituitary 
ectopic or eutopic. 
Frequency of mutations: 
approximately 1%. [31-
34] 
Dominant or 
recessive. 
Heterozygous 
mutations with 
incomplete 
penetrance or rare 
homozygous 
mutations. [35, 36] 
OTX2 Lack of forebrain and 
midbrain, olfactory 
placode, optic placodes. 
[38] 
Anophthalmia, APH, 
ectopic posterior 
pituitary, absent 
infundibulum. 
Frequency of mutations: 
2-3% of 
anophthalmia/microphtha
lmia cases. [37, 38] 
Dominant. 
Heterozygous 
mutations with 
haploinsufficiency 
or dominant 
negative effect. [39, 
40] 
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SOX2 Poor growth, reduced 
fertility, central nervous 
system abnormalities, 
anophthalmia; pituitary 
hypoplasia with reduction 
in all cell types. 
Homozygous null 
mutants: embryonic 
lethal. [44, 45] 
Hypogonadotropic 
hypogonadism; APH, 
abnormal hippocampi, 
bilateral 
anophthalmia/microphtha
lmia, abnormal corpus 
callosum, learning 
difficulties, oesophageal 
atresia, sensorineural 
hearing loss, 
hypothalamic hamartoma. 
Frequency of mutations: 
3.5-10%. [41-43] 
Dominant. 
De novo 
heterozygous 
mutations, as well 
as gene deletions, 
with 
haploinsufficiency 
effect. [44, 45] 
SOX3 Poor growth, weakness, 
craniofacial 
abnormalities, ACC, 
hypothalamic and 
infundibular 
abnormalities. [47] 
IGHD and mental 
retardation, 
hypopituitarism; APH, 
infundibular hypoplasia, 
EPP, midline 
abnormalities. 
Frequency of mutations: 
6% (duplications), 1.5% 
(mutations). [46] 
X-linked recessive. 
[47] 
GLI2 N.A. Holoprosencephaly, 
hypopituitarism, 
craniofacial 
abnormalities, 
polydactyly, single nares, 
single central incisor, 
partial ACC. 
Frequency of mutations: 
1.5%. [48] 
Dominant. 
Heterozygous 
mutations with 
incomplete 
penetrance, variable 
phenotypic 
expression, and 
with 
haploinsufficiency 
effect. [48] 
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LHX3 Hypoplasia of Rathke’s 
pouch. [52] 
GH, TSH, gonadotropin 
deficiency with pituitary 
hypoplasia. ACTH 
insufficiency variable. 
Short, rigid cervical 
spine. Variable 
sensorineural hearing 
loss. 
Frequency of mutations: 
1.3%. [49-51] 
Recessive. 
Homozygous and 
compound 
heterozygous 
mutations, as well 
as gene deletions. 
[52] 
LHX4 Mild hypoplasia of 
anterior pituitary. [53] 
GH, TSH, cortisol 
deficiency, persistent 
craniopharyngeal canal 
and abnormal cerebellar 
tonsils; APH, 
ectopic/eutopic posterior 
pituitary, absent 
infundibulum. 
Frequency of mutations: 
1.2%. [53, 54] 
Dominant. [55, 56] 
PROP1 Hypoplasia of anterior 
pituitary with reduced 
somatotropes, lactotropes, 
thyrotropes, corticotropes 
and gonadotropes. [60, 
65] 
GH, TSH, PRL, and 
gonadotropin deficiency. 
Evolving ACTH 
deficiency. Enlarged 
pituitary with later 
involution. 
Frequency of mutations: 
1.1% sporadic cases, 
29.5% familial cases. [57-
62] 
Recessive. 
Homozygous 
mutations and gene 
deletions. [63-65] 
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POU1F1 Anterior pituitary 
hypoplasia with reduced 
somatotropes, lactotropes 
and thyrotropes. [66, 67] 
Variable anterior pituitary 
hypoplasia with GH, 
TSH, and PRL 
deficiencies. 
Frequency of mutations: 
3.8% sporadic cases, 18% 
familial cases. [66-69] 
Dominant or 
recessive. [70-72] 
Table 1. Comparison of disorders of the pituitary gland: phenotype and pattern of 
inheritance. ACC: agenesis of corpus callosum; APH: anterior pituitary hypoplasia; 
CPHD: combined pituitary hormone deficiency; EPP: ectopic posterior pituitary; IGHD: 
isolated growth hormone deficiency; SOD: septo-optic dysplasia; N.A.: not available. 
 
Genetic mutations are more commonly found in familial, rather than sporadic, cases of 
hypopituitarism, however, the overall incidence of mutations in any known transcription 
factor or signalling molecule involved in the embryology and physiology of the 
pituitary gland and axis is low. Causative genetic mutations are found in only 5-10% of 
patients with hypopituitarism, indicating that several genes involved in the pathways of 
pituitary gland development remain to be identified. [1, 73, Dattani, personal 
communication] An overview of the complex network of transcription factors and 
signalling molecules emanating both from the ventral diencephalon and the developing 
Rathke’s pouch is presented in Figure 3. 
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Figure 3. Schematic representation of the developmental cascade of genes 
implicated in mouse and human pituitary development. In the mouse, the first sign 
of pituitary development occurs at 7.5 days post coitum (dpc) with the development of 
the hypophyseal placode, a thickening of the ectoderm in the midline of the anterior 
neural ridge. At approximately 9 dpc, the placode forms a rudimentary Rathke’s pouch. 
By 10.5 dpc, a region of the ventral diencephalon above the Rathke’s pouch gives rise 
to the infundibulum from which the posterior pituitary and pituitary stalk will derive. At 
12.5 dpc, the Rathke’s pouch is juxtaposed to the diencephalon and completely 
separated from the underlying oral ectoderm, its lumen persists as the cleft separating 
the anterior and intermediate lobes. [1] Corticotrope cells expressing Pomc begin to be 
detected in the intermediate lobe. [74] Thyrotropes are observed at 14.5 dpc, 
characterised by the expression of thyroid-stimulating hormone, beta chain (Tshb), 
within the anterior lobe. The expression of Gh and Prl marks the differentiation of 
somatotrope and lactotrope lineages, respectively, beginning at 15.5 dpc. The 
gonadotropes are the last cell type to emerge, beginning at 16.5 dpc with the onset of 
luteinizing hormone, beta polypeptide (Lhb) expression, followed by follicle-
 29 
stimulating hormone, beta polypeptide (Fshb). [75, 76] Bone morphogenetic protein 4 
(Bmp4) is the earliest secreted signalling molecule expressed in the ventral 
diencephalon, arising at 8.5 dpc. It is required for induction and maintenance of the 
Rathke’s pouch, and for its regionalisation that allows the emergence of the different 
endocrine cell types. [75, 77] Bmp4 also regulates early expression of Isl LIM 
homeobox 1 (Isl1) and Lhx3 in the developing anterior pituitary, [78, 79] Isl1 being the 
first LIM protein to be expressed during pituitary development at 8.5 dpc. [75] In 
human, both LHX3 and LHX4 are also expressed along the rostro-caudal length of the 
neural tube. [80] Lhx3 activates Hesx1 promoter to ensure its early expression. Hesx1 is 
one of the earliest markers of the Rathke’s pouch, it functions as a transcription 
repressor and its down-regulation is required for cell determination, and in particular for 
Prop1 to function as activator. [81] The switch of expression from the repressor Hesx1 
to the activator Prop1 is an important step during development of the pituitary gland 
because it is required for emergence of both the Pou1f1 (Gh, Prl and Tsh) and 
gonadotrope lineages, and therefore cell determination. [82-84] Sox2 and Sox3, are 
expressed throughout the central nervous system with particularly high levels in the 
ventral diencephalon. [85, 86] Sox2 is also expressed in the early ectoderm including the 
Rathke’s pouch. Its expression is down-regulated as endocrine cell differentiation 
proceeds, but it is maintained in the progenitor proliferative zone around the lumen. [85] 
In human, SOX2 has a critical role in the development of the hypothalamo-pituitary 
axis. Between weeks 4.5-9, SOX2 is expressed throughout the embryonic central 
nervous system, including strong expression within the Rathke’s pouch which is 
maintained during the development of the anterior pituitary, as well as in the overlying 
presumptive hypothalamus. SOX2 also shows an overlapping domain of expression with 
LHX3 within the Rathke’s pouch and the developing anterior lobe, and acts as a 
regulator and activator of LHX3 during pituitary development. [87] By 14.5 dpc, 
expression of Sox3 is also initiated in the developing pituitary, in a small subset of 
Pou1f1-positive cells. [86] Expression of Paired-like homeodomain transcription factor 
1 (Pitx1) is first detected in the anterior ectoderm at 8.0 dpc, and in the Rathke’s pouch 
by 9.5 dpc, where its expression is maintained in all hormone-producing cell types. 
Pitx1 interacts with Pou1f1 and GATA-binding protein 2 (Gata2) resulting in 
synergistic activation of the promoters of the Prl and Gh genes. [88, 89] Moreover, 
Pitx1 synergizes with T-box 19 (Tbx19) and with Steroidogenic Factor 1 (SF1) to 
activate Pomc and Lhb expression, respectively. [74, 90] Pitx2 exhibits a large degree of 
sequence identity with Pitx1 and is similarly capable of activating the promoters of 
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most of the pituitary hormone genes, suggesting functional redundancy. [91, 92] Also, 
Bmp2, first expressed at 10.5 dpc, seems to induce the proliferation and determination 
of the Pou1f1 lineage and gonadotropes. [75, 93] Early signalling includes Sonic 
hedgehog (Shh) and Gli pathways, [94, 95] while terminal differentiation requires 
fibroblast growth factors (Fgfs) and Bmp signalling down-regulation. [75, 96, 97] 
Moreover, a pathway involving signalling via Wingless-type MMTV integration site 
family (Wnt) and Notch genes appear to be essential for Prop1 maintenance and to 
prevent early differentiation and allow the generation of diverse endocrine cell types 
(particularly, of Pou1f1-dependent lineages). [98-100] Otx2 is expressed early in 
development, and is required for maintenance of the forebrain and correct Hesx1 
expression. [101, 102] As early as week 7 of gestation, strong expression of OTX2 is 
detected in the diencephalon of the human foetal brain, and later in the hypothalamus 
and pituitary gland. [103] Both OTX2 and sine oculis homeobox, drosophila homolog 
of, 6 (Six6) are also expressed in the developing eye and human foetal retina. [104, 105] 
RP: Rathke’s pouch. 
 
The advent of the high-throughput high-resolution genome-wide array technology has 
provided new instruments for the screening of patients with complex and/or specific 
clinical phenotypes, whose (genetic) aetiology remains undisclosed. Amongst them, up 
to 90% of patients with pathology of the pituitary gland lack an aetiological diagnosis. 
[106-108] 
 
 
 
1.2. Copy Number Variations (CNVs) 
 
Structural variations involve large stretches of human genomic deoxyribonucleic acid 
(DNA). They account for at least 12% of the human genome in which hundreds of 
genes reside, conceivably playing a role also in functional variability. [109, 110] 
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1.2.1. Definition and Origin of CNVs 
 
A copy number variation (CNV), a form of structural variation, is defined as a DNA 
segment, longer than 1 kilobase (kb) to several megabases (Mb), with a variable copy 
number compared with a reference genome and/or amongst individuals. [111-113] 
CNVs may either be inherited or sporadic, caused by de novo mutations, and they arise 
both in the germline and in somatic cells. [114] CNV appears to be a major driving 
force and enhancing mechanism in evolution. [115-117] 
There are at least two main mechanisms for formation of CNVs: non-allelic 
homologous recombination (NAHR) and non-homologous end joining (NHEJ). [115] 
NAHR mediates the vast majority of recurrent CNVs, where the breakpoints are located 
within low copy repeats (LCRs). [118] LCRs are region-specific sequences that occur 
twice or a few times in a genome, with a degree of identity >95% and length >1 kb. 
[119] In particular, LCRs longer than 10 kb and with sequence identity equal or greater 
than 97% can lead to local genomic instability, and provide extensive homology for 
NAHR. [120] Homologous recombination is used in repair of DNA breaks and gaps, in 
particular double-strand break (DSB), including during chromosome segregation and 
recombination at meiosis. Homologous recombination is a mechanism of accurate DNA 
repair, that utilises another identical sequence as a template to repair the damaged DNA 
strand. [121] However, the presence of LCRs can lead to misalignment of chromosomes 
or chromatids, recruitment of a template sequence in a non-allelic position, and mediate 
NAHR. In turn, NAHR can result in unequal crossing-over and structural genomic 
rearrangements. [115, 122] 
In contrast to NAHR, NHEJ is a pathway of DNA DSB repair that does not require 
homology or uses very short microhomology of 2 to 25 complementary base pairs (bp); 
the latter repair mechanism is also referred to as microhomology-mediated end joining 
(MMEJ). [115, 123] In NHEJ, the DNA break ends are directly ligated without the need 
for a homologous template to guide repair. Therefore, the product of repair often 
contains additional nucleotides and complex DNA end junctions, and NHEJ is prone to 
errors that lead to genetic change including CNV. [115, 122, 123] NHEJ mediates non 
recurrent genomic rearrangements where structural changes can be complex, and most 
non recurrent CNVs occur at sites of very limited homology. [124] 
More recent models focus on perturbation of DNA replication as the origin of CNV. 
Fork stalling and template switching (FoSTeS) is a mechanism based on DNA 
 32 
replication error, where the DNA replication fork stalls; the lagging DNA strand 
disengages from the original template and anneals, or switch, to another replication fork 
in physical proximity, by virtue of microhomology, priming or reinitiating DNA 
synthesis. [125] FoSTes is now superseded by the new microhomology-mediated break-
induced replication (MMBIR) model. In MMBIR, when a single double-strand end 
results from replication fork collapse, the broken end from the collapsed fork can anneal 
to any single-stranded template with which it shares microhomology and that occurs in 
physical proximity, and repair and restart DNA synthesis in a new replication fork. 
[115, 126] If, instead of a sister molecule, the broken end invades the homologous 
chromosome and/or a homologous sequence in a different chromosomal position, 
MMBIR can result in the genesis of CNVs. [122, 126] FoSTeS and MMBIR appear to 
be major mechanisms for generating, particularly, non recurrent CNVs that have a 
complex structure in the human genome. [127, 128] 
 
 
1.2.2. Effects of CNVs in Complex Disorders 
 
The total number, position, size, type, and population distribution of CNVs in the 
human genome remain elusive. [129, 130] Between 9 and 18% of heritable variation 
could be associated to changes in copy numbers. [131] CNVs may be responsible for 
genetic heterogeneity and human phenotypic variability by modifying the expression 
levels of a single dosage-sensitive gene or a contiguous set of dosage-sensitive genes 
that map within the aneuploid segments. [122, 130, 132, 133] Alternatively, a structural 
variation could affect the expression of the gene/s that map in its flanking regions 
and/or of neighbouring normal copy-number genes that lie outside the boundaries of the 
CNV interval. [131, 133] The influence of genes that vary in dosage due to copy 
number change on the relative transcription levels of neighbouring genes may be 
mediated by regulatory elements. Moreover, if enhancer or repressor sequences map 
within a dosage-sensitive genomic interval, a CNV can disrupt the appropriate level of 
ribonucleic acid (RNA) and thus the protein production from that transcription unit. 
[116, 117, 122] CNVs could also induce a modification of the positioning of a genomic 
region and dissociate, especially long-range, enhancer and repressor elements from their 
controlled transcription unit. Therefore, CNVs can exert an effect on gene regulation 
and expression via position effect. [134-136] 
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A number of disorders and human phenotypes associated with CNVs have been 
described, as well as disease susceptibility or resistance to disease conferred by CNVs. 
[133, 137-141] 
In the complex disorder Cri-du-chat syndrome, the DNA copy-number changes were 
mapped in 94 patients who had been carefully evaluated for the presence of the 
characteristic cry, speech delay, facial dysmorphisms, and degree of mental retardation 
(MR). The study localised the region associated with the cry to 1.5 Mb in distal 
5p15.31, speech delay to 3.2 Mb in 5p15.32-15.33, and facial dysmorphic features to 
2.4 Mb in 5p15.2-15.31. Three regions, MRI-III, were identified that differently affect 
the presentation of MR amongst patients with different size 5p deletions. Moreover, a 
significant percentage of patients with severe MR were found to have copy number 
changes in addition to the 5p deletion. [142] 
In a study of 26 patients with clinical features of growth pathology Sotos syndrome, 4 
potentially pathogenic copy number changes were detected. They involved 4 different 
chromosome regions: deletions of 10p12.32-p12.31, 14q13.1, Xq21.1-q21.31 and a 
duplication of 15q11.2-q13.1, and they varied in size from 155 kb to 13.36 Mb. The 
overall detection rate of novel abnormalities was 15%, and the chromosome region 
10p12.32-p12.31 contained a candidate gene for overgrowth, plexin domain-containing 
protein 2 (PLXDC2), to be screened in a larger cohort of patients. [143] 
A cohort of individuals with midline defects, consisting of 83 patients with syndromic 
cleft lip and cleft palate and of 104 cases of non-syndromic cleft lip and cleft palate, 
were analysed with the aim of identifying deletions and duplications of candidate gene 
loci. One subject was identified with a 2.7 Mb deletion at the 22q11.21 chromosome 
region. Five patients had deletions encompassing the interferon regulatory factor 6 
(IRF6) gene, associated with midline disorder Van der Woude syndrome. One 
individual was found to harbour a 3.2 Mb de novo deletion at chromosome 6q25.1-25.2, 
and another individual a 2.2 Mb deletion at chromosome 10q26.11-26.13 inherited from 
the mother who also had cleft lip. Both deletions were considered to be causally 
associated with the phenotypes of the patients. [144] 
In patients presenting with a pathological phenotype and constitutional de novo 
apparently balanced chromosome rearrangement, complex cryptic genomic imbalances 
have been found at or near the breakpoints, and also on chromosomes unrelated to the 
originally diagnosed rearrangement. [145-148] In a 16-year old patient affected with 
severe mental retardation and a cytogenetically visible rearrangement at the end of the 
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long arm of chromosome 9, a duplication of ~400 kb upstream of a ~2.4 Mb triplication 
followed by a duplication of ~130 kb of chromosome 9q34.3 were detected. [149] 
Amongst patients with various degrees of developmental delay (DD) and/or dysmorphic 
features and congenital malformations, deletions on chromosome 1q44 and 13q31.1 
were detected in one individual, and loss of heterozygosity (LOH) of the entire 
chromosome 2 was identified in another. These findings also provided further evidence 
of the presence of a critical region for the development of microcephaly and corpus 
callosum abnormalities in children with distal 1q deletions, and represented the fourth 
report of inheritance of two copies of the whole chromosome 2 from one parent (father) 
only and no copies from the other parent, i.e. paternal uniparental disomy (UPD) of 
chromosome 2. [150] 
 
The phenotypic effects of CNVs and their mechanisms of pathology still remain to be 
fully clarified, and more complex scenarios can be envisaged, like the inheritance of 
two or more CNVs at different loci from two healthy parents by an affected child. [122, 
151] 
Finally, it is possible that detected CNVs might not be associated with the pathology 
under investigation, but might equally represent at-risk alleles for late-onset disorders or 
recessive diseases. The implications must be considered when informed consent is 
requested. [152] 
 
 
 
1.3. Single Nucleotide Polymorphisms 
(SNPs) 
 
Data on the occurrence of sporadic genomic disorders have shown a rate of arising of 
CNV at least 2 to 4 orders of magnitude higher than that of point mutations. [138, 153] 
CNVs are estimated to encompass more total nucleotides than single nucleotide 
polymorphisms (SNPs), that represent another source of variation and contribute to 
determining phenotypic variability in humans. [109, 122] 
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1.3.1. Definition of SNPs 
 
A SNP is a genome position in the DNA sequence at which there are, typically, two or 
more different nucleotide residues (alleles) in the population. [154] Each variant, or 
polymorphism, occurs at a minor allelic frequency (the lowest allele frequency at a 
locus) of at least 1% in the given population, and one allele is usually more common 
than the other/s. A SNP allele that is common in one geographical or ethnic group may 
be much rarer in another. [154, 155] 
SNPs are widespread throughout the genome. There are an estimated 15 million SNPs 
in the human genome. [156] If SNPs lie in a coding region of a gene, they are 
distinguished into non-synonymous or synonymous depending on whether they do or do 
not change the protein amino acid sequence, respectively. SNPs lying in non-coding 
regions of genes or intergenic regions between genes may have an impact on gene 
splicing processes or transcription factor binding and hence on human genetic and 
phenotypic diversity. [154-156] 
SNPs are introduced into the genome by spontaneous germline mutation of single 
nucleotides in the course of evolution. [156] Although genomic diversity during human 
reproduction is maintained by genetic recombination during meiosis, chromosomal 
segments tend to be transmitted as specific combinations of linked SNP alleles referred 
to as haplotypes. [154, 157] This implicates that a single SNP (also referred to as tag 
SNP) can act as a genomic marker within a given haplotype to predict the genotype of 
the surrounding region, which is described as linkage disequilibrium. [154, 156] 
SNPs that are biallelic, or binary, are well suited to automated, high-throughput 
genotyping (determine which allele is present at a given genomic polymorphic 
position). Operationally, the two alleles of a SNP are often arbitrarily labelled as A and 
B. Therefore, when each individual inherits one copy of a SNP position from each 
parent, the genotype at a SNP site can be represented by either AA, AB or BB. [154, 
155] 
 
 
1.3.2. Role of SNPs in Disease Gene Discovery 
 
Any two copies of the entre human genome share 99.9% of DNA sequence. Within the 
0.1% of nucleotide sites where human genomes differ from one another, common 
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patterns exist, and approximately 90% of sequence variation among individuals is due 
to common variants. [154] 
The HapMap is a genome wide catalogue of the common patterns of genetic variants 
that occur in humans, based on the identification of SNPs in haplotypes with a 
frequency of 5% or higher, and the way they are distributed amongst four population 
samples of different ancestral geographic origin: Yoruban (YRI) of Nigeria, Japanese 
(JPT), Han Chinese (CHB), and northern and western European (CEU). [154, 158, 159] 
The DNA samples were extracted from cell lines established from blood samples 
collected from a total of 270 individuals. In the first stage of the construction of the 
HapMap database, all SNPs were genotyped in the full set of 270 DNA samples. In the 
second step, the common haplotypes, each with a frequency of at least 5%, were 
defined. Eventually, in the third phase, the tag SNPs were identified. Common 
haplotypes, within which SNPs are strongly associated and therefore tend to be 
inherited together, were characterised, and tag SNPs, that uniquely identify each one of 
these haplotypes via linkage disequilibrium, were recognised. [154, 158, 159] 
Detecting tag SNPs allows to genotype only a percentage (300,000 to 600,000) of the 
whole of the 15 million common SNPs in the human genome, that is sufficient to 
identify each of the common haplotypes uniquely. Moreover, the tag SNPs contain 
much of the information about the common patterns of variation in the genome to 
predict the remainder of the common SNPs in that region and the pattern of genetic 
variation. As a result, only a few tag SNPs are genotyped directly, while the other SNPs 
are captured through linkage disequilibrium correlations with the tag SNPs. [160] 
A set of sequence variants in the genome can, therefore, serve as genetic markers to 
detect associations between a particular genomic region and a disease, whether or not 
the markers themselves have functional effects. [161] While hundreds of genes for 
human rare diseases, in which mutation of a single gene is necessary and sufficient to 
cause disease, have been discovered, for common complex diseases, linkage studies 
have been much less successful in locating causative genetic variants, consistent with a 
more complex genetic architecture where each variant locus individually contributes 
only modestly to disease risk and aetiology. [155] Such conditions include diabetes, 
cancer, stroke, autoimmune pathology, schizophrenia, depression and asthma. [162, 
163] 
The HapMap dataset, that represents a SNP map of the common haplotypes and their 
tagging SNPs, constitutes a platform for disease association studies, where the 
haplotypes in individuals with a disease are compared to the haplotypes of a 
 37 
comparable group of individuals without a disease (the controls). If a particular 
haplotype occurs more frequently in affected individuals compared with controls, a gene 
influencing the disease may be located within or near that haplotype. The search for the 
causative variants/genes can then be limited to the region/s showing association with the 
disease. [158, 161] This aims, in particular, at facilitating genome wide association 
studies, as well as analysis where a gene has been implicated in causing disease by 
chromosomal position relative to linkage peaks, known biological function or 
expression pattern. [155] 
 
With the increasing number of SNPs genotyped by the HapMap project, it has become 
possible to correlate structural and SNP variation. However, because the frequency of 
individual, polymorphic and rare, CNVs in the general population has not yet been 
determined and the HapMap collection is intended to sample common SNPs and 
haplotypes, it is not known how well these samples reflect copy-number variability in 
humans. The structural variation may also vary among different populations to an extent 
yet unknown, and the sample size may be too small for discovering CNV genotypes that 
represents each of the four HapMap populations. Moreover, no clinical information are 
obtained by the HapMap project, therefore the structural variation ascertained from the 
HapMap samples is not necessarily benign or neutral. Finally, it is noteworthy that, 
since the source of the DNA for HapMap samples is transformed lymphoblastoid cell 
lines, it may be impossible to assess true germline CNVs. [154] 
Recently, a study has confirmed that common CNVs are tagged by SNPs and so have 
been indirectly explored through SNP studies. [163] To address the issue of the role of 
common CNVs in genetic susceptibility to common disease, a genome-wide study of 
association between CNVs and eight common human diseases was undertaken in 
~19,000 individuals at 3,432 polymorphic CNVs. It was concluded that common CNVs 
are unlikely to contribute greatly to the genetic basis of common human diseases. 
However, three loci were identified, where CNVs were associated with disease: 
immunity-related GTPase family, M (IRGM) for Crohn’s disease, human leukocyte 
antigen (HLA) for Crohn’s disease, rheumatoid arthritis, and type 1 diabetes, and 
transmembrane glycoprotein tetraspanin 8 (TSPAN8) for type 2 diabetes. [163] In each 
case the locus had previously been identified in SNP-based studies. [129, 164, 165] 
Significantly, systematic CNV differences between DNAs derived from blood and cell-
lines were also confirmed. [163] 
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The more commonly occurring CNVs that show a lack of linkage disequilibrium with 
nearby SNPs might indicate that the structural variants have arisen repeatedly. [109] 
Ancestral non-recurrent structural variants are expected to show linkage disequilibrium 
with SNPs on their original haplotype, as they arise only once. [130, 166] If so, their 
presence or absence may be inferred by typing selected tagging SNPs. [167, 168] 
Flanking SNPs can potentially be combined into a more informative haplotype to be 
used as a proxy for simple CNV events. [130] However, CNVs associated with rare 
sporadic genomic disorders often arise in regions of complex genomic structure, and 
this limits the extent to which these variants can be genotyped using tagging SNPs. 
[169] 
 
 
 
1.4. Array Techniques 
 
Chromosome abnormalities detected by routine karyotyping are a known cause of 
spontaneous abortions and growth pathology including developmental delay, multiple 
congenital anomalies (MCA) and dysmorphic features. Chromosome abnormalities are 
observed in 50% of spontaneous first trimester abortions and 1% of all liveborn babies. 
Clinical phenotypes may arise from gene dosage imbalance, but routine cytogenetic and 
molecular techniques can be insufficiently sensitive to detect chromosome 
rearrangements that are either submicroscopic in size (<3 Mb) or limited to a specific 
genomic locus or both. [170] Fluorescent in Situ Hybridisation (FISH) using probes 
which localise at the subtelomeric regions of the chromosomes identifies a 
submicroscopic rearrangement, considered causative of the clinical phenotype, in 
approximately 5% of patients with DD/MCA, growth impairment, facial dysmorphic 
features, and a family history of DD. [171, 172] 
Array-based technologies have enabled high resolution screening of the whole human 
genome in one experiment, for the diagnosis of copy number changes and genomic 
disorders in patients with DD and MCA. These platforms have the potential to improve 
the diagnostic yield of genetic abnormalities, and to replace the more time-consuming 
and less cost-effective, sequential locus-specific testing for microdeletion and 
microduplication syndromes. [173] 
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1.4.1. Bacterial Artificial Chromosome (BAC) Based 
Arrays 
 
Array comparative genomic hybridisation (CGH) allows the genome wide screening of 
CNVs in a single overnight hybridisation. [174-177] The technique was largely 
developed based on the use of bacterial artificial chromosome (BAC) clones spotted on 
a glass slide array grid. The principles of the methodology are described in Figure 4. 
 
 
Figure 4. BAC clones based array CGH. The genomic DNA of a patient (test DNA) is 
labelled by a fluorochrome (green Cy 3 in the Figure) and genomic DNA of a normal 
control subject (reference DNA) is labelled by a different fluorochrome (red Cy 5 in the 
Figure). The two DNAs are cohybridised on an array grid of mapped genomic DNA 
fragments (BAC clones) spotted on a glass slide. The fluorescence is captured using a 
scanner. The fluorescence ratio is measured by a software and presented in graphic 
form. Copy number is proportional to the fluorescent [test/reference] ratios. In the 
Figure, the diploid status is presented in yellow, a genomic duplication in the patient 
(test) DNA is marked in green, while deletions are coloured in red. Genomic gains or 
losses are plotted on charts, and can be traced back to their genomic loci, chromosome, 
and physical position. Dup: duplication, del: deletion, Mb: Megabase. 
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The resolution of array CGH depends on the distance between the interrogating probes 
mapped on the array grid, and it is limited by the number of clones that can be deposited 
on the array. BAC-based array CGH was traditionally developed with a coverage of 
approximately 1 clone per Mb. [173] 
It has been proposed that a combined approach of conventional karyotyping, FISH of 
the subtelomeric regions of the chromosomes, and array CGH would lead to an 
aetiological diagnosis in about 20% of patients with DD/MCA. [178] The percentage of 
submicroscopic rearrangements among individuals with unexplained DD exceeds that 
of microscopically visible alterations. [178] An overall incidence of 20% 
submicroscopic copy number changes was confirmed in a cohort of 140 patients, 
selected on the basis of a complex clinical phenotype including DD/MCA and 
dysmorphic facial features and a normal routine cytogenetic karyotype, studied by array 
CGH. [179] Excluding subtelomeric rearrangements, clinically relevant interstitial 
submicroscopic imbalances were identified in 8% of patients. Taking into consideration 
all reported studies, the authors concluded that array CGH screening, with a resolution 
of at least 1 Mb, could detect a de novo intrachromosomal alteration in at least 8.8% 
patients with DD/MCA. [179] In addition, three patients were identified to harbour a 
mosaicism for a structural chromosome rearrangement. One of them showed monosomy 
7 in as little as 7% of the cells, confirming that array CGH also allows the detection of 
low grade mosaicism. [180] 
The resolution limit of array CGH, as defined by the smallest pathogenic CNV 
identified, was set at approximately 0.25 Mb. [181] 
 
 
1.4.2. Oligonucleotide Based Arrays 
 
A disadvantage of BAC arrays is that they contain repetitive human DNA sequences, 
which cause a cross hybridisation, translating into a background noise in the 
hybridisation. The use of a blocking reagent like Cot-1 DNA, 50-300 bp DNA enriched 
for repetitive sequences, in the hybridisation solution suppresses nonspecific 
hybridisation. Even then, though, the signal-to-noise ratio still suffers from background 
noise. [173] Oligonucleotide arrays have the advantage that they can be chosen to be 
free of repetitive sequences, and provide high quality results due to a robust signal-to-
 41 
background ratio. [111, 173, 182] In these platforms, oligonucleotide probes are 
immobilised as arrays on a flat surface of glass or silica, and the oligonucleotides 
typically range in size from 20 to 80 nucleotides. [173, 183] High-density synthetic 
oligonucleotide arrays are capable of identifying genome wide aberrations at high 
resolution. [184] The array technology has, therefore, shifted from BAC-based array 
CGH, containing genomic clones at 1 Mb intervals, towards higher resolution array 
platforms that use oligonucleotides. [111, 182, 185] 
 
 
1.4.3. Single Nucleotide Polymorphism (SNP) Arrays 
 
High-density whole genome SNP array is a high-throughput technique that allows 
interrogation of hundreds of thousands up to millions of SNPs in a single assay. The 
SNP mapping technology makes use of oligonucleotide arrays to genotype genome-
wide SNPs. [173, 184, 186, 187] The principles of the methodology are described in 
Figure 5. 
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Figure 5. Affymetrix oligonucleotide-based SNP mapping array. In SNP genotyping 
platforms, oligonucleotides are used to interrogate the whole genome at unprecedented 
resolution. SNPs on the mapping arrays are selected based on reproducibility and 
physical distribution across the genome. [111, 185] Oligonucleotides are specific to 
known SNPs. Contrary to array CGH, a reference DNA from a control subject is not 
required, as the SNP map of a DNA reference dataset, like HapMap, can be utilised. 
[173] Each SNP on the array is interrogated by a set of probes that are each 25-
nucleotide long. A probe is designed to be complementary, or very nearly 
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complementary, to the DNA sequence harbouring the SNP site. Because SNP alleles 
only differ in one nucleotide, the hybridization conditions for all probes on the array 
allow for the target DNA to hybridize to mismatched probes. Therefore, each 25-mer 
oligonucleotide probe is either a perfect match (PM; perfectly complementary to one of 
the SNP alleles), or a mismatch (MM; identical to a perfect match probe except that the 
centre base is altered so as to be perfectly complementary to neither allele). The purpose 
of the MM probe is to measure background noise and evaluate specificity in binding. 
[186] A number of additional probe quartets are designed on both strands, sense and 
antisense, with the centre position shifted a number of nucleotides up- or downstream of 
the SNP site. This is to provide data redundancy when interrogating each SNP region. 
[188] DNAseI: deoxyribonuclease I, PCR: polymerase chain reaction, RE: restriction 
enzyme; PMA: Perfect Match allele A, MMA: Mismatch allele A, PMB: Perfect Match 
allele B, MMB: Mismatch allele B. 
 
The combination of SNP database, like HapMap, and high-density SNP array allows the 
use of SNPs as informative polymorphic markers for Mendelian hereditary diseases, 
complex traits and common disorders. [189] The copy number of any given genomic 
region containing the SNP can be inferred by the SNP genotyping and CNVs can be 
detected by differences in hybridisation intensity. [130, 190, 191] Array platforms that 
combine genomic copy number quantification and SNP genotyping offer the 
opportunity to perform genome-wide studies that might detect disease susceptibilities 
related either to a CNV or a SNP. [130, 173] A summary of the characteristics of the 
different SNP array products in the Affymetrix genotyping range is given in Table 2. 
[192] 
 
 100K 500K SNP 5.0 SNP 6.0 
Restriction 
enzyme 
XbaI and 
HindIII 
NspI and 
StyI 
NspI and 
StyI 
NspI and StyI 
Number of SNPs 116,204 500,568 500,568 906,600 
Median distance 
between markers 
8.5 kb 2.5 kb 2.5 kb <700 bp 
Average 
heterozygosity for 
each SNP 
0.3 0.3 0.31 26.7-28.5% 
depending on 
population 
Table 2. Differences between Affymetrix SNP array platforms. 
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SNP arrays have applications in copy number variation and whole genome association 
studies. The power of SNP arrays to interrogate a significant proportion of human 
genetic variation has facilitated genome-wide association studies where DNA samples 
of large numbers of affected (cases) and unaffected (controls) individuals are 
interrogated. The data are mined for statistically significant differences in allele 
frequencies between the two groups. [186] In common human pathologies, such as 
coronary artery disease or diabetes, the associated variant/genotype is putatively either a 
disease predisposition allele or in linkage disequilibrium with such an allele. [193, 194] 
Genome-wide SNP genotyping on oligonucleotide platforms can be used for discovery 
and mapping of CNVs in the human genome with a virtually unlimited resolution, and 
their association with clinical phenotypes. [173, 187, 190] With the highest resolution 
platforms, SNP array analysis should theoretically detect all known syndromes with 
CNV aetiology as well as new ones. [111, 122, 181] 
While other array-based methods, like array CGH, can detect only genomic gains or 
losses, the approach of combining genotypes and copy number estimation in SNP array 
technology has the additional advantage of detecting chromosomal abnormalities that 
do not alter copy number, but that can play an important role in pathology, such as copy 
number neutral loss of heterozygosity (LOH) and uniparental disomy (UPD). [173, 184, 
186] 
LOH is a form of allelic imbalance that can result from the complete loss of an allele or 
from an increase in copy number of one allele relative to the other, resulting in regions 
of LOH with or without copy number change, respectively. [187] Copy number neutral 
LOH can be due to UPD. [184] 
UPD represents an allelic imbalance when one allele is deleted leading to reduplication 
or amplification of the other parental allele. This results in genomic regions with 
homozygous SNP calls but a copy number of two or higher. [186] UPD can be 
pathological when the wild-type allele (e.g. maternal) is missing and two copies of a 
mutant allele (e.g. paternal) are present, or due the imbalance of an imprinted gene, that 
is expressed differently when inherited by one parent or the other. [195] 
Moreover, SNP arrays use genotype data to determine the molecular origin of UPD, as 
well as the parent of origin of a deletion or duplication that has arisen de novo. [184, 
196] 
Finally, the high resolution of SNP array provides more precise breakpoint definition 
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and disease loci mapping, which allows subtle phenotypic heterogeneity to be 
distinguished at a molecular level. [184] 
 
 
1.4.4. Known and Emerging Syndromes 
 
In a cohort of 100 children with idiopathic MR, and normal results of standard 
karyotype analysis, chromosome imbalances were found in 11 patients by use of whole 
genome 100K SNP array. De novo deletions, as small as 178 kb, were detected in 8 
patients, de novo duplications, as small as 1.1 Mb, in 2 cases, and one instance of 
previously undetected mosaic trisomy of chromosome 9 was also recorded. [197] 
Similar results were obtained, utilising the same SNP array platform, in a group of 104 
unselected patients with idiopathic MR. The genome-wide screening detected deletions 
as small as 20 kb, when covered by at least 3 SNPs, and duplications as small as 150 kb, 
when covered by at least 6 SNPs. Overall, putative disease-causing or de novo 
aberrations were detected in 9.1% of patients, and the detection rate was stated to be 
independent from clinical pre-selection of patients. [152] Previously undetected de novo 
chromosomal deletions were also identified in a small cohort of children with MCA, 
who had had a normal high-resolution karyotype and subtelomeric FISH analysis, by 
means of genome-wide 100K SNP array. [198] 
Multiple commercially available SNP array platforms, including the Affymetrix 250K 
SNP NspI array and the Affymetrix 250K SNP StyI array, were used to detect CNVs in 
318 patients with MR/MCA. Abnormalities were found in 22.6% of patients, including 
6 CNVs that overlapped known microdeletion/duplication syndromes, 8 CNVs that 
overlapped recently described emerging syndromes (3q29 microduplication syndrome, 
3 cases of 16p11.2 microdeletion syndrome, 2 cases of 16p13.11 microduplication 
syndrome, 22q11 duplication syndrome, and 22q11.2 distal deletion syndrome), 63 
potentially pathogenic CNVs (in 52 patients), and two mosaic trisomies for an entire 
chromosome. The authors proposed a novel diagnostic approach for patients with 
MR/MCA, by first analysing each patient by means of SNP array instead of 
conventional karyotyping. [181] 
The Affymetrix 500K SNP array platform was utilised in a study of 100 patients with 
idiopathic intellectual disability of unknown cause and their unaffected parents. 
Pathogenic genomic imbalances were found in 16 out of 100 patients. The same authors 
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had previously screened a cohort of 100 children with idiopathic DD by means of 
lower-resolution 100K SNP array, and pathogenic genomic imbalance had been found 
in 11 of them. Ten out of these 11 patients, together with 44 more patients from the 
same study, were included in the second cohort screened by 500K SNP array, and re-
tested. The 500K SNP array platform identified all 10 previously detected pathogenic 
genomic copy number changes and at least one additional pathogenic CNV, that had not 
been detected with the 100K SNP array platform. Many benign CNVs were also 
detected during the screening with the 500K SNP array platform. [199] 
A similar comparison, between two separate array platforms with different resolution, 
was performed in the study of 70 patients affected by idiopathic MR and dysmorphic 
features. In order to reduce the number of false positives, parameters were set to filter 
the results and consider only imbalances greater than 75 kb in size. In the comparison, 
the higher-resolution Affymetrix 6.0 SNP array platform confirmed its increased ability 
to detect small CNVs, and disclosed potentially pathogenic CNVs in 6% of patients, 
that had not been identified during the study with the lower-density oligonucleotide 
array. [200] 
 
 
1.4.5. Disease Gene Mapping 
 
Three unrelated patients with severe psychomotor retardation, epilepsy or febrile 
seizures, muscular hypotonia and variable brain and minor anomalies showed de novo 
interstitial microdeletions involving 5q14.3-q15. Molecular karyotyping, by means of 
Affymetrix 100K SNP array and Illumina 550K SNP array, allowed to identify and 
refine 3 overlapping deletions measuring 5.7, 3.9 and 3.6 Mb, respectively. The 
boundaries and sizes of the deletions in the three patients were different, but an 
overlapping region of around 1.6 Mb in 5q14.3 was defined, which harboured 5 genes. 
Amongst the 5 genes were: G protein-coupled receptor 98 (GPR98), a known epilepsy 
gene, and a second candidate gene, LysM, putative peptidoglycan-binding, domain 
containing 3 (LYSMD3), for the other central nervous system symptoms of the novel 
emerging 5q14.3 microdeletion syndrome. [201] 
 
Chromosomal rearrangements have been detected in 5-10% of patients with autism 
spectrum disorder (ASD). Array CGH was utilised to test the hypothesis that de novo 
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CNV is associated with ASD, by screening the genomic DNA of patients, unaffected 
subjects, and their respective parents. De novo CNVs were found to be significantly 
associated with autism (P = 0.0005), and were identified in 12 out of 118 (10%) of 
patients with sporadic autism, in 2 out of 77 (3%) of patients with an affected first-
degree relative, and in 2 out of 196 (1%) of controls. The authors concluded that de 
novo copy number mutations represent a significant risk factor for ASD. [202] 
Further candidate chromosome regions and genes have been identified utilising high 
density SNP array platforms. In a cohort of 54 families with ASD patients, 
microcephalin 1 (MCPH1) gene copy number changes were detected in three patients, 
implicating MCPH1 in chromosome band 8p23.1 as an ASD susceptibility gene. [203] 
A large cohort of 996 individuals of European ancestry affected by ASD and their 
parents were genotyped with Illumina 1M SNP array and compared to 1,287 matched 
controls. The affected population was found to carry a higher number of rare (<1% 
frequency) CNVs than controls (1.19 fold, P = 0.012). Novel ASD loci that were 
affected by CNVs in cases and not in the control population were identified: SH3 and 
multiple ankyrin repeat domains 2 (SHANK2), synaptic RAS-GTPase-activating protein 
1 (SYNGAP1) and discs large-associated protein 2 (DLGAP2), and the X-linked locus 
patched domain-containing protein 1 (PTCHD1). No CNVs affecting these candidate 
genes were found in an additional 3,677 European controls, implicating these rare 
genomic variants as ASD risk factors. [204] 
 
LOH is a prominent characteristic of most human cancers. Two types of acquired LOH 
are observed in tumours: deletions and copy neutral UPD. In a study of 301 patients 
with haematological malignancies, 250K SNP array technology was applied to detect 
previously cryptic chromosomal changes, particularly UPD. Acquired UPD was shown 
to be a common chromosomal defect in myeloid malignancies, and mapping minimally 
overlapping segmental UPD regions has the potential to identify both known and novel 
pathogenic mutations. [205] 
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1.5. Hypothesis and Major Outcomes 
 
The clinical data of a large number of children and adults who present with a pathology 
of the pituitary gland of unknown aetiology are entered into the database of 
endocrinological patients of the Great Ormond Street Hospital. Amongst them, a cohort 
of patients with a complex clinical phenotype, including MCA, dysmorphic features and 
impaired growth and development was selected to undergo a genome-wide screening of 
copy number changes with high-throughput high-resolution array-based technique. 
Congenital hypopituitarism can be triggered by environmental insults, such as viral 
infections, vascular or degenerative damage, exposure to alcohol and/or drugs, and 
maternal age. Genetic mutations have been identified in genes responsible for pituitary 
development and function. However, only up to 10% of patients affected by 
hypopituitarism have recognised mutations in known genes. Novel genomic regions and 
candidate genes remain to be identified, the disruption of which is responsible for 
congenital pathology of the pituitary gland. 
An analytical workflow was drawn up to screen the multiple CNVs detected in the 
cohort of patients. The presence of two pathogenic genomic imbalances, chromosome 
6q terminal duplication and chromosome 11q terminal deletion, was confirmed in one 
patient, and the breakpoints were defined at high resolution. A previously undetected 
interstitial deletion of chromosome 22q was diagnosed in a patient with hypopituitarism 
and the complex cardiac malformation tetralogy of Fallot. 
A further patient with the same association of hypopituitarism and tetralogy of Fallot 
harboured a submicroscopic rearrangement in the chromosome region 1p36.33. This 
CNV and three more regions of genomic imbalance, detected by SNP array in two 
patients, were assessed as potentially pathogenic CNVs. 
Novel genes involved in the pathways of pituitary development are candidates for 
mutation screening by direct sequencing in larger cohorts of patients, in order to 
ascertain their prevalence and role in the aetiology and pathophysiology of 
hypopituitarism. 
A nucleotide sequence variant, leading to a non-synonymous amino acid change, was 
identified in exon 2 of barH-like homeobox gene 2 (BARX2), that had not been reported 
before in the literature or in public databases. A non-sense mutation was found in exon 
4 of OTX2, compatible with the clinical phenotype of the patient, that comprises of 
severe eye defects as well as pathology of the pituitary gland. 
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2. METHODS 
 
 
 
 
2.1. Patients 
 
At the moment of starting the project, the database of endocrinological patients seen at 
the Great Ormond Street Hospital and other national and international centres contained 
1,697 index cases. 
 
 
2.1.1. Patients Selected for High Resolution Genome-
wide Copy Number Change Screening 
 
A checklist of selection criteria was drawn up and applied to the clinical records 
contained in the database, in order to identify patients with a complex pituitary 
phenotype (i.e. associated with DD and/or MCA and/or dysmorphic features), who have 
the highest likelihood of harbouring submicroscopic chromosome imbalances. [171, 
206, 207] The checklist was compiled on the basis of the results obtained by the study 
of the subtelomeric regions of the chromosomes, [171] and by screening with array 
CGH. [206, 207] A total of ten patients were selected, including two patients who were 
already known to carry individual chromosome 11q abnormalities. 
A detailed pro-forma was designed for the project to be filled in for each patient 
included in the screening, with the aim of collecting consistent data across the whole 
cohort of patients under investigation. The patient pro-forma was divided into sections 
to log anamnestic, clinical, endocrinological and genetic information. Appendix A 
contains a copy of the Patient Pro-forma. 
DNA samples were already stored for the majority of patients included in the database. 
In all cases, high resolution genome-wide copy number change screening was carried 
out on DNA extracted from fresh blood, as it has been shown in an array CGH 
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screening that clonal anomalies can arise in vitro in cultured cell lines. [208] 
 
 
2.1.2. Patients Selected for Mutation Analysis. 
 
A list of 72 patients with uncomplicated pituitary pathology, characterised by GHD and 
MRI evidence of a small pituitary gland and infundibulum and an ectopic posterior 
pituitary gland, were chosen to undertake mutation analysis in the novel candidate gene 
BARX2. One patient was already known to carry an apparently balanced chromosome 
translocation involving chromosome band 11q24. 
 
A list of 35 patients with an association of pituitary and eye pathology, with or without 
DD and learning or behavioural difficulties, and/or MCA mainly of the brain and 
kidneys, were chosen to undertake mutation analysis in two novel candidate genes 
BMP4 and OTX2. Three of these patients were also included in the high resolution 
genome-wide copy number change screening. 
 
When a mutation was found in a patient, DNA samples extracted from fresh blood were 
obtained from both parents, and the status of the mutation was assessed by direct 
sequencing. 
 
 
 
2.2. Affymetrix GeneChip 250K Sty1 
Mapping Array 
 
The Affymetrix GeneChip 250K Sty1 SNP mapping array was chosen to perform 
genome-wide copy number change analysis. 
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2.2.1. Quality Control of DNA 
 
Two microliters (concentration: 250 ng/μl) of total genomic DNA were submitted for 
each patient. The integrity of each DNA sample was verified by electrophoresis on a 
0.8% agarose gel before submission. A volume of 100 ml of 0.8% agarose gel was 
prepared by adding 0.8 grams of agarose to 100 ml of a 1.0X 
Tris/Borate/Ethylenediamineetracetic acid (EDTA) (TBE) solution, obtained by adding 
1 volume (20 ml) of 5.0X TBE solution to 4 volumes (80 ml) of distilled water. The 
solution was swirled to mix, heated in a microwave for a total of 1 minute and 30 
seconds, and cooled under tap water. Subsequently, 1.5 μl of 10 mg/ml ethidium 
bromide (EtBr) solution were added, and the solution was swirled to mix. The gel was 
poured into the tank with pre-inserted combs, and left to set for 45 minutes. The first 
well of each row of the gel was loaded with 4 μl of 100 bp DNA ladder. For each 
sample, 1 μl of DNA was added to 1 μl of Orange G loading buffer and mixed with 10 
μl of double distilled water (ddH2O). For each sample, the total volume of 12 μl was 
split into two aliquots, 4 μl and 8 μl, and loaded onto the gel. The gel was submerged in 
1.0X TBE buffer to run at 90-95 V (~60 mA), and eventually examined on the 
ultraviolet (UV) light-box. 
 
 
2.2.2. Sample Processing with Affymetrix GeneChip 
250K Sty1 Mapping Array 
 
The DNA samples were processed at University College London Genomics by Kerra 
Pearce, using the Affymetrix GeneChip 250K Sty1 Mapping Array and reagents. The 
samples were processed according to the manufacturer’s standard protocol. Briefly, 250 
ng of total genomic DNA was digested with Sty1 restriction enzyme. Adaptor 
oligonucleotides were ligated onto the ends of the digested fragments. Three polymerase 
chain reactions (PCRs) per sample were carried out to amplify a subset of digested 
DNA, using a single primer specific to the adaptor oligonucleotide sequence. PCR 
conditions were optimised to preferentially amplify DNA fragments within an optimal 
set size range. The yield of the PCR amplification was evaluated by spectrophotometry, 
and the size distribution of the amplified fragment was validated by agarose gel 
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electrophoresis. Samples giving low yield or improper size distribution were re-
amplified or eliminated. Negative controls containing no DNA were run during the 
digestion/ligation steps and for each PCR assay to monitor for potential external DNA 
contamination. The PCR-amplified product for each sample was purified and 
fragmented with deoxyribonuclease I (DNAseI). The resulting fragments were end-
labelled with Biotin, and hybridised onto the 250K Sty1 Mapping arrays overnight. The 
arrays were washed and stained with a biotinylated antibody and Phycoerythrin-
conjugated Streptavidin to produce an amplified fluorescent signal (using the Fluidics 
Station 450, Affymetrix). The arrays were scanned using the Scanner 3000 
(Affymetrix). The raw fluorescent signal intensity measurements were extracted using 
the Affymetrix GeneChip Operating Software (GCOS) and the Affymetrix GeneChip 
Genotyping Software (GTYPE 4.1), to generate genotype calls (.DAT and .CEL files). 
[192] The optimal SNP genotype call rate for each experiment was set at  95%, with 
an acceptable threshold of 85%. 
 
 
2.2.3. Copy Number Analysis 
 
Upon receiving the .DAT and .CEL files, a copy number profile of the whole genome of 
each patient was produced using the GTYPE plug-in Affymetrix Copy Number 
Analysis Tool (CNAT 4.0). [192] For each patient, the genotype data was extracted into 
a .CPH file from the relevant .CEL file by running Batch Analysis in GTYPE 4.1. The 
analysis method used to determine genotype calls was a Dynamic Model (DM) based 
algorithm. [209] 
 
 
2.2.4. Reference Subsets of the International HapMap 
Project Dataset 
 
Two reference sets were built by downloading a subset of .CEL files from the 
international HapMap project Affymetrix GeneChip 500K Sty1 mapping array data 
bank. [210] The .CEL files were transferred into the GCOS/GTYPE framework, and the 
.CPH files were created as described above. At the time of this study, the international 
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HapMap project dataset on the Affymetrix GeneChip Sty1 arrays consisted of: 30 CEU 
trios (90 samples), 90 CHB and JPT individual samples, and 90 YRI individual 
samples. The two reference sets were built according to the CNAT 4.0 User Guide 
instructions for submicroscopic chromosome abnormalities testing. [211] Briefly, the 
size (n) of the reference set had to be n  25; ethnicity-match was not mandatory for n  
25, while mixed gender reference sets had to be excluded. Sex-match was relevant to 
facilitate the interpretation of the results on chromosome X: when the reference set of 
all male samples was used, the denominator for the logarithmic (log) ratios on 
chromosome X was automatically set to 1 as the test sample was analysed against an 
haploid set for chromosome X. The reference sets were therefore created as follows: 22 
CHB and JPT and 20 CEU individual male samples to test male patients, 23 CHB and 
JPT and 10 CEU individual female samples to test female patients. The copy number 
calculation was obtained by comparing the SNP intensities of the sample arrays against 
the intensity distribution of the reference sets, by running CNAT 4.0 Batch Analysis. 
 
 
2.2.5. Batch Analysis Workflow Parameters 
 
The CNAT 4.0 Batch Analysis Workflow was optimised for submicroscopic 
chromosome abnormalities detection. [211] Briefly, the probe-level normalisation was 
specified as median scaling, genomic smoothing (GS) lengths of both 0.1 and 0 Mb 
were utilised, a 5-State Hidden Markov Model (HMM) was applied to determine the 
prior value and estimate the SD of each copy number (CN) state (0-1-2-3-4). In 
particular, for a GS bandwidth equal to 0.1 Mb, the prior value was set uniformly at 0.2 
for CN states 0 through 4, SD for CN state 2 was set at 0.07 and SD for CN states 0, 1, 
3, 4 was set at 0.09; for a GS bandwidth equal to 0 Mb, the prior value was set 
uniformly at 0.2 for CN states 0 through 4, the SD for CN state 2 was set at 0.19 and SD 
for CN states 0, 1, 3, 4 was set at 0.25. The other user-tunable HMM parameter, 
transition decay length, was set at 0.1 Mb. The post-HMM processing option, adjust 
outliers, was switched off. 
The software CNAT 4.0 is implemented with the University of California Santa Cruz 
(UCSC) genome browser. [212] At the time of performing this study, the UCSC 
genome browser was based on the March 2006 human reference sequence assembly by 
the National Center for Biotechnology Information (NCBI) Build 36.1. [213] 
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2.3. Genomic Sequencing 
 
 
2.3.1. Primer Design 
 
The primers were initially designed using the online tools provided by UCSC and/or 
NCBI. [212, 213] Subsequently, each pair of primers was manually adjusted after 
verification with Basic Local Alignment Search Tool (BLAST) from NCBI, [213] and, 
for OTX2, also by comparison with data published in the literature. [37, 40] 
The primer pairs utilised for the PCR amplification of all coding exons, including 
intron-exon boundaries, of BARX2, BMP4, and OTX2 are listed in Table 3, Table 4, and 
Table 5, respectively. 
 
Exon Forward Primer Reverse Primer 
Product 
size (bp) 
1 5’-GCTACCCGCTCTCCTCC-3’ 5’-TCCCTTAACTTAACCCTTCC-3’ 448 
2 5’-TGTCAGACAGACCTCAGCC-3’ 5’-CCACAATGGGAGCAAGTC-3’ 465 
3 
5’-AGCAGGATCCCATCTCTC-3’ 5’-CCAAACTGCCAAATGGTC-3’ 248 
5’-AGCAGGATCCCATCTCTCCTG-3’ 5’-CCCAAACTGCCAAATGGTCCG-3’ 248 
4 5’-GCAACGTGAGGTTATACTGG-3’ 5’-TTCTCTCCCTACTCTCCCTG-3’ 425 
Table 3. Primer pairs used for genomic sequencing of BARX2. Two different sets of 
primers were used for exon 3. 
 
Exon Forward Primer Reverse Primer 
Product 
size (bp) 
3 5’-CCCTCCATTTCTAGCCCTAA-3’ 5’-GGGTTTGATGTAACCCGAAC-3’ 582 
4_1 5’-TAGGTTTCCCCTGCATAAGC-3’ 5’-GCTTAGGGCTACGCTTGG-3’ 642 
4_2 5’-ATTAGCCGATCGTTACC-3’ 5’-GTCCAGCTATAAGGAAGC-3’ 590 
Table 4. Primer pairs used for genomic sequencing of BMP4. Exon 4 was covered by 
two sets of primers amplifying overlapping fragments of the whole exon. 
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Exon Forward Primer Reverse Primer 
Product 
size (bp) 
3 5’-CTCGCCTAGTCCGTGCTCT-3’ 5’-GGAACAGGGTGTTGCATCC-3’ 395 
4 5’-CGGAAACGCCTATGACTGAGA-3’ 5’-TTTCAAGCCTTCCTTCAGTCC-3’ 325 
5_1 5’-ACGGGAGCCATTCTTGTCCTTAAGG-3’ 5’-CCCAAAGTAGGAAGTTGAGCCAGCA-3’ 409 
5_2 5’-TCTAGCACTTCAGTCCCGACCATTG-3’ 5’-TGGCTAAAACTGGAATGTCCAGCCC-3’ 536 
Table 5. Primer pairs used for genomic sequencing of OTX2. Exon 5 was covered by 
two sets of primers amplifying overlapping fragments of the whole exon. 
 
 
2.3.2. Suspension and Aliquots of Primers 
 
Primers were obtained dessicated and were resuspended in ddH2O according to the 
manufacturer instructions, to achieve a concentration of 1 μg/μl. The stock was divided 
into three aliquots, and one aliquot was utilised to prepare sub-aliquots of primers at 
concentrations of 50 ng/μl and 20 ng/μl, to be used in PCR and sequencing reactions, 
respectively. 
 
 
2.3.3. DNA Aliquots 
 
An aliquot of pre-extracted DNA sample from each patient and control (concentration: 
250 ng/μl) was diluted in ddH2O with a dilution 1:10. To perform a PCR amplification, 
2 μl of DNA of each sample were transferred onto a plate. 
 
 
2.3.4. PCR Protocol 
 
A quantity of 2.0 μl of genomic DNA, pre-extracted from fresh blood, from each patient 
was transferred onto a PCR plate, together with one control DNA sample. 
The ingredients of the standard PCR reaction mix were added in the order listed in 
Table 6. Before the addition of the DNA Polymerase, the reaction mix was moved onto 
ice, together with the plate of DNA samples, and all subsequent work was conducted on 
ice. A volume of 23 μl of the PCR reaction mix was added to each 2 μl DNA sample on 
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the plate to reach a final reaction volume of 25 μl, and also to an empty well on the plate 
as a negative control for DNA contamination. The plate was covered with a plastic lid 
or tape pad. 
 
Reaction Mix x 1 sample  Final concentration 
10X Taq Reaction buffer 2.5 μl 1X 
50 mmol/l MgCl2 0.75 μl 1.5 mmol/l 
2.0 mmol/l dNTPs 2.5 μl 200 μmol/l 
Forward Primer 1.0 μl 50 ng/μl 
Reverse Primer 1.0 μl 50 ng/μl 
ddH2O 15.15 μl  
Taq DNA Polymerase 0.1 μl  
DNA 2.0 μl  
Final Reaction Volume 25 μl  
Table 6. Standard PCR reaction mix. dNTPs: deoxynucleoside triphosphates. 
 
A quantity of 2.5 μl of the enhancing agent 10% dimethyl sulfoxide (DMSO) (final 
concentration 1%) was added to the PCR reaction mix to amplify exon 1 of BARX2. The 
PCR amplification of exon 2 of BARX2 was performed either without or, preferentially, 
with the addition of 7.5 μl of the enhancing agent 5.0 mol/l Betaine (final concentration 
1.5 mol/l). Both DMSO and Betaine act by inhibiting DNA secondary structures. In all 
cases, the volume of ddH2O was adjusted to reach the final reaction volume of 25 μl. 
The optimal PCR annealing temperatures determined for each pair of primers utilised in 
the study are listed in Table 7. 
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Exon Annealing Temperature (°C) 
BARX2 
1 54 
2 60 
3 60 
4 57 
BMP4 
3 58 
4_1 58 
4_2 60 
OTX2 
3 60 
4 60 
5_1 60 
5_2 60 
Table 7. PCR annealing temperatures. Annealing temperatures for PCR amplification 
of all coding exons of BARX2, BMP4, and OTX2. 
 
A total of 35 PCR programme cycles were run to amplify exons 1, 2 and 3 of BARX2, 
and all exons of BMP4 and OTX2; 30 cycles were run for the PCR amplification of 
exon 4 of BARX2. The denaturation step of the PCR reaction was run at 94 ºC, and the 
elongation phase was run at 72 ºC, as described in Table 8. 
 
Step Temperature (ºC) Running Time 
1 94 4 min 
2 94 30 s 
3 annealing 30 s 
4 72 30 s 
go to 2 repeat 29 or 34 cycles 
5 72 2 min 
Table 8. Scheme of the PCR running programme. The annealing temperature and the 
number of cycles changed for each pair of primers, as described in Table 7 and in the 
text. 
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To evaluate the yield of PCR amplification of each experiment, an aliquot of 5 μl of 
PCR product from each sample was mixed with an equal volume of tracking dye and 
loaded and run on a 1% agarose gel. A volume of 100 ml of 1% agarose gel was 
prepared as described above (paragraph 2.2.1.), by adding 1 gram of agarose to 100 ml 
of a 1.0X TBE solution. 
 
 
2.3.5. Purification of PCR Products 
 
PCR products were purified either with the ExoSAP method or with the microCLEAN 
single-reagent kit and protocol. 
 
In the ExoSAP method, the ExoSAP master mix was made up by 1 μl of 20 U/μl 
Exonuclease I (ExoI), 2 μl of 1 U/μl Shrimp Alkaline Phosphatase (SAP) and 2.0 μl of 
ddH2O, to reach a final volume of 5 μl, that was added to an aliquot of 15 μl of PCR 
product. The ExoSAP master mix was prepared and kept on ice throughout the 
procedure. The ExoSAP programme was run in a thermal cycler at 37 ºC for 30 min, at 
80 ºC for 15 min, and at 4 ºC for 10 s. The amount of DNA in the PCR product was 
quantified using a 1:20 dilution of the plasmid pGEM 32f(+). Ten microliters of a mix 
of 5 μl of diluted plasmid (initial DNA concentration of 200 ng/μl) and 5 μl of tracking 
dye were loaded in the first well of each row of a 2% agarose gel, producing a band 
with a content of DNA equal to 50 ng. The other wells of the gel were loaded with 10 μl 
of a mix of 5 μl of ExoSAP product and 5 μl of loading dye. The amount of DNA 
contained in each PCR product was determined by visual comparison with the plasmid 
pGEM 32f(+) band. 
 
According to the microCLEAN single-reagent kit protocol, an equal volume of 3 μl of 
microCLEAN was added to 3 μl of PCR product, mixed by spinning for 10 s and 
vortexed briefly, and left to rest at room temperature for 5 minutes. Plates of PCR 
products were, subsequently, spun for 40 min at 50 Hz and temperature of around 21 ºC. 
The supernatant was removed by spinning the plate upside-down on a layer of tissue 
paper at 10 Hz for 1 min. Tubes containing PCR products were spun for 8 min at ~215 
Hz and temperature of around 21 ºC. The supernatant was completely removed 
manually with a pipette. 
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2.3.6. Sequencing Reaction 
 
Direct sequencing of BARX2 was carried out using the BigDye Terminator v3.1 method 
for PCR products purified with the ExoSAP method, as follows. A quantity of 3 μl of 
each ExoSAP-PCR product was transferred into a well of a new sequencing plate 
(compatible with the MegaBace DNA Analysis System). The whole procedure was 
carried out on ice, and a quantity of 12 μl of the sequencing reaction mix was added to 
each well, to reach a final reaction volume of 15 μl. The sequencing reaction mix was 
made up with the reagents listed in Table 9. 
 
Sequencing Mix x 1 sample 
BigDye Terminator v3.1 2.0 μl 
5X Sequencing Buffer 3.0 μl 
PCR Forward Primer (50 ng/μl) 1.0 μl 
ddH2O 6.0 μl 
ExoSAP-PCR product (DNA) 3.0 μl 
Final Reaction Volume 15 μl 
Table 9. Sequencing reaction mix for BARX2 following ExoSAP method. 
Sequencing reaction mix for PCR products purified with the ExoSAP method. 
 
The primer added to the sequencing mix was the same utilised in the PCR amplification 
of each exon of BARX2, at the same concentration of 50 ng/μl. In the sequencing 
reaction the forward primer was used for each exon of BARX2. One sequencing 
programme was used for all exons of BARX2, as outlined in Table 10. 
 
Step Temperature (ºC) Running Time 
1 95 2 min 
2 95 20 s 
3 55 10 s 
4 60 4 min 
go to 2 repeat 34 cycles 
5 20 2 min 
6 4 Forever 
Table 10. Sequencing programme for BARX2. 
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After running the sequencing programme, the PCR products were submitted to a 
desalting treatment with the Sephadex purification protocol. The MultiScreen Column 
Loader was loaded by completely filling the wells with Sephadex G-50. The excess of 
Sephadex G-50 was carefully collected by scraping the surface of the plate and put back 
in the container. A MultiScreen 96-well filter plate was placed on top of the filled 
Multi-Screen Column Loader and the two plates were flipped over, and the bottom of 
the Multi-Screen Column Loader was tapped firmly a few times (on average 3 times) to 
let all Sephedex powder fall out of the wells of the Multi-Screen Column Loader and 
into the wells of the MultiScreen 96-well filter plate. The Multi-Screen Column Loader 
was then removed. A volume of 300 μl of ddH2O was added to each well of the filter 
plate containing the Sephadex powder, the plate was wrapped in parafilm, and incubated 
at room temperature until the Sephedex powder inflated. The Sephadex filter plate was 
then weighed and spun for 5 min at 910 g and 4 ºC with the appropriate counterbalance, 
in order to pack the Sephadex column. The water tray was emptied. A volume of 150 μl 
of ddH2O was added to each well of the Sephadex filter plate, the plate was weighed, 
spun again for 5 min at 910 g and 4 ºC with the appropriate counterbalance, and 
emptied from the waste. The Thermowell wash plate was replaced with a new 96-well 
collection plate. 
A volume of 10 μl of ddH2O was added to each sample in the sequencing plate, 
producing a final volume of 25 μl. The 25 μl samples from the sequencing plate were 
carefully added to the top of the packed column of Sephadex in the Sephadex filter 
plate, making sure to load the samples to the centre of the Sephadex column, without 
touching the column itself or loading along the wall of the well. The Sephadex filter 
block was weighed and spun for 5 min at 910 g and 4 ºC with the appropriate 
counterbalance. The Sephadex filter plate was removed, and the sample plate was dried 
and held at 4 °C until submission to sequencing with MegaBace DNA Analysis System. 
 
Direct sequencing of BARX2 was carried out using the BigDye Terminator v3.1 method 
for PCR products purified with the microCLEAN method, as follows. The whole 
procedure was carried out on ice. In order to cost-effectively decrease the volume of 
BigDye Terminator v3.1 utilised for each reaction, a BigDye Terminator v3.1 premix 
was prepared by adding 1 volume of BigDye Terminator v3.1 to 1 volume of 5X 
Sequencing Buffer and to 3 volumes of ddH2O. The final reaction volume was 5.0 μl 
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per sample. The BigDye Terminator v3.1 premix was used to make up the definitive 
sequencing reaction mix with the reagents listed in Table 11. 
 
Sequencing Reaction Mix x 1 sample 
BigDye Terminator v3.1 premix 4.0 μl 
PCR Primer (20 ng/μl) 1.0 μl 
ddH2O 5.0 μl 
Final Reaction Volume 10 μl 
Table 11. Sequencing reaction mix for BARX2 following microCLEAN method. 
Sequencing reaction mix for PCR products purified with microCLEAN. 
 
The primers added to the sequencing mix were the same utilised in the PCR 
amplification of the exons of BARX2. In the sequencing reaction both forward and 
reverse primer were used for exons 2 and 3, while the forward primer only was used for 
the sequencing of exons 1 and 4. The primer concentration for the sequencing reaction 
was 20 ng/μl. A volume of 10 μl of the sequencing mix was added to each well of the 
plate of purified PCR products. One sequencing programme was used for all exons of 
BARX2, and for both the forward and reverse primer of exons 2 and 3. The sequencing 
programme is outlined in Table 12. 
 
Step Temperature (ºC) Running Time 
1 96 1 min 
2 96 30 s 
3 56 15 s 
4 60 4 min 
go to 2 repeat 34 cycles 
5 20 2 min 
6 4 Forever 
Table 12. Sequencing reaction programme for BARX2. A lower concentration of 
both BigDye Terminator v3.1 enzyme and primer was utilised. 
 
After running the sequencing programme, the PCR products were purified with a NaAc-
EtOH precipitation mix, consisting of 2.0 μl of NaAc 3.0 mol/l, pH 5.2 and 50 μl of 
100% EtOH, per sample. A volume of 50 μl of the precipitation mix was added to each 
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well of the sequence plate, the plate was sealed, vortexed gently, and left at room 
temperature for 20 min. Subsequently, the plate was weighed and spun with a 
counterbalance for 40 min at 67 Hz and temperature around 21 ºC. The supernatant was 
removed by emptying the plate into a sink. The PCR products were further washed by 
adding 50 μl of 70% EtOH into each well. The plate was weighed again and spun with a 
counterbalance for 10 min at 67 Hz and temperature around 21 ºC. The supernatant was 
removed by emptying the plate into a sink, and subsequently spinning the plate upside 
down on a layer of tissue paper for 1 min at 5 Hz. A volume of 10 μl of deionised 
formamide was added to each well, and the plate was sealed and stored in a fridge 
compartment until submission to sequencing with ABI 3730 DNA Analyser. 
 
For the direct sequencing of BMP4 and OTX2, both the BigDye Terminator v3.1 and the 
BigDye Terminator v1.1 protocols for PCR products purified with the microCLEAN 
method were utilised. The protocol designed for the sequencing reaction carried out 
with the BigDye Terminator v3.1 method was adjusted to the use of the BigDye 
Terminator v1.1, as shown in Table 13. 
 
BigDye Terminator v1.1 
Sequencing Reaction Mix 
x 1 sample 
BigDye Terminator v1.1 0.5 μl 
5X Sequencing Buffer 1.5 μl 
5.0 mol/l Betaine 2.0 μl 
PCR Primer (20 ng/μl) 0.1 μl 
ddH2O 5.9 μl 
Final Reaction Volume 10 μl 
Table 13. BigDye Terminator v1.1 sequencing reaction mix. 
 
The primers added to either the BigDye Terminator v3.1 or BigDye Terminator v1.1 
sequencing mix were the same ones utilised in the PCR amplification of the exons of 
BMP4 and OTX2. In the sequencing reaction, both forward and reverse primer were 
used for all exons of both genes. The primer concentration was 20 ng/μl. A volume of 
10 μl of the sequencing mix was added to each well of the plate of purified PCR 
products, and the same sequencing programme utilised for BARX2 was used for both 
forward and reverse primer, for all exons of both BMP4 and OTX2 (Table 12). After 
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running the sequencing programme, the PCR products were purified with the NaAc-
EtOH precipitation mix and protocol, as described above for BARX2. 
When using the BigDye Terminator v3.1 method, a volume of 10 μl of deionised 
formamide was added to each well. 
According to the BigDye Terminator v1.1 protocol, each PCR product was re-
suspended in 10 μl of 1:10 dilution of 1X Tris-EDTA (TE) Buffer. 
The plate was then sealed and stored in a fridge compartment until submission to 
sequencing with ABI 3730 DNA Analyser. 
 
The genomic sequences of all exons of BARX2, BMP4 and OTX2 were analysed with 
the software Sequencher 4.7. 
 
 
 
2.4. Restriction Digestion 
 
A restriction enzyme digestion was performed following the identification of a 
nucleotide change in exon 4 of OTX2 in one patient. The status of the mutation was 
assessed in 60 controls. 
 
 
2.4.1. Selection of Restriction Enzyme 
 
The online tool REBsites from the Restriction Enzyme data BASE - REBASE was 
utilised to identify the restriction enzyme for the digestion protocol. [214, 215] The 
restriction enzyme BfaI that cut, differentially, both the wild-type and the mutated 
sequence was selected; the cut in the wild-type sequence was used as a positive control 
of the restriction enzyme’s activity. BfaI cleaved the wild-type sequence once and the 
mutated sequence twice. The predicted results and products of the two digestions are 
summarised in Table 14. 
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Length (bp) 5' Enzyme 5' Base 3' Enzyme 3' Base 
wild-type 
208 BfaI 118 none 325 
117 None 1 BfaI 117 
mutation 
122 BfaI 204 none 325 
117 None 1 BfaI 117 
86 BfaI 118 BfaI 203 
Table 14. Predicted digests with the restriction enzyme BfaI. 
 
 
2.4.2. Restriction Digestion Protocol 
 
Exon 4 of OTX2 was amplified by PCR in 60 controls, following the protocols 
described above. The PCR products were transferred onto a plate, together with the 
samples of the patient in whom a mutation in exon 4 of OTX2 had been identified by 
direct sequencing, and of both parents of the patient. The PCR fragments were purified 
with microCLEAN single-reagent kit utilising an equal volume of 5 μl of PCR product 
and 5 μl of microCLEAN reagent. At the end of the procedure, the pellet in each well 
was re-suspended in 5 μl of ddH2O, and left for 5 min at room temperature. The 
restriction digestion was carried out by adding 15 μl of a reaction master mix on top of 
the 5 μl of purified PCR product and mixing thoroughly avoiding the creation of air 
bubbles, to reach a final reaction volume of 20 μl, as shown in Table 15. The whole 
procedure was carried out on ice, until the time of starting the reaction. 
 
Reaction Mix x 1 sample Final concentration 
BfaI 5,000 U/ml 1 μl 5 U 
10X NEBuffer 4 2 μl 1X 
ddH2O 12 μl  
Purified PCR product 5 μl  
Final Reaction Volume 20 μl  
Table 15. Restriction digestion reaction mix. 
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The plate was incubated in a water bath at 37 ºC for 3 hours. The results of the 
restriction digestion were evaluated by electrophoresis on a 2% agarose gel. A volume 
of 100 ml of 2% agarose gel was prepared as described above (paragraph 2.2.1.), by 
adding 2 grams of agarose to 100 ml of a 1.0X TBE solution. An aliquot of 10 μl of 
restriction digestion product from each sample was mixed with a volume of 5 μl of 
tracking dye and loaded onto the gel. An aliquot of 10 μl of restriction digestion 
reaction mix without PCR product was loaded, with 5 μl of tracking dye, as a negative 
control for DNA contamination. A volume of 10 μl of PCR product from a control DNA 
sample, that did not undergo the restriction digestion, was also mixed with 5 μl of 
tracking dye and loaded onto the gel, as a negative control for restriction enzyme 
activity. 
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3. RESULTS 
Patient Selection for CNV Analysis 
 
Summary of results: 
 A checklist of inclusion criteria was designed to select the patients to screen for 
genomic copy number changes by means of high-resolution SNP array; 
 The patients were selected from the database of endocrinological patients of the 
Great Ormond Street Hospital. The clinical records were divided into groups 
according to the primary endocrinological diagnosis. Within each diagnostic 
group a separation was made between patients who presented with an isolated 
endocrinological pathology and patients with a complex clinical phenotype, in 
order to facilitate the application of the checklist; 
 The evaluation of the database allowed the identification of a recurrent 
association between hypopituitarism and the rare cardiac malformation tetralogy 
of Fallot; 
 A total of 10 patients were selected through the process to undergo whole 
genome testing for chromosome imbalances; 
 Amongst the selected patients, one child and one young adult, both affected by 
severe hypopituitarism, were already known to carry an unbalanced and an 
apparently balanced rearrangement of chromosome 11q, respectively. 
 
 
 
3.1. Checklist of Inclusion Criteria 
 
In order to select the patients to be screened with high resolution genome-wide array, a 
list of inclusion criteria was compiled, and subsequently formalised into a checklist of 
selection criteria, presented in Table 16. The likelihood of harbouring a genomic copy 
number change increased with the number of criteria relevant to each patient and the 
overall score. A total score of at least 8 and the presence of at least one criteria from 
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section 4. (aside from 4. a) endocrinological disorders) were necessary for inclusion in 
the screening. 
 
Checklist of Selection Criteria Score 
1. Family history  
a) non-consanguineous parents 
      consanguineous parents 
0 
-1 
b) multiple miscarriages 1 
c) ‘chromosomal phenotype’, mainly major congenital 
malformations, in a close relative 
2 
2. Apparently balanced chromosome translocation in a patient with an 
abnormal clinical phenotype 
6 
3. Known monogenic disease within a more complex clinical phenotype 4 
4. Complex clinical phenotype including  
a) endocrinological disorders mandatory 
b) developmental delay/behavioural problems 3 
c) microcephaly, growth abnormalities 1 
d) major congenital anomalies of at least one organ and/or system 
unrelated to the pituitary gland and the brain (limbs and heart, in 
particular) 
3 
e) facial dysmorphic features (at least 2-3) 1 
f) other clinical problems 1 
Table 16. Checklist of selection criteria. 
 
Developmental delay and mental retardation are the most common marker for the 
selection of patients to undergo screening for submicroscopic chromosome 
abnormalities. However, in the present study the essential inclusion criteria was the 
endocrinological disorder/s presented by each patient. The other inclusion criteria 
focused on the association of the endocrinological phenotype with indicators of a 
genomic imbalance as the aetiology. 
1. a) An accurate family tree can usually confirm or rule out whether a genetically 
significant degree of consanguinity is present between the parents of a patient. This was 
relevant because parental consanguinity represents a risk factor for diseases with 
Mendelian autosomal recessive inheritance, rather than gene dosage imbalance due to 
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chromosomal submicroscopic abnormalities. 
1. b) and c) A family history of recurrent miscarriages and/or a complex clinical 
phenotype in a close relative, similar to or different from the one presented by the 
patient under study, are suggestive of the presence of a balanced chromosome 
translocation in the family, that gave rise to a genomic imbalance and a pathological 
phenotype in the patient. The observation of a complex clinical phenotype in a close 
relative, different from the one shown by the patient, can be due to the concomitant 
presence of reciprocal derivative unbalanced chromosome translocations. 
2) An abnormal clinical phenotype can be associated with an apparently balanced 
chromosome translocation (or other anomaly, e.g. inversion), defined by karyotyping on 
G-banding, and preferably at International System for human Cytogenetic 
Nomenclature (ISCN) +550. For patients who presented with such an association, and 
who were potential candidate for high resolution genome-wide copy number change 
screening, it was particularly important to obtain information regarding any other 
molecular cytogenetic investigation carried out (e.g. FISH of the subtelomeric regions 
of the chromosomes, sequential specific loci FISH). The results of these investigations, 
when available, were weighed into the selection process. 
3) Patients with a recognised monogenic disease within a more complex clinical 
phenotype were considered to be ideal candidates for harbouring a submicroscopic 
chromosome imbalance. In fact, the patient’s phenotype could arise from a contiguous 
gene syndrome including the gene responsible for the known diagnosed condition, as 
well as a novel candidate gene for the endocrinological phenotype and pathology of the 
pituitary gland. 
4. a) The endocrinological phenotype of each patient was pivotal in guiding the 
selection process. All patients entered into the screening presented with variable degree 
and manifestations of pathology of the pituitary gland. 
4. b) Variable degrees of DD, neurobehavioural problems and learning difficulties are 
the most common finding in patients with gene dosage imbalance, and were frequently 
associated with the endocrinological phenotype in the cohort of patients under study. 
DD and MCA represent the stronger markers that point towards the presence of a 
submicroscopic genome anomaly. 
4. c) Apart from DD and MCA, growth abnormalities and microcephaly are considered 
common markers of a genetic aetiology and of gene dosage imbalance underlying the 
clinical phenotype of the patient. Growth abnormalities are also a strong indicator of 
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impaired function of the pituitary gland. Therefore, this aspect of the clinical phenotype 
of each patient was carefully considered. 
4. d) The pituitary gland and the nervous system (brain) are tightly connected 
anatomically, embryologically, as well as functionally (in the neuro-endocrine system). 
Consequently, the combination of endocrinological and neurological symptoms, and 
underlying pituitary gland and brain malformations, is observed in several conditions. 
Therefore, the presence of major congenital malformation/s involving at least one other 
unrelated, distant organ and/or system was deemed necessary to define a complex 
clinical phenotype. 
4. e) The thorough examination and detection of facial dysmorphic features in a patient 
can represent an useful instrument to guide the diagnosis. Also, the presence of a 
minimum number of 2-3 facial dysmorphic features, within a complex clinical 
phenotype, seems to increase the likelihood of identifying a genetic aetiology of the 
phenotype, as a submicroscopic genomic imbalance. The presence of dysmorphic 
features was evaluated in each patient, when the relevant information were available in 
the database, and, in particular, subsequently, when a patient could be examined in 
person. 
4. f) Each clinical problem and aspect of the phenotype of each patient was taken into 
consideration during the selection process. 
 
 
 
3.2. Database of Endocrinological 
Patients 
 
All 1,697 clinical records included in the database of endocrinological patients were 
evaluated, and a list of 1,168 index cases was compiled, for whom sufficient 
information were available in the database. The index cases were subsequently divided 
into groups according to the primary endocrinological diagnosis. When information on 
the endocrinological phenotype of the patient were not available at the moment of 
starting the study, the clinical records were divided into groups according to the 
principal diagnosis suggestive of, or commonly associated with, an endocrinological 
disorder. A list of all primary diagnoses entered in the database and the relevant 
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number of patients are reported in Table 17, first and second columns. Within each 
diagnostic group, a separation was made between patients who presented with an 
isolated endocrinological or endocrine-related pathology, and patients who showed an 
association with other symptoms within a complex phenotype. Associations with 
environmental and/or acquired pathologies and/or multifactorial diseases observed in 
the general population (e.g. asthma) were not considered significant when defining a 
complex clinical phenotype. The numerical results of this subdivision are shown in 
Table 17, third column. 
 
Primary diagnosis Number of 
patients 
Patients with 
complex phenotype 
SOD 359 65 
CPHD/panhypopituitarism (with or without 
structural anomalies of the pituitary gland) 
304 48 
IGHD 251 27 
ONH 44 3 
GHD (not better characterised) 28 1 
Midline defects 18 12 
Holoprosencephaly (HPE) 16 5 
Short stature (not better characterised) 16 2 
Miscellaneous pathology of pituitary gland (e.g. 
pituitary enlargement) 
13 2* 
Micro-/anophthalmia 8 4 
HH 8 3 
Thyroid gland pathology 7 - 
Obesity 7 - 
GH neurosecretory dysfunction (GHNSD) 5 - 
Constitutional delay of growth and puberty 
(CDGP) 
4 - 
Cortisol deficiency 4 - 
GHD associated to Fanconi anemia (FA) 4 - 
Insulin-dependent diabetes mellitus (IDDM) 4 - 
Sanjad-Sakati Syndrome 4* - 
Congenital adrenal hypoplasia (CAH) 3 - 
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Leri-Weill dyschondrosteosis 3* - 
Pancreas pathology 3 - 
ACC 2 1 
Ambiguous genitalia 2 - 
DI 2 1 
Ovary agenesis 2 - 
Miscellaneous (e.g. absent uterus) 47 5 
Total number of patients 1168 179 
Table 17. Numerical breakdown of the 1,168 index cases. The clinical records 
included in the database of endocrinological patients were classified according to the 
primary diagnosis. The number of patients who presented with a complex clinical 
phenotype is also shown for each group. *Familial case; ACC: Agenesis of Corpus 
Callosum; CPHD: Combined Pituitary Hormone Deficiency; DI: Diabetes Insipidus; 
GH: Growth Hormone; GHD: Growth Hormone Deficiency; HH: Hypogonadotropic 
Hypogonadism; HPE: Holoprosencephaly; IGHD: Isolated Growth Hormone 
Deficiency; ONH: Optic Nerve Hypoplasia; SOD: Septo-Optic Dysplasia; -: no patients. 
 
 
 
3.3. Association of Hypopituitarism 
with Tetralogy of Fallot 
 
Amongst the 1,168 clinical records included in the database, six patients were identified 
who presented with the association of pathology of the pituitary gland and Tetralogy of 
Fallot (ToF). A list was compiled, and the summary of the symptoms associated with 
ToF in each one of these patients, together with their primary endocrinological 
diagnoses, is shown in Table 18. 
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ID Primary diagnosis Other symptoms 
Other endocrinological symptoms 
5066 Midline defects (bilateral cleft lip and 
palate) 
Anosmia 
HH 
5135 DI Epilepsy, bilateral cleft lip and palate 
Hypothyroidism, IUGR 
5608 SOD Bilateral aplasia of the retina 
CPHD 
5745 IGHD Midline defects 
5859 CPHD DD, tracheo-oesophageal fistula, 
laryngomalacia, duodenal web, 
known unbalanced karyotype: 
46,XY,add(5)(q11.2).ish 
dup(5)(q22q11.2)(WCP5+)de novo; 
deceased 
6168 CPHD Exomphalos 
Short stature, hypoplastic anterior 
pituitary 
Table 18. Patients with hypopituitarism and Tetralogy of Fallot. CPHD: Combined 
Pituitary Hormone Deficiency; DD: Developmental Delay; DI: Diabetes Insipidus; HH: 
Hypogonadotropic Hypogonadism; IGHD: Isolated Growth Hormone Deficiency; 
IUGR: Intrauterine Growth Retardation; SOD: Septo-Optic Dysplasia; ID: patient 
Identification number. 
 
Patient 5859 was born from non-consanguineous parents, two weeks post-term, with a 
low birth weight of 2.4 kg. The patient unfortunately died at the age of 10 years. At 
birth, he had presented with ToF, that had required surgical intervention, a tracheo-
oesophageal fistula, laryngomalacia, and duodenal web. Subsequently, he had shown 
DD and he had been diagnosed with hypopituitarism treated with GH, thyroxine and 
hydrocortisone. He was found to have a de novo partial inverted duplication of 
chromosome 5q. 
On the basis of the preliminary information available in the database, the clinical 
phenotype of patient 5066 was deemed compatible with the diagnosis of Kallmann 
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syndrome. ToF had not been previously reported in Kallmann syndrome, however, 
congenital heart defect (CHD) is part of the clinical phenotype of this condition. The 
patient was, therefore, referred for further molecular cytogenetics analysis of the 
chromosome region Xp22.3 and the Kallmann syndrome interval gene 1 (KALIG1), in 
order to confirm or exclude the diagnosis, and was not considered to be a candidate for 
the screening with the 250K SNP array platform. 
Four more cases of the association between variable degrees and manifestations of 
pathology of the pituitary gland and ToF were identified in the database of 
endocrinological patients: one patient had a primary endocrinological diagnosis of SOD 
with CPHD, one patient had a primary diagnosis of CPHD, one of IGHD, while one 
patient had DI and central hypothyroidism. 
ToF is a complex and severe cardiac malformation presenting with the characteristic 
association of a ventricular septal defect (VSD), aorta overriding the VSD and right 
ventricle, pulmonary outflow tract stenosis and right ventricular hypertrophy. It 
constitutes ~10% of all CHD, and it has an incidence of 1/2500 newborns in the general 
population. 
When only considering the patients without an aetiological diagnosis, the incidence of 
ToF in the database of endocrinological patients under study was of 4 over 1,168 index 
cases, equal to 1/292. This value is ~8.5 times greater than the one observed in the 
general population (1/2500). The cohort of endocrinological patients was pre-selected, 
and therefore biased, on the basis of the presence of pathology (versus the general 
population). However, the significant number of cases of association of ToF with 
hypopituitarism led to consider this recurrent association of interest for the high 
resolution genome-wide copy number screening with 250K SNP array platform. 
 
 
 
3.4. Patient 6089 with Chromosome 
11q Deletion Syndrome 
 
Patient 6089 was born at term from non-consanguineous parents. At birth, he presented 
with bilateral cryptorchidism and skeletal malformations: hemi-vertebrae at multiple 
levels, multiple rib anomalies, including fusion of the right VII and VIII ribs, radial 
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shortening, short middle phalanx with clinodactyly; he also suffered from neonatal 
transient megakaryocytic thrombocytopenia. Subsequently, the patient presented with 
stature below the 3rd percentile, and severe GHD was diagnosed with undetectable 
levels of IGF1; an MRI targeted at evaluating the morphology of the pituitary gland 
demonstrated anterior pituitary hypoplasia, ectopic posterior pituitary, and absence of 
the rostrum of the corpus callosum. The patient responded extremely well to GH 
replacement therapy, and his growth velocity was restored to normal. 
Patient 6089 carried a complex unbalanced chromosome rearrangement comprising of a 
partial terminal duplication of the long arm of chromosome 6, and a partial terminal 
deletion of chromosome 11q. His unbalanced karyotype was defined by routine 
cytogenetics as: 46,XY,del(11q24.2qter) dup(6q25.3qter)mat der. The chromosome 
imbalances derived from a maternal reciprocal translocation. 
 
 
 
3.5. Patient 18905640 with Karyotype 
46,XY,t(11q;22q) 
 
A patient from China presented with panhypopituitarism, pituitary dwarfism with only 
scanty anterior pituitary tissue in a small sella turcica, and absent pituitary stalk, and 
carried an apparently balanced chromosome translocation between chromosomes 11q24 
and 22q13, karyotype: 46,XY,t(11;22)(q24;q13). [216] At the age of 21 years, the 
patient did not show any sign of cognitive impairment. [Yang, personal communication] 
The chromosome translocation had been defined cytogenetically at low resolution; a 
DNA sample was obtained from this patient to perform 250K SNP array analysis, 
although no cell suspension for FISH analysis was available. 
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3.6. Clinical Details of the Patients 
Included in the CNV Analysis 
 
The checklist of selection criteria was applied to each one of the 179 patients who 
presented with pathology of the pituitary gland within a complex clinical phenotype, 
and, therefore, a clinical history and symptoms compatible with the presence of an 
imbalance of multiple genes (contiguous gene syndrome). 
Ten patients were eventually selected to undergo high resolution genome-wide copy 
number change screening, with the 250K SNP mapping array platform. Amongst them: 
3 patients had a primary endocrinological diagnosis of IGHD, 2 patients had a diagnosis 
of SOD, 2 of CPHD/panhypopituitarism, 2 had growth deficiency and short stature, and 
1 patient had DI. The clinical phenotypes of these patients, together with their primary 
endocrinological diagnoses, and the scores according to the checklist are reported in 
Table 19. 
 
ID Endocrinological phenotype Other symptoms Score 
18905640 Panhypopituitarism, pituitary 
dwarfism: scanty anterior 
pituitary tissue in small sella 
turcica, absent pituitary stalk 
Abnormal fusion of the humeral 
head and acromions bilaterally 
9 
4754 SOD, CPHD Severe DD, gastro-intestinal 
malformation, myelodysplastic 
syndrome, facial dysmorphic 
features 
8 
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4997 Growth deficiency, bilateral 
cryptorchidism 
Severe prematurity (born at week 
33 of gestation), DD, bilateral 
cleft lip and palate, bilateral 
epibulbar dermoids, right 
microphthalmia, micrognathia, 
multiple hemi and butterfly 
vertebrae, bilateral renal 
dysplasia, chronic renal failure, 
urethral multiplication, skin tags 
16 
5135 DI, central hypothyroidism, 
IUGR, post-natal growth 
deficiency 
DD, epilepsy, ToF, bilateral cleft 
lip and palate 
10 
5608 SOD, GHD, TSHD DD, ToF, bilateral aplasia of the 
retina and optic disc, hearing loss, 
facial dysmorphic features 
11 
5745 IGHD DD, ToF, midline defects, facial 
dysmorphic features 
10 
6089 Severe GHD with 
undetectable levels of IGF1, 
short stature <3rd percentile, 
bilateral cryptorchidism, 
anterior pituitary hypoplasia, 
EPP, absence of the rostrum 
of the corpus callosum 
Multiple skeletal malformations: 
hemi-vertebrae, fusion of the right 
VII and VIII ribs, radial 
shortening, short middle phalanx, 
clinodactyly, facial dysmorphic 
features, transient neonatal 
megakaryocytic thrombocytopenia 
9 
6110 Postnatal growth deficiency Perinatal asphyxia, DD, 
microcephaly, cortical dysplasia, 
seizures, bilateral 
blepharophimosis, microphthalmia 
and coloboma, renal dysplasia, 
thrombocytopenia 
12 
6168 Hypopituitarism, hypoplastic 
anterior pituitary gland, short 
stature 
DD, ToF, exomphalos 9 
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JD98 IGHD, hypoplastic anterior 
pituitary gland, short stature 
Moderate DD, hypoplasia of the 
optic chiasma and left optic nerve, 
retinal rod-cone dystrophy, atrial 
septal defect, leg asymmetry, mild 
facial asymmetry and dysmorphic 
features, white forelock, hyper- 
and hypopigmented skin patches 
12 
Table 19. Ten patients selected for high resolution genome-wide copy number 
change screening. The endocrinological diagnosis, associated symptoms, and relevant 
scores according to the checklist are reported. CPHD: Combined Pituitary Hormone 
Deficiency; DD: Developmental Delay; DI: Diabetes Insipidus; EPP: Ectopic Posterior 
Pituitary; GHD: Growth Hormone Deficiency; IGF1: Insulin-like Growth Factor 1; 
IGHD: Isolated Growth Hormone Deficiency; IUGR: Intrauterine Growth Retardation; 
SOD: Septo-Optic Dysplasia; ToF: Tetralogy of Fallot; TSHD: Thyroid-Stimulating 
Hormone Deficiency; ID: patient Identification number. Patient 6089 had karyotype: 
46,XY,del(11q24.2qter) dup(6q25.3qter)mat der. Patient 18905640 had karyotype: 
46,XY,t(11;22)(q24;q13). 
 
Patient 6089 was known to have an unbalanced karyotype comprising a partial terminal 
deletion of chromosome 11q. Because of the association between the chromosome 
anomaly and his complex phenotype, that included severe GHD and multiple anomalies 
of the pituitary gland’s anatomy, this patient was selected for the screening for further 
investigation. Moreover, the presence of a known chromosome imbalance constituted a 
positive control during the optimisation and validation of the CNAT 4.0 Batch Analysis 
Workflow for the Affymetrix GeneChip 250K Sty1 Mapping Array. 
Patient 4754 presented with an unique association of two severe and aetiologically 
unrelated pathologies, namely SOD and myelodysplastic syndrome (MDS), that had not 
been reported before in the literature, and that suggested the possibility of an underlying 
contiguous gene deletion/duplication syndrome. 
Four patients, 5135, 5608, 5745 and 6168, presented with the association between 
hypopituitarism and ToF. 
Three patients, 4997, 6110 and JD98, presented with complex phenotypes including 
growth defects, DD, eye pathology, and multiple congenital anomalies. 
Patient 18905640 suffered from panhypopituitarism associated with minor skeletal 
defects, without cognitive impairment. The demonstration of an apparently balanced 
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chromosome translocation during routine karyotyping identified this patient as a 
candidate to harbour a submicroscopic imbalance in a candidate genomic region for 
pathology of the pituitary gland. 
 
While the application of the checklist to the cohort of 179 patients with complex 
pituitary phenotypes was based on the preliminary information available in the 
database, for each one of the 10 patients eventually selected for the CNV screening, the 
standardised patient pro-forma designed for the project was filled in. Patients 5608, 
6089 and JD98 were seen in person by the author. For patient 5135, complete and 
detailed clinical notes were made available to the author, and for patient 18905640 the 
patient pro-forma was filled in by his physician according to the author’s instructions. 
For the other five patients, clinical information regarding each patient were made 
available to the author, however, the quantity and quality of the information varied with 
their source. 
 
The cohort of patients selected for CN change screening on 250K SNP array platform 
was restricted to the number of ten. This poses limitations to the extrapolation of data, 
as discussed in chapter 6.4. 
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4. RESULTS 
CNV Analysis 
 
Summary of results: 
 The 250K SNP array platform was utilised to perform genome-wide copy 
number change analysis in 10 patients with a complex clinical phenotype, 
including pathology of the pituitary gland; 
 An analytical workflow was drawn to screen the multiple CNVs detected in the 
cohort of patients, and CNVs were detected in all patients; 
 The presence of two pathogenic genomic imbalances, chromosome 6q terminal 
duplication and chromosome 11q terminal deletion, was confirmed in one 
patient, and the breakpoints were defined at high resolution; 
 An interstitial deletion of chromosome 22q was diagnosed in a patient with 
hypopituitarism and tetralogy of Fallot; 
 A submicroscopic rearrangement in the chromosome region 1p36.33 was found 
in a second patient with the association of hypopituitarism and tetralogy of 
Fallot; this CNV and three more genomic regions, affected by the presence of a 
CNV, were investigated as potential candidate regions for pathology in 
individual patients; 
 Further 359 individual CNVs were assessed in terms of gene content, overlap 
with published databases of structural variations in the human genome, and for 
gene expression in the pituitary gland. 
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4.1. 250K SNP Array to Perform 
Genome-wide Copy Number Change 
Analysis 
 
The Affymetrix GeneChip 250K Sty1 SNP mapping array contains probes for the 
detection of around 2.38×10
5
 SNPs. Their genome-wide distribution allows for a large-
scale genotype and copy number analysis. 
The GTYPE 4.1 plug-in CNAT 4.0 software package, provided by Affymetrix, for CN 
analysis and graphical visualisation was chosen for the analysis of copy number profiles 
of all 10 patients selected for the screening. The CN profiles were initially assessed by 
visual inspection of the log2 Ratio and CN State plots of each autosome and 
chromosome X. Subsequently, the results of the interrogation of each SNP (i.e. the 
extrapolated copy number status, and statistic significance of the analysis) were also 
exported from CNAT 4.0 into Microsoft Excel spreadsheets for numerical analysis. 
The whole genome profile of each one of the 10 patients was screened for regions with 
copy number smaller than 2, to indicate putative losses, and larger than 2, to indicate 
putative gains, applying the CNAT 4.0 batch analysis workflow with a genomic 
smoothing of 0.1 Mb (as detailed in paragraph 2.2.5.). 
 
 
 
4.2. Ethical Approval and Informed 
Consent 
 
The personal and clinical data of the patients included in the study are stored in 
compliance with the Data Protection Act 1998. The project has received full research 
ethical approval (revised in 2009). 
A signed assent/consent form was obtained from each patient (and/or their legal 
guardians) included in the study. All participants received a patient/parents information 
sheet, detailing the aim of the study and the use of the participants’ DNA sample to 
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study changes associated with the development and pathology of the pituitary gland. A 
copy of the information sheet is enclosed as Appendix B. 
 
 
 
4.3. Analytical Workflow for the 
Screening of Multiple CNVs 
 
The great majority of the CNVs found in the cohort of 10 patients were expected to 
represent genomic polymorphisms and not to be causative of the clinical phenotype 
presented by the patients under study. For the current project, a decisional workflow 
was designed by the author in order to filter the total of CNVs, and to identify the 
potentially pathogenic ones. The outline of the decisional process workflow is presented 
in Figure 6. 
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Figure 6. Workflow of the decisional process. The decisional process was divided into 
three phases: the width of the bases of each trapezium are approximately proportional to 
the number of CNVs that entered and exited each phase of the process; the height of 
each trapezium is approximately proportional to the timescale required by each one of 
the three phases the process was divided into. 
 
For the first phase of the screening process, a Microsoft Excel spreadsheet was created 
for each chromosome (all autosomes and chromosome X) with the CN profile, exported 
from CNAT 4.0, of all 10 patients. The CN profiles were manually compared across the 
 83 
whole cohort of 10 patients, and along the entire length of each chromosome, both 
visually and numerically, to identify CNVs shared by multiple patients. 
A CNV was defined as shared when it fulfilled the following two criteria: 
1) the percentage of overlap was equal or greater than 50% of the SNPs; 
2) it was found in 2 or more patients, with at least 2 patients presenting with 
diverse established clinical diagnosis and/or non-overlapping clinical 
phenotypes. 
When a CNV was present, in the same CN state, in only 2 patients with a degree of 
compatibility of their clinical phenotypes, the CNVs were further investigated in phase 
2 of the process. Equally, when only 2 patients with unrelated clinical phenotypes 
carried a CNV involving the same SNPs but present in different CN states, i.e. CN 1 in 
one patient and CN 3 or CN 4 in the other patient, the CNVs were further investigated 
in phase 2 of the process. 
Shared CNVs were considered not to be causative of the clinical phenotype in any 
individual patient, and were not investigated further. 
 
The software CNAT 4.0 is implemented with the UCSC genome browser, and this tool 
was utilised in phase 2 of the process to assess the gene content of all unique CNVs. To 
this aim, the numerical output from Microsoft Excel spreadsheets was manually 
uploaded to UCSC genome browser to examine each CNV. 
Although the absence of gene content within a CNV does not define a CNV as a benign 
(polymorphic) variant in the human population, the decision was made to utilise the 
criteria of presence versus absence of gene content within a CNV in the proposed 
decisional workflow. This decision was coherent with the selection of a cohort of 
patients with complex clinical phenotypes to undergo genome-wide CN screening, as 
such complex phenotypes, affecting the development of multiple organs, might reflect 
an underlying contiguous gene microdeletion/microduplication syndrome. The latter 
would be characterised by the dosage imbalance of two or more genes, including one 
relevant to the pituitary phenotype. 
It is acknowledged that the rationale behind the criteria of phase 2 of the decisional 
workflow, however, poses a limitation to the identification of disruption of regulatory 
sequences and/or transcription units, which could lead to a pathological phenotype. 
 
In phase 3 of the decisional process, each unique CNV was assessed in terms of overlap 
with published databases of genomic structural variations, and each known gene within 
 84 
unique CNV was assessed in terms of gene function, gene pathways, protein domain/s, 
existing link to disease loci, known mutations, and gene expression in the pituitary 
gland. 
 
 
 
4.4. SNP Genotype Call Rates 
 
The first step in the screening with Affymetrix GeneChip 250K Sty1 SNP Mapping 
Array was the evaluation of the SNP genotype call rates, from the .DAT or .CEL file, 
performed by GTYPE 4.1. The overall performance of the assay is determined by the 
SNP call rate. The percentages of SNP call rate for all 10 patients included in the study 
are reported in Table 20; the mean value was 95.78%. Patient 6110 had a SNP call rate 
of 94.97%, considered to be not significantly different from the optimal cut-off of 95%. 
Patient 5745 had a SNP call rate of 90.55%, below the average, that was attributed to a 
less good quality of the DNA sample. This value is above the acceptable threshold of 
85% and potential ‘no calls’ in regions of interest were taken into account during the 
analysis. 
 
Patient ID SNP Call Rate % 
6089 97.02 
18905640 96.70 
JD98 97.46 
5608 96.58 
5135 96.07 
4754 95.10 
5745 90.55 
6110 94.97 
4997 96.55 
6168 96.84 
Table 20. SNP call rates. Percentage of SNP Call Rate for each one of the 10 patients 
studied with the Affymetrix GeneChip 250K Sty1 Mapping Array. 
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4.5. Detection of Multiple CNVs 
 
The whole genome CN profile of each one of the 10 patients was initially assessed by 
visual inspection of the log2 Ratio and CN State plots of each chromosome. 
Subsequently, the CNAT 4.0 output for all SNPs of each autosome and chromosome X 
of each patient were exported to Microsoft Excel spreadsheets, and numerical analysis 
of the SNP CN state was performed. Tracks of CN profiles were also generated in 
CNAT 4.0 and exported to UCSC genome browser for purposes of visualisation and 
analysis. 
A CNV was identified when at least two consecutive SNPs were present in CN state 
different from 2, applying the CNAT 4.0 batch analysis workflow with a genomic 
smoothing of 0.1 Mb (as detailed in paragraph 2.2.5.). The boundaries of the CNV were 
arbitrarily defined by the first and last SNP present in CN different from 2, with the aim 
of increasing specificity. However, it is acknowledged that the exclusion of the genomic 
regions lying between each boundary of the CNV, as defined, and the first neighbouring 
SNP in CN 2 decreased sensitivity and potentially led to loss of information. This 
limitation was taken into consideration during the analysis, and overcome by a revision 
of the CNV breakpoints when necessary. 
 
A total of 3857 CNVs were found, involving all autosomes and chromosome X, and in 
all the patients. 
 
 
4.5.1. Distribution of CNVs per Patient 
 
CNVs were found in all patients, with a great variability in the number of CNVs per 
patient: the mean value was 386, with a SD of 133 (approximation of both mean and SD 
is to the nearest unity), while the range was [186 - 611]. No genomic regions in CN 
state equal to 0 (putative homozygous deletion) were detected in any of the 10 patients. 
The ratio of 2608 genomic gains, incorporating CN 3 and CN 4, to 1249 genomic 
losses, CN 1, was ~2:1. The breakdown of the number of different types of CNVs per 
patient is shown in Figure 7. 
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Figure 7. Distribution of CNVs per patient. Breakdown of the number of different 
types of CNVs in each one of the 10 patients in the cohort under study. CN: Copy 
Number. 
 
 
4.5.2. Distribution of CNVs per Chromosome 
 
CNVs were found in all chromosomes. Figure 8 represents the breakdown of different 
types of CNVs per each chromosome in the total of 10 patients. The mean value of 
CNVs per chromosome was 168 (SD = 130; approximation of both measurements to the 
nearest unity), while the range was [19 - 547]. The mean value of CNVs in CN 1 per 
chromosome was 54 versus 113 CNVs in CN 3 plus CN 4 per chromosome. 
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Figure 8. Distribution of CNVs per chromosome. Visual and numerical representation 
of the breakdown of the different types of CNVs per chromosome in the whole cohort 
of 10 patients. CN: Copy Number. 
 
 
 
4.6. Distribution of Unique CNVs per 
Patient 
 
The comparative analysis of the CN profiles across the whole cohort of 10 patients 
revealed that 3289 CNVs were shared (as defined in chapter 4.3.), and that only 568 
(~15%), of the 3857 CNVs originally found in all autosomes and chromosome X, were 
unique to one patient. All unique CNVs were entered into phase 2 of the screening 
process, as potentially pathogenic genomic imbalances for that patient. 
No genomic regions in CN state equal to 4 were detected in one patient only. The 568 
unique CNVs showed a 1.2:1 ratio (approximated to one decimal place) of 306 genomic 
gains (CN 3) to 262 genomic losses (CN 1). The ratio demonstrated a relative increase 
in the number of genomic losses to genomic gains amongst the unique CNVs, when 
compared to the results (ratio ~2:1) calculated on the total number of CNVs. 
Unique CNVs were found in all patients, with a mean value of 57 with a SD of 33 
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(approximation of both mean and SD is to the nearest unity). The range of variability in 
the number of unique CNVs per patient, [24 - 129], was smaller than what observed in 
the overall number of CNVs. The detailed breakdown of the number of different types 
of unique CNVs per patient is shown in Figure 9. 
 
 
Figure 9. Number of unique CNVs per patient. Breakdown of the number of different 
types of unique CNVs for each one of the 10 patients in the cohort under study. CN: 
Copy Number. 
 
Assessing the gene content of each unique CNV revealed that 202 unique CNVs did not 
contain any gene, while 366 (~64%), of the 568 unique CNVs originally found in all 
autosomes and chromosome X, contained at least one known gene. The 366 unique 
CNVs with a gene content showed a 1:1 ratio of 187 genomic gains (CN 3) to 179 
genomic losses (CN 1). The ratio demonstrated a relative increase in the number of 
genomic losses to genomic gains amongst the unique CNVs containing at least one 
gene, when compared to the results (ratio 1.2:1 approximated to one decimal place) 
calculated on all unique CNVs. 
Six categories were arbitrarily created to represent the distribution of the unique CNVs 
according to gene content: 0, 1, 2, 3, 4, 5 or more. The distribution of unique CNVs in 
gene content categories per CN state is presented in Figure 10. 
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Figure 10. Distribution of unique CNVs in number of genes categories. The numbers 
of unique CNVs in CN state 1 and unique CNVs in CN state 3 belonging to each 
number of genes category are shown. CN: Copy Number. 
 
Unique CNVs with gene content were found in all patients with a range of [12 - 92]. 
The numerical breakdown of the different types of unique CNVs with gene content per 
patient is shown in Figure 11. 
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Figure 11. Number of unique CNVs with gene content per patient. Breakdown of the 
numbers of the two different types of unique CNVs, CN 1 and CN 3, containing at least 
one gene, for each one of the 10 patients in the cohort under study. CN: Copy Number. 
 
 
 
4.7. Pathogenic Chromosome 
Imbalances 
 
Pathogenic copy number changes were first identified by visual inspection of the log2 
Ratio and CN State plots produced by CNAT 4.0. The DNA sample of patient 6089, 
who was known to harbour a complex chromosome rearrangement, was also utilised as 
a positive control to validate the CNAT 4.0 Batch Analysis parameters. The presence of 
two genomic imbalances was confirmed in patient 6089, and a further pathogenic 
chromosome interstitial deletion was diagnosed in patient 5135. The genomic 
imbalances harboured by the two patients underlie known contiguous gene deletion 
syndromes. 
The breakpoints of the pathogenic genomic imbalances were refined by rerunning the 
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CNAT 4.0 batch analysis without genomic smoothing (GS = 0 Mb), and exporting the 
CNAT 4.0 output to Microsoft Excel spreadsheets for numerical analysis of the log2 
Ratio and CN State of SNPs within and flanking the detected region of copy number 
change. 
 
 
4.7.1. Chromosome 6q Terminal Duplication and 
Chromosome 11q Terminal Deletion 
 
In patient 6089, the presence of both the partial terminal duplication of chromosome 6q 
and the partial terminal deletion of chromosome 11q was confirmed. The graphical 
output of CNAT 4.0 demonstrating the 6q duplication and the 11q deletion is shown in 
Figure 12 and Figure 13, respectively. 
 
 
Figure 12. Chromosome 6q duplication in patient 6089. Graphical output of CNAT 
4.0, from top to bottom log2 Ratio plot and Copy Number State plot of chromosome 6 
of patient 6089, demonstrating the presence of a terminal duplication of the long arm of 
chromosome 6 (arrows). 
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Figure 13. Chromosome 11q deletion in patient 6089. Graphical output of CNAT 4.0, 
from top to bottom log2 Ratio plot and Copy Number State plot of chromosome 11 of 
patient 6089, demonstrating the presence of a terminal deletion of the long arm of 
chromosome 11 (arrows). 
 
The breakpoints of the two genomic imbalances were finely mapped within 29 kb and 
26 kb intervals on chromosome 6q and chromosome 11q, respectively, as shown in 
Table 21. The size of both the 6q duplication and the 11q deletion was ~10 Mb. 
 
Chromosome 
locus 
Breakpoint SNP Physical 
position 
CN 
6q25.3 Terminal duplication SNP_A-1951614 160,562,518 2 
SNP_A-1904727 160,591,490 3 
11q24.2 Terminal deletion SNP_A-2022234 124,370,133 2 
SNP_A-2275217 124,396,305 1 
Table 21. Breakpoints of the genomic imbalances in patient 6089. CN: Copy 
Number. 
 
According to clinical reports published in the literature of cases of trisomy 6q 
overlapping with the region duplicated in patient 6089, the terminal duplication of the 
long arm of chromosome 6 was deemed accountable for the skeletal malformations 
found in patient 6089. [217-219] 
The partial deletion of the long arm of chromosome 11 is a clinically recognised 
syndrome characterised by DD, transient megakaryocytic thrombocytopenia (Paris-
Trousseau syndrome), growth deficiency with length or height below the 5th percentile, 
cryptorchidism, congenital malformations and facial dysmorphic features. [220] 
 93 
Clinical information on 108 Italian patients with del11q syndrome became available 
during the course of the project, [Mattina, personal communication; data not presented 
in this study] and upon revision we identified at least 14 patients who showed signs of 
pituitary function impairment (e.g. severe growth deficiency, lack of spontaneous 
pubertal development), supporting the existence of a novel gene involved in the 
pathology of the pituitary gland in patient 6089, and in del11q syndrome. 
 
 
4.7.2. Chromosome 22q11.21 Interstitial Deletion 
 
The screening with the Affymetrix GeneChip 250K Sty1 SNP Mapping Array revealed 
the presence of an interstitial deletion of chromosome 22q in patient 5135, as shown in 
Figure 14; the patient’s karyotype was defined as 46,XY,del(22)(q11.21q11.21). 
 
 
Figure 14. Chromosome 22q deletion in patient 5135. Graphical output of CNAT 4.0, 
from top to bottom log2 Ratio plot and Copy Number State plot of chromosome 22 of 
patient 5135, demonstrating the presence of an interstitial deletion of chromosome 22q 
(arrows). 
 
The breakpoints of the genomic imbalance were refined by repeating the CN analysis 
with GS equal to 0 Mb, the telomeric breakpoint was finely mapped within a 42 kb 
interval, the centromeric breakpoint fell within a larger interval, between the two 
defining SNPs, of 258 kb, as shown in Table 22. The size of the deletion was 3 Mb. 
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Chromosome locus Breakpoint SNP Physical position CN 
22q11.21 Centromeric SNP_A-2200145 17,012,376 2 
SNP_A-4283311 17,270,967 1 
22q11.21 Telomeric SNP_A-2185542 20,303,319 1 
SNP_A-4277437 20,345,144 2 
Table 22. Breakpoints of the chromosome 22q11 interstitial deletion in patient 
5135. CN: Copy Number. 
 
The breakpoints coincided with the two 22-specific low-copy repeats (LCR22s) that 
flank and facilitate the recurrence of the ~3 Mb microdeletion of 22q11.2. More than 
85% of individuals with deletions in the 22q11.2 chromosome region carry the same ~3 
Mb imbalance, that also overlapped the deletion in patient 5135. The presence of the 
interstitial deletion of chromosome 22q11.2 was independently confirmed by FISH with 
locus specific probe, and the karyotype of the patient was reported as: 46,XY.ish 
del(22)(q11.2q11.2)(D22S75-). 
The patient’s medical history and phenotype were reviewed by the author after the 
identification of the chromosome imbalance. Patient 5135 was born from non-
consanguineous parents, at term with a low birth weight of 2.2 kg. At the age of 1 
month, upon detection of severe hypernatremia, the diagnosis of central DI was made. 
The patient also suffered from central hypothyroidism, post-natal growth deficiency, 
DD, epilepsy, and presented with ToF, bilateral cleft lip and palate, absent thymus, 
small umbilical hernia, and facial dysmorphic features. At the age of 6 1/2 months, all 
auxological parameters, length, weight and head circumference, were below the 0.4th 
percentile. An MRI of the brain showed plagiocephaly, but no intracranial structural 
malformations and midline defects, nor anomalies of the anatomy of the pituitary gland. 
The patient successfully underwent surgery to repair his CHD, he developed recurrent 
respiratory infections, but his immunological profile showed that all values were within 
the normal ranges. Overall, the clinical phenotype of the patient was compatible with 
the diagnosis of del22q11.21 syndrome. 
The association of 22q11.21 deletion syndrome and DI has never been reported in the 
literature. The deletion detected in our patient (including the 258 kb wide centromeric 
breakpoint interval) contained 42 characterised genes, but none of them had a known 
involvement in the pathology or development of the posterior or anterior pituitary gland. 
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Nine different chromosome loci associated with central DI have been mapped to seven 
different chromosomes. They include the locus, on chromosome 20p13, of isolated 
neurohypophyseal diabetes insipidus, as well as eight more loci of diseases that can 
present with central DI. The list of all known genomic loci associated with central DI is 
presented in Table 23. All nine loci were investigated for CN changes in patient 5135, 
but no CNVs were detected. 
 
OMIM 
number 
Associated disease Genomic 
locus 
#136760 Frontonasal Dysplasia 1; FND1 Frontonasal Dysplasia, 
included; FND, included 
1p21-p13 
#157170 Holoprosencephaly 2; HPE2 2p21 
#182230 Septooptic Dysplasia Pituitary Hormone Deficiency, 
Combined, 5, included; CPHD5, included 
3p21.2-
p21.1 
#604292 Ectrodactyly, Ectodermal Dysplasia, and Cleft Lip/Palate 
Syndrome 3; EEC3 
3q27 
#222300 Wolfram Syndrome 1; WFS1 Wolfram-Like Syndrome, 
Autosomal Dominant, included 
4p16.1 
#604928 Wolfram Syndrome 2; WFS2 4q22-q24 
%129900 Ectrodactyly, Ectodermal Dysplasia, and Cleft Lip/Palate 
Syndrome 1; EEC1 
7q11.2-
q21.3 
#611087 Polyhydramnios, Megalencephaly, and Symptomatic 
Epilepsy; PMSE 
17q23.3 
#125700 Diabetes Insipidus, Neurohypophyseal 20p13 
Table 23. List of known genomic loci of central DI. The associated diseases and the 
relevant OMIM (Online Mendelian Inheritance in Man) numbers are also shown. 
 
 
 
4.8. Potentially Pathogenic CNVs 
 
Four more submicroscopic rearrangements were found in 3 patients, that were 
investigated as potentially having a disease-causing role in relation to the phenotype of 
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each patient. The CNVs were assessed by visual inspection of the log2 Ratio and CN 
State plots, and by numerical analysis of the SNP CN profiles exported into Microsoft 
Excel spreadsheets. 
The limited size of the cohort of 10 patients and especially the absence of a cohort of 
controls have potentially posed limitations to the extrapolation and inference of data 
regarding the pathogenic versus polymorphic nature of CNVs detected by the screening, 
as also discussed in chapter 6.4. 
 
 
4.8.1. Chromosome 22q12.3 Interstitial Deletion 
 
Screening the whole genome profile of patient 18905640 for regions with smoothed 
copy number different from 2, applying the CNAT 4.0 batch analysis workflow with a 
genomic smoothing of 0.1 Mb, did not reveal any clearly pathogenic genomic 
imbalance by visual inspection of the log2 Ratio and CN State plots of each autosome 
and chromosome X. A total of 15 unique CNVs with gene content in CN 1 and a total of 
12 unique CNVs with gene content in CN 3 were identified. 
The patient was known to carry an apparently balanced chromosome translocation 
between chromosomes 11 and 22, defined, at low resolution routine karyotyping, as 
46,XY,t(11;22)(q24;q13). One of the unique CNVs with gene content present in CN 
state 1 was located inside the chromosome band 22q12.3, compatible with the 
cytogenetic definition of the patient’s translocation breakpoint at low resolution. CNAT 
4.0 batch analysis with GS = 0 Mb was run, targeted to the genomic regions tentatively 
identified cytogenetically as the translocation breakpoints. The CN profiles were 
exported from CNAT 4.0 both to UCSC genome browser, for the purpose of 
visualisation, and to Microsoft Excel spreadsheets to allow the numerical analysis of the 
log2 Ratio and CN State of the SNPs covering the chromosome regions of interest. 
The breakpoints of the CNV in CN state 1 identified in the chromosome region 22q12.3 
were refined as shown in Table 24. The genomic imbalance had a size of 352 kb, 
including both the centromeric and the telomeric first flanking SNP in CN state 2. The 
centromeric and telomeric breakpoints were finely mapped within 21 kb and 3 kb 
intervals, respectively. Both breakpoints fell inside a coding gene. The CN profile of 
chromosomes 22q12.3 was exported to the UCSC genome browser as shown in Figure 
15. 
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Chromosome locus Breakpoint SNP Physical position CN 
22q12.3 Centromeric SNP_A-2131773 35,050,725 2 
SNP_A-2102323 35,071,686 1 
22q12.3 Telomeric SNP_A-2301610 35,399,975 1 
SNP_A-1892611 35,403,134 2 
Table 24. Breakpoints of the chromosome 22q12.3 deletion in patient 18905640. 
CN: Copy Number. 
 
 
Figure 15. Chromosome region 22q12.3 of patient 18905640 in UCSC genome 
browser. Visualisation in UCSC genome browser of a custom track corresponding to 
the CN profile of chromosome region 22q12.3 of patient 18905640 exported from 
CNAT 4.0. The CNAT 4.0 batch analysis was run with GS = 0 Mb. From top to bottom: 
CNAT 4.0 CNState profile track, chromosome band localisation, overlapping genomic 
imbalances associated with a pathological phenotype in human entered in the database 
DECIPHER, OMIM loci, UCSC genes, tissue expression data according to GNF Gene 
Expression Atlas 2, overlapping genomic structural variants detected in healthy 
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individuals entered in the database of genomic variants (DGV). The two full (orange) 
bars at the extremities of the CNAT 4.0 CNState profile track represent the SNPs in CN 
state 2 flanking the genomic deletion, the half (orange) bars represent each SNP present 
in CN 1 inside the deletion. DECIPHER entry coloured green represents a duplication. 
OMIM-associated gene loci are represented by blue bars, OMIM-associated morbid loci 
are represented by red bars. The GNF Expression Atlas 2 data on seventy-nine human 
tissues are grouped by tissue median in eight arbitrary categories: a green bar indicates 
under-expression, a red bar indicates over-expression. The DGV entry coloured blue 
represents a genomic loss, the DGV entry coloured red represents a genomic gain, the 
DGV entry coloured green represents the presence of both genomic loss and genomic 
gain. 
 
The genomic deletion, as present in patient 18905640, did not appear in the DGV, that 
catalogues documented structural variations and genomic polymorphisms in healthy 
individuals, and is interfaced with UCSC. However, it partly overlapped large genomic 
structural variants reported in the DGV. DECIPHER is an online database of 
(submicroscopic) chromosomal imbalances and clinical phenotypes in humans. [221] 
The entry corresponding to a chromosome imbalance overlapping the 22q12.3 deletion 
found in patient 18905640 referred to a male individual with agenesis or hypoplasia of 
the corpus callosum, cleft palate and midline cleft upper lip, hypospadias, small penis 
and VSD. However, the chromosome imbalance was a duplication, with a size of ~18 
Mb, spanning from chromosome band 22q12.3 to 22q13.33. 
The 22q12.3 deletion in patient 18905640 contained 5 characterised genes that are listed 
in Table 25, together with notes on their putative function, and expression in the 
pituitary gland. 
 
Symbol Name Function Expression 
TXN2 Thioredoxin 2 Nuclear gene that encodes 
mitochondrial redox-active protein, 
may play a role in the regulation of 
mitochondrial membrane potential and 
against oxidant-induced apoptosis 
- 
FOXRED2 FAD-dependent 
oxidoreductase 2 
Contains FAD-dependent 
oxidoreductase domain 
+ 
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EIF3D Eukaryotic 
translation initiation 
factor 3, subunit D 
Part of multiprotein complex that binds 
to the 40S ribosome, helps maintain the 
40S and 60S subunits in a dissociated 
state, and promotes the binding of 
methionyl-tRNAi and mRNA 
- 
CACNG2 Calcium channel, 
voltage-dependent, 
gamma-2 
Thought to stabilize the calcium 
channel in an inactive (closed) state 
++ 
MYH9 Myosin heavy chain 
9 
Involved in cytokinesis, cell motility, 
and maintenance of cell shape 
- 
Table 25. Genes located inside the 352 kb genomic deletion (22q12.3) of patient 
18905640. The expression in the pituitary gland is according to GNF Gene Expression 
Atlas 2; -: ratio <1, +: ratio slightly >1, ++: ratio moderately >1. FAD: Flavin Adenine 
Dinucleotide. 
 
CACNG2. The telomeric breakpoint of the deletion, mapped within a 3 kb interval, fell 
inside the gene CACNG2. It has been observed that the phosphorylation of threonine 
(Thr)-321 of the CACNG2 protein impairs its interaction with the genes discs large, 
drosophila, homolog of, 1 (DLG1) and DLG4; DLG1 gene is deleted in the 3q29 
microdeletion syndrome and is an autosomal homologue of an X-linked mental 
retardation gene, DLG3. [222] At the age of 21 years, patient 18905640 did not show 
any sign of cognitive impairment. [Yang, personal communication] 
 
MYH9. Defects in MYH9 have been found to underlie a large group of autosomal 
dominant allelic disorders that include: May-Hegglin anomaly (MHA), i.e. 
macrothrombocytopenia and leukocyte inclusions; Sebastian syndrome, characterised 
by macrothrombocytopenia and leukocyte inclusions different from MHA; Epstein 
syndrome, characterised by macrothrombocytopathy, sensorineural hearing loss and 
nephritis; Fechtner syndrome, that presents with the association of 
macrothrombocytopenia, leukocyte inclusions and Alport-like clinical features, i.e. 
sensorineural deafness, cataracts and nephritis; macrothrombocytopenia and progressive 
sensorineural hearing loss; Alport syndrome (i.e. ocular lesions, sensorineural hearing 
loss and nephritis) with macrothrombocytopenia; non-syndromic sensorineural deafness 
type 17, characterised by progressive hearing impairment and cochleosaccular 
degeneration. [223, 224] Individuals with mutations in the motor domain of MYH9 
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presented with severe thrombocytopenia and developed nephritis and deafness before 
the age of 40 years, while individuals with mutations in the tail domain had a much 
lower risk of non-congenital complications and significantly higher platelet counts. A 
genotype-phenotype correlation was established evaluating mutations in the four most 
frequently affected residues of MYH9 (70% of cases): mutations at residue 1933 did not 
induce kidney damage or cataracts and caused deafness only in the elderly, those in 
position 702 resulted in severe thrombocytopenia and produced nephritis and deafness 
at a juvenile age, while alterations at residue 1424 or 1841 resulted in intermediate 
clinical phenotypes. [224] The symptoms caused by mutations of MYH9 have age-
dependant penetrance and variable expression. 
The centromeric breakpoint of the 22q12.3 deletion in patient 18905640, mapped within 
a 21 kb interval, fell inside the MYH9 gene; the deletion involved only the terminal 42 
kb of MYH9, while two copies of most of its exons were preserved. A full blood count 
of patient 18905640, performed at the age of 19 years, only showed normocytic 
anaemia, and the patient did not show clinical signs of hearing impairment at the age of 
21 years. 
 
Overall, a causative relationship between the 352 kb deletion of chromosome region 
22q12.3 and the hypopituitarism with anomalies of the anatomy of the pituitary gland in 
patient 18905640 could not be established. However, it remains possible that the 
deletion in the chromosome region 22q12.3 represents a loss of genomic material at the 
level of the translocation breakpoint. 
 
 
4.8.2. Chromosome Region 11q24.2 Imbalance and 
KIRREL3 Gene 
 
Patient 18905640 had a severe pituitary phenotype overlapping with the one presented 
by patient 6089 with del11q syndrome. It was, therefore, hypothesised that the 
breakpoint of the translocation, carried by patient 18905640, in the genomic region 
11q24 could affect a novel gene involved in the development and pathology of the 
pituitary gland, also underlying the pathogenesis of the hypopituitarism in del11q 
syndrome. 
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The ~10 Mb genomic region present in CN 1 in patient 6089 was screened for 
submicroscopic CN changes, potentially associated with the translocation breakpoint, in 
patient 18905640, by running the CNAT 4.0 batch analysis with GS = 0 Mb. Only one 
unique CNV with gene content was detected. The CNV was located in the chromosome 
region 11q24.2 and had an overall size of 52 kb, including both the centromeric and the 
telomeric first flanking SNP in CN state 2. Within the genomic imbalance, both a small 
deletion and a small duplication were present. The CNAT 4.0 batch analysis with GS = 
0 Mb allowed to precisely define the breakpoints, as shown in Table 26. 
 
Chromosome locus Breakpoint SNP Physical position CN 
11q24.2 Centromeric SNP_A-4302114 126,187,928 2 
SNP_A-4251263 126,191,973 1 
11q24.2 Telomeric SNP_A-2205137 126,233,398 3 
SNP_A-4295359 126,240,403 2 
Table 26. Breakpoints of the chromosome 11q24.2 rearrangement in patient 
18905640. The breakpoints were defined by numerical analysis of the SNP log2 Ratio 
and CN State by exporting the CNAT 4.0 output to a Microsoft Excel spreadsheet. CN: 
Copy Number. 
 
The centromeric and telomeric breakpoints were finely mapped within 4 kb and 7 kb 
intervals, respectively. Both breakpoints fell inside a coding gene, kin of IRRE-like 3 
(KIRREL3), that was the only gene involved in the 52 kb submicroscopic chromosome 
rearrangement. The CN profile of chromosomes 11q24.2 was exported to UCSC 
genome browser, as shown in Figure 16. 
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Figure 16. Chromosome region 11q24.2 of patient 18905640 in UCSC genome 
browser. Visualisation in UCSC genome browser of a custom track corresponding to 
the CN profile of chromosome region 11q24.2 of patient 18905640 exported from 
CNAT 4.0. The CNAT 4.0 batch analysis was run with GS = 0 Mb. From top to bottom: 
CNAT 4.0 CNState profile track, chromosome band localisation, overlapping genomic 
imbalances associated with a pathological phenotype in human entered in the database 
DECIPHER, OMIM loci, UCSC genes, overlapping genomic structural variants 
detected in healthy individuals entered in the database DGV. The two (orange) bars at 
the extremities of the CNAT 4.0 CNState profile track represent the SNPs in CN state 2 
flanking the genomic imbalance, the half-height (orange) bars represent each SNP 
present in CN 1 (genomic deletion) and the 1.5-height (orange) bars represent each SNP 
present in CN 3 (genomic duplication) inside the submicroscopic chromosome 
rearrangement. DECIPHER entries coloured green represent a duplication, DECIPHER 
entries coloured red represent a deletion. OMIM-associated gene locus is represented by 
a blue bar, OMIM-associated morbid locus is represented by a red bar. No tissue 
expression data were available from GNF Gene Expression Atlas 2. The DGV entry 
coloured blue represents a genomic loss. 
 
There was no significant overlap between the genomic imbalance detected in patient 
18905640 and entries in the DGV. The four entries into the DECIPHER database, 
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corresponding to chromosome imbalances overlapping the rearrangement found in 
patient 18905640, referred to patients with very complex clinical phenotypes, with 
genomic imbalances ranging in size between 11 Mb and 27 Mb, and whose 
endocrinological phenotype was not known. 
The submicroscopic chromosome rearrangement affected only the gene KIRREL3. 
KIRREL3 is 576 kb in size, located between genomic positions 125,799,613 and 
126,375,976, and contains 16 coding exons. The submicroscopic chromosome 
rearrangement and imbalance, present in patient 18905640, caused the loss of one copy 
of 5-9 kb and the gain of one copy of 35-42 kb within the last intron of the gene, as 
detailed in Table 27. 
 
Chromosome locus SNP Physical position CN 
11q24.2 SNP_A-4302114 126,187,928 2 
SNP_A-4251263 126,191,973 1 
11q24.2 SNP_A-2074406 126,197,407 1 
SNP_A-2087740 126,198,020 3 
11q24.2 SNP_A-2205137 126,233,398 3 
SNP_A-4295359 126,240,403 2 
Table 27. CN profile of the 52 kb genomic rearrangement in 11q24.2 of patient 
18905640. Results of the numerical analysis of the SNP log2 Ratio and CN State by 
exporting the CNAT 4.0 output with GS = 0 Mb to a Microsoft Excel spreadsheet. The 
52 kb genomic imbalance consists of both a genomic deletion (CN 1) and duplication 
(CN 3). CN: Copy Number. 
 
KIRREL3 is located ~1.7 Mb centromeric to the gene friend leukemia virus integration 1 
(FLI1), located in the chromosome region 11q24.3, identified as the candidate gene for 
the pathogenesis of Paris-Trousseau syndrome in 11q deletion syndrome. KIRREL3 is a 
member of the nephrin-like protein family, which includes also KIRREL and KIRREL2. 
It encodes for a single-pass cell membrane protein. The cytoplasmic domains of these 
proteins interact with the C-terminus of podocin, and the genes are expressed in the 
kidney and specifically in podocytes of kidney glomeruli. Therefore, it has been 
hypothesised that KIRREL3 could be involved in the hematopoietic supportive capacity 
of stroma cells. [225] 
The genes KIRREL and KIRREL2 have not been associated with human pathology, 
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while heterozygous missense mutations of KIRREL3 have been found to be responsible 
of autosomal dominant mental retardation 4 (MRD4). Amongst the mutations, an amino 
acid substitution in a highly conserved residue within the cytoplasmic domain of the 
protein, caused by a mutation in exon 16 of the gene, was identified in a female patient 
with mild MR. [226] The clinical phenotype of patients with point mutations of 
KIRREL3 seemed to consist of MR only, varying in degrees from mild to severe. 
 
The detection of both a genomic deletion (CN 1) and duplication (CN 3) within the 52 
kb genomic imbalance of chromosome 11q24.2 in patient 18905640 can be regarded as 
suggestive of the presence of a submicroscopic rearrangement of genomic material at 
the level of the chromosome translocation breakpoint. The 52 kb imbalance corresponds 
to a submicroscopic rearrangement affecting the last intron of KIRREL3. At the age of 
21 years, patient 18905640 did not show any sign of cognitive impairment. However, 
genomic sequencing of KIRREL3 in a large cohort of patients with isolated 
hypopituitarism and/or hypopituitarism associated with DD would have been necessary 
to clarify the potential contribution of KIRREL3 to the pathology of the pituitary gland 
manifested by patient 18905640, as well as in 11q deletion syndrome, as discussed in 
paragraph 6.1.1. 
 
 
4.8.3. Chromosome 1p36.33 Deletion 
 
Patient 5608 presented with SOD, CPHD (GH, TSH and ACTH deficiency) and 
precocious puberty, associated with ToF. Other symptoms included: mild DD, 
hypotonia, bilateral aplasia of the optic disc and of the retina with severe visual 
impairment, hearing impairment, mild facial asymmetry and facial dysmorphic features. 
The CN change screening with Affymetrix GeneChip 250K Sty1 SNP Mapping Array 
with GS = 0.1 Mb identified a subtelomeric interstitial deletion of chromosome 
1p36.33. The telomeric and centromeric breakpoints of the genomic imbalance were 
mapped by numerical analysis of the SNP log2 Ratio and CN State by running the 
CNAT 4.0 batch analysis with GS = 0 Mb, and exporting the output to a Microsoft 
Excel spreadsheet; the results are shown in Table 28. 
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Chromosome locus Breakpoint SNP Physical position CN 
1p36.33 Telomeric SNP_A-2118217 1,355,433 2 
SNP_A-1866065 1,468,016 1 
1p36.33 Centromeric SNP_A-1799863 1,878,229 1 
SNP_A-1908463 2,017,761 2 
Table 28. Breakpoints of the chromosome 1p36.33 deletion in patient 5608. CN: 
Copy Number. 
 
The telomeric and centromeric breakpoints fell within 112 kb and 139 kb intervals, 
respectively, while the size of the genomic deletion was 662 kb, including both the 
telomeric and the centromeric first flanking SNP in CN state 2. Because of the relatively 
large size of both, telomeric and centromeric, breakpoint intervals, a conservative 
approach was chosen: only SNPs in CN state 1 were taken into consideration for the 
purpose of mapping and defining the genomic deletion for further study. The deletion 
was, therefore, mapped between genomic physical positions 1,468,016-1,878,229, and 
the size of the deletion was 410 kb. 
 
The 410 kb submicroscopic chromosome deletion detected in patient 5608 was not 
present in any other patient in the cohort under study, while it partly overlapped with 
the genomic imbalance that underlies the clinically recognised 1p36 microdeletion 
syndrome. Monosomy 1p36 deletion syndrome results from a heterozygous deletion of 
the most distal chromosomal band on 1p, and it is the most common terminal deletion in 
humans, with an estimated incidence of ~1/5000 births. [227] The clinical phenotype is 
characterised by DD, hypotonia, seizures, micro- and brachycephaly, growth deficiency, 
CHD, ophthalmologic findings, hearing loss and distinct facial dysmorphic features. 
[228-231] A detailed comparison between the complex clinical phenotype of patient 
5608 and the most common symptoms of 1p36 deletion syndrome is shown in Table 29. 
 
1p36 deletion syndrome (%) Patient 5608 
DD  100 + 
Behavioural disorders 47 - 
Microcephaly 65 - 
Brachycephaly 65 + 
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Large anterior 
fontanel/delayed closure 
of anterior fontanel 
77 n.d. 
Seizures 44-72 - 
CNS structural defects 
(e.g. cerebral atrophy, 
polymicrogyria, ACC) 
88 SOD 
Hypotonia 87-100 + 
Growth retardation n.d. + 
Hypothyroidism (with 
elevated TSH) 
20 central 
Hearing loss (mainly 
sensorineural) 
82 + 
Visual impairment 
(hypermetropia/myopia) 
52-67 + 
Visual inattentiveness 64 + 
Cleft lip/palate, bifid 
uvula 
17 + 
CHD 66-71 + 
Urogenital anomalies 
(e.g. cryptorchidism, 
hypospadias) 
25-26 - 
Camptodactyly n.d. + 
Clinodactyly of the V 
finger 
n.d. + 
Facial dysmorphic 
features: 
prominent forehead n.d. - 
deep-set eyes 100 + 
asymmetric ears n.d. + 
posteriorly rotated/low-set 
ears 
40 + 
flat nasal bridge 100 + 
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midface hypoplasia 100 + 
long philtrum 100 + 
pointed chin 100 - 
Table 29. Comparison between the clinical symptoms of patient 5608 and 1p36 
deletion syndrome. The frequency given to each symptom of 1p36 deletion syndrome 
(expressed as percentage of patients displaying the symptom) was obtained by pooling 
the results of multiple screenings. [228-231] ACC: Agenesis of Corpus Callosum; 
CHD: Congenital Heart Defect; CNS: Central Nervous System; DD: Developmental 
Delay; SOD: Septo-Optic Dysplasia; TSH: Thyroid-Stimulating Hormone. +: present; -: 
absent; n.d.: not determined. 
 
The diagnosis of 1p36 deletion syndrome is routinely achieved by locus specific FISH 
with at least two subtelomeric region probes, or by array CGH. The consensus FISH 
probes utilised for the detection of pathogenic deletions of 1p36 are: the telomere 
region-specific probes D1Z2-CEB108/T7 (SpectrumGreen, Vysis) and the more 
centromeric probe p58 containing the CDC2L1/2 locus (SpectrumOrange, Vysis). [231] 
However, it has also been suggested that, in cases with interstitial deletions and/or 
complex rearrangements, a targeted FISH approach with additional probes might be 
necessary. [229] 
 
A cell line was obtained from a fresh blood sample of patient 5608, and FISH was 
performed with three locus specific probes for the subtelomeric region of chromosome 
1p: CEB108/T7, D1Z2, and p58 (CDC2L1/CDC2L2), by Mr Rodger Palmer (Molecular 
Cytogenetics Section, Regional Cytogenetics Laboratory, Great Ormond Street Hospital 
NHS Trust). All three probes returned a positive hybridisation signal on the 
subtelomeric region of the short arm of both chromosomes 1. 
The CN profile of chromosomes 1p36.33 of patient 5608 was exported from CNAT 4.0 
to UCSC genome browser, for the purpose of visualisation. Data regarding the locus 
specific probes utilised for FISH analysis were superimposed on the UCSC graphical 
output for analytical purposes, as shown in Figure 17. 
 
 108 
 
Figure 17. Chromosome region 1p36.33 of patient 5608 in UCSC genome browser. 
Visualisation in UCSC genome browser of a custom track corresponding to the CN 
profile of chromosomes 1p36.33 of patient 5608 exported from CNAT 4.0. The CNAT 
4.0 batch analysis was run with GS = 0 Mb. The diagram of the Vysis 1p36 probe 
region covered by FISH was superimposed onto the UCSC graphical output. From top 
to bottom: diagram of the Vysis 1p36 Probe Region, CNAT 4.0 CNState profile track, 
chromosome band localisation, overlapping genomic structural variants detected in 
healthy individuals entered in the database DGV. The orange bars of the CNAT 4.0 
CNState profile track represent each SNP present in CN state 1 within the genomic 
deletion. The DGV entry coloured blue represents a genomic loss, the DGV entry 
coloured red represents a genomic gain, the DGV entry coloured green represents the 
presence of both genomic loss and genomic gain. The positioning of the p58/CDC2L2 
(orange) probe was arranged in the diagram according to the instructions supplied by 
the manufacturer (Abbott Molecular, Vysis) at the moment of performing FISH on the 
cell line of patient 5608. 
 
The CEB108/T7-D1Z2 probes (green) hybridised to the subtelomeric region of both 
chromosomes 1p, consistently with the fact that the probes were telomeric to the distal 
breakpoint of the interstitial deletion of 1p36.33 detected in patient 5608, as defined by 
SNP mapping array. 
The estimated gap between the telomeric and the more centromeric, p58 
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(CDC2L1/CDC2L2), FISH probes was 600 kb (according to the manufacturer). The p58 
(CDC2L1/CDC2L2) probe was localised inside the chromosome CN 1 imbalance 
detected in patient 5608. The genomic deletion carried by patient 5608 was defined by 
12 SNPs, on average 1 SNP per 34 kb. However, the SNPs were unevenly distributed, 
resulting in a 153 kb gap, between physical positions 1,500,664-1,653,691, where no 
SNP coverage was present. The probe p58 (CDC2L1/CDC2L2) that, according to 
manufacturer’s data, is 110 kb in size fell inside the interval with lack of SNP coverage 
on the 250K Sty1 array. The chromosome imbalance in CN 1 detected in patient 5608 
also involved a number of SNPs centromeric to the localisation of the probe p58 
(CDC2L1/CDC2L2), that were not covered by the standard locus specific FISH. 
Moreover, the 1p36.33 genomic region appeared to be rich in polymorphic structural 
variations, as reported by the DGV. Both duplications and deletions of the genomic 
locus where probe p58 (CDC2L1/CDC2L2) hybridises have been entered into the DGV 
as genomic variants. 
The apparent discrepancy between the results of the Affymetrix GeneChip 250K Sty1 
SNP Mapping Array and the locus specific FISH analysis could potentially reflect a 
complex rearrangement and genomic imbalance in the chromosome region 1p36.33 of 
patient 5608, as discussed in paragraph 6.2.2. 
 
 
4.8.4. Chromosome 9q34.11 Interstitial Deletion 
 
Patient 4754 presented with the unique association of two severe and aetiologically 
unrelated pathologies: SOD and MDS, that had not been reported before in the 
literature. The patient also suffered from severe DD, CPHD, and a gastro-intestinal 
malformation. The association of SOD and MDS was considered of particular interest, 
because it suggested that the complex phenotype of patient 4754 was due to a 
contiguous gene microdeletion/microduplication syndrome, and that the location of a 
known gene responsible for one of the two pathologies, i.e. MDS could potentially lead 
to the identification of a candidate chromosome region, and eventually a novel gene 
involved in the other aspect of the phenotype, namely SOD and CPHD. 
 
A total of 104 entries were present in the database OMIM that referred to MDS. The 
great majority of them were not relevant to the investigation of the phenotype presented 
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by patient 4754 and its molecular bases, corresponding to fusion genes and somatic 
mutations, or were purposely excluded as no information was given about their genomic 
loci. The chromosome region 5q has a predominant role in the etiopathogenesis of 
MDS, as the deletion of all or part of the long arm of chromosome 5 is a frequent clonal 
chromosomal abnormality in MDS, especially the subtype refractory anaemia. Genes 
within the 5q common deleted region are candidates for MDS, and the CN profile of 
chromosome 5q of patient 4754 was screened for unique CNVs with gene content, and 
no CNVs were found. 
Two more genomic loci were investigated: protein-tyrosine phosphatase, nonreceptor-
type, 11 (PTPN11) and runt-related transcription factor 1 (RUNX1). The PTPN11 gene 
is located in chromosome 12q24.1 and mutations in this gene are associated with a 
particular type of MDS, i.e. juvenile myelomonocytic leukemia (JMML), that 
constitutes approximately 30% of childhood cases of MDS. De novo germline 
heterozygous mutations of the gene have also been found in patients with features of 
Noonan syndrome and JMML. [232] The gene RUNX1, located on chromosome 
21q22.3, encodes a hematopoietic transcription factor and heterozygous mutations of 
RUNX1 cause an autosomal dominant, usually familial, platelet disorder with the 
development of acute myeloid malignancies. In one family, members of three 
generations presented with thrombocytopenia, hypospadias in males, umbilical hernia, 
and at least one member was diagnosed with MDS (characterised by progressive 
anaemia and neutropenia) at the age of 41 years. [233] No unique CNVs with gene 
content were detected at either genomic locus in patient 4754. 
 
Eleven entries were present in the database OMIM that referred to SOD. Heterozygous 
mutations in the paired box gene 6 (PAX6), located in 11p13, are responsible for a wide 
spectrum of eye defects, including bilateral hypo- or aplasia and coloboma of the optic 
nerve, that overlap with the SOD spectrum. [234] The CN profile of patient 4754 was 
screened for unique CNVs with gene content at this genomic locus, as well as at 
selected genomic and morbid loci, that are known to be involved in hypopituitarism, 
listed in Table 1. No unique CNVs with gene content were detected at any of these 
genomic loci in patient 4754. 
 
By cross referencing the lists of OMIM entries, no candidate chromosome region could 
be identified for the association of SOD with MDS. In order to try and identify a novel 
genomic locus for this unique association, the whole genome CN profile of patient 
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4754 was screened for unique CNVs with gene content after running the CNAT 4.0 
batch analysis with GS = 0.1 Mb. An interstitial deletion of chromosome 9q34.11 was 
detected. 
The centromeric and telomeric breakpoints of the genomic imbalance were mapped by 
numerical analysis of the SNP log2 Ratio and CN State by running the CNAT 4.0 batch 
analysis with GS = 0 Mb, and exporting the output to a Microsoft Excel spreadsheet; the 
results are shown in Table 30. 
 
Chromosome locus Breakpoint SNP Physical position CN 
9q34.11 Centromeric SNP_A-1831060 129,365,085 2 
SNP_A-1783471 129,525,184 1 
9q34.11 Telomeric SNP_A-1887680 129,821,717 1 
SNP_A-4254903 129,841,977 2 
Table 30. Breakpoints of the chromosome 9q34.11 deletion in patient 4754. CN: 
Copy Number. 
 
The centromeric and telomeric breakpoints fell within 160 kb and 20 kb intervals, 
respectively. Because of the relatively large size of the centromeric breakpoint interval, 
a conservative approach was chosen: only SNPs in CN state 1 were taken into 
consideration for the purpose of mapping and defining the genomic deletion for further 
study. The deletion was, therefore, mapped between genomic physical positions 
129,525,184-129,821,717, and the size of the deletion was 296 kb. 
The 296 kb submicroscopic chromosome deletion detected in patient 4754 was not 
present in any other patient in the cohort under study, and it did not overlap with any 
chromosome rearrangement entered in the database DECIPHER nor in the DGV. The 
genomic deletion contained the whole length of the gene endoglin (ENG), that is 40 kb 
in size and the genomic locus of which maps between physical positions 129,617,112-
129,656,868. 
 
Heterozygous mutations of the ENG gene cause the autosomal dominant disorder 
hereditary hemorrhagic telangiectasia type 1 (HHT1). HHT1 is a vascular dysplasia 
leading to telangiectases and arteriovenous malformations of skin, mucosa, and viscera. 
The full clinical phenotype of the condition is characterised by: epistaxis and 
gastrointestinal bleeding, telangiectases on the mucosal surface of the tongue, lips, face, 
conjunctiva, ears and fingers, pulmonary arteriovenous malformations, cerebrovascular 
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malformations that can lead to intracranial haemorrhage, intrahepatic arteriovenous 
shunts associated with fibrosis and/or cirrhosis, retinal vascular malformations, and 
visceral involvement of other organs including kidneys, ovaries, spleen and lymph 
nodes. [235-237] HHT1 is highly penetrant, with at least one manifestation in 97% of 
patients, but penetrance is age-dependent. More than 90% of patients become 
symptomatic by the age of 21 years. In 62% of patients, a clinical diagnosis is achieved 
by the age of 16 years, with epistaxis being the presenting feature in 90% of cases; the 
mean age of onset of epistaxis is 12 years. [238-241] 
Mutations of ENG disrupt the function of the encoded protein and cause pathology via 
haploinsufficiency. Therefore, the deletion of the entire ENG gene would have been 
likely to cause clinical symptoms of HHT1 in patient 4754. 
 
Patient 4754 was born in 1988 and has crossed the mean age of onset of symptoms of 
HHT1. Unfortunately, the patient was lost to follow-up and it was not possible to obtain 
an updated clinical review of his phenotype. Several factors could have potentially 
prevented the diagnosis of HHT1 from being made in the patient, unless specifically 
sought, namely the age-dependent penetrance of HHT1 symptoms, the complex and 
severe clinical phenotype of the patient, and the presence of MDS that could have 
complicated the interpretation of episodes of haemorrhage. 
To the author’s knowledge, this would represent the first instance of the detection of the 
disruption of ENG on a SNP array platform. However, it would have been necessary to 
confirm the presence of the whole gene deletion of ENG by an independent molecular 
testing. 
Finally, the confirmation of the deletion of ENG would warrant further investigation of 
the 9q34.11 chromosome region with the aim of identifying novel candidate genes for 
both MDS and SOD. 
 
 
 
4.9. Risk Assessment of Unique CNVs 
 
The interface of CNAT 4.0 with UCSC genome browser allowed to determine the gene 
content of each unique CNV, and the information available for each known gene: 
function, gene pathways, protein domain/s, existing link to OMIM disease loci, known 
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mutations and their mode of inheritance. In assessing gene parameters, particular 
attention was paid to the potential involvement of each gene in the development (e.g. 
gene pathways) and pathology (e.g. known OMIM loci) of the pituitary gland. 
The interface with the UCSC genome browser was also utilised to check each unique 
CNV with gene content for gene expression in the pituitary gland, based on data from 
the GNF Gene Expression Atlas 2 of seventy-nine human tissues run over Affymetrix 
microarrays. Expression data in the pituitary gland were available for all but 5 genes 
within unique CNVs in CN state 1 and 4 genes within unique CNVs in CN state 3. 
Finally, the UCSC genome browser was used to check each unique CNV with gene 
content against CNV databases for healthy individuals: the DGV and other databases of 
genomic structural variations interfaced with UCSC. The cumulative percentages of 
CNVs, divided into the two subtypes CN 1 and CN 3, that overlapped fully or partly or 
did not overlap with genomic imbalance/s already included in the DGV are reported in 
Figure 18. 
 
 
Figure 18. Cumulative percentages of CNVs overlapping with the DGV. The 
cumulative percentages of unique CNVs with gene content overlapping with genomic 
imbalance/s already included in the catalogue of the DGV are shown per each subtype 
of CNVs, CN 1 and CN 3. CN: Copy Number. 
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Overall, ~34% of unique CNVs with gene content overlapped with documented 
polymorphisms described in the DGV, and more than half (~57%) of unique CNVs with 
gene content overlapped at least partly (or fully) with genomic imbalances reported in 
the DGV. The number of CNVs in CN 3 that did not overlap with the DGV was lower 
than the number of CNVs in CN 1. Nearly half (48%) unique CNVs in CN 1 with gene 
content did not overlap with any genomic polymorphism included in the catalogue of 
the DGV; for unique CNVs in CN 3 with gene content, the percentage dropped to 37%. 
 
Selected genomic loci that are known to be involved in hypopituitarism, listed in Table 
1, were screened for CNVs in all patients under study, in order to rule out the presence 
of a contiguous gene genomic imbalance that included a gene already known to be 
involved in pituitary gland pathology. No CNVs overlapping with the selected morbid 
loci were identified in any of the patients, supporting the hypothesis that novel genomic 
regions and genes remain to be identified that play a role in pituitary development and 
function. 
Equally, the small cohort of patients with the recurrent association of hypopituitarism 
and ToF, present in the database of endocrinological patients, proved to be 
genotypically heterogeneous, as no CNVs overlapping the previously identified 
5q11.2q22 duplication were detected. Four patients affected by variable degrees and 
manifestations of pathology of the pituitary gland and ToF were included in the 
screening with the 250K Sty1 SNP mapping array. In particular, the genomic region 
5q11.2q22 had been identified as a potential candidate chromosome locus, because a 
fifth patient 5859, unfortunately deceased, had been found to carry a de novo inverted 
duplication of chromosome 5q, 46,XY,add(5)(q11.2)dup(5)(q22q11.2). The 
chromosome region 5q11.2q22 was screened for CN changes running the CNAT 4.0 
batch analysis with GS = 0 Mb in all four patients, but no unique CNVs with gene 
content were detected. 
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4.10. Outcome of the Analytical 
Workflow for the Screening of Multiple 
CNVs 
 
The decisional process workflow allowed to filter the total of 3857 CNVs initially found 
in the cohort of 10 patients, in order to identify the potentially pathogenic ones. The 
mean of CNVs per patient was reduced from 386 total CNVs per patient to 37 unique 
CNVs with gene content per patient. The decisional process tentatively catalogued gains 
(CN 3) as genomic polymorphisms more frequently than losses (CN 1), progressively 
increasing the ratio of CN 1 to CN 3 from 1:2 to 1:1. The outline of the outcome of the 
decisional process workflow is presented in Figure 19. 
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Figure 19. Outcome of the analytical workflow for the screening of multiple CNVs. 
The numbers and percentages of CNVs filtered in each phase of the decisional process 
are shown, together with the changing ratio of CNVs in CN 1 to CNVs in CN 3. CN: 
Copy Number. 
 
The progressive increase of the CN 1:CN 3 ratio indicated that a higher percentage of 
unique CNVs in CN 3 than unique CNVs in CN 1 did not contain any gene. However, 
when only unique CNVs with presence of gene content were taken into consideration, 
the cumulative percentages of unique CNVs per CN state demonstrated that CNVs in 
CN 1 tended to hold fewer genes than CNVs in CN 3 (data shown in Figure 10). 
The shared versus unique criteria utilised in the first phase of the decisional process, 
based on the comparative analysis of all CNVs across the whole cohort of 10 patients, 
allowed to reduce the total number of CNVs initially detected of ~85%. Overall, the 
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percentage of CNVs identified in the whole cohort of 10 patients gradually decreased 
from 100% to 6-9%, by applying the decisional workflow. The final percentage depends 
on the weight attributed to the comparison of the unique CNVs with gene content 
against the DGV, during phase 3 of the decisional process. 
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5. RESULTS 
Candidate Gene Mutation Analysis 
 
Summary of results: 
 The gene BARX2 was selected as a potential novel candidate gene for pituitary 
development and pathology, following a bioinformatic prediction targeting the 
chromosome region 11q24.2qter affected by rearrangements in two patients 
included in the cohort under study, as well as in the del11q syndrome. Mutation 
analysis of BARX2 was performed in a cohort of 71 selected patients; 
 Two genes, that play a role in the embryological development of the pituitary 
gland, OTX2 and BMP4, were screened for mutations in a cohort of 35 patients 
presenting with a complex pituitary and clinical phenotype; 
 A nucleotide sequence variant, leading to a non-synonymous amino acid change, 
was identified in one patient in exon 2 of BARX2, that had not been reported 
before in the literature nor in public databases; 
 A non-sense mutation was found in exon 4 of OTX2, compatible with the 
clinical phenotype of the patient that comprised of severe eye defects as well as 
pathology of the pituitary gland. 
 
 
 
5.1. BARX2 
 
BARX2 is a member of the homeobox gene family of transcription factors, its coding 
region spans approximately 14 kb and it is contained within 4 exons. The gene encodes 
a protein of 279 amino acids, with a homeodomain encompassing 60 amino acids (108-
167), that works as transcriptional regulator via sequence-specific DNA binding. [242-
244] BARX2 is located on chromosome 11q24.3, ~560 kb telomeric to the gene FLI1, 
also located in the chromosome region 11q24.3. FLI1 encodes a transcription factor that 
plays a role in megakaryopoiesis, and strong evidence has been collected that support its 
role in causing Paris-Trousseau syndrome in patients with 11q deletion syndrome. 
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[245, 246] Chromosome 11q deletion syndrome is a contiguous gene deletion disorder, 
but no candidate gene for the endocrinological phenotype has been identified. 
The ~10 Mb terminal deletion of chromosome 11q in patient 6089 was identified as the 
candidate chromosome region to harbour the novel gene responsible for the severe 
pathology of the pituitary gland. Although this chromosome region proved to be gene-
rich (it contained 134 characterised genes at the moment of conducting the study), a 
bioinformatic prediction was attempted. The bioinformatic prediction was performed 
using Gene Sorter from UCSC, targeting the 11q24.2qter chromosome region, and 
interrogating a list of genes that were already known to be mutated in patients with 
pathology of the pituitary gland, namely HESX1, LHX4, POU1F1 and PROP1. These 
genes were chosen because their mutations give rise to pathological conditions that have 
characteristics in common with what observed in patient 6089, in terms of clinical 
phenotype, morphology of the pituitary gland on MRI, and/or inheritance. Each one of 
these genes was input into Gene Sorter to look for genes with Pfam domain similarity 
and BLASTP protein homology. For all four genes, the search of a gene with Pfam 
domain similarity within the 11q24.2qter chromosome region returned only one 
positive result: BARX2. The search for a gene, within the 11q24.2qter chromosome 
region, with significant protein homology based on the BLASTP E-value gave a 
positive result only for two genes, HESX1 and PROP1; in both cases the positive result 
was BARX2. The results, including the numerical values, of the bioinformatic prediction 
are summarised in Figure 20. 
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Figure 20. Results of the bioinformatic prediction targeted at the chromosome 
region 11q24.2qter. The bioinformatic prediction of a candidate gene in the 
11q24.2qter chromosome region was based on the similarity of the Pfam domain and 
the E-values of the BLASTP protein homology search. Both E-values, reported in the 
BLASTP column, were significantly smaller than 0.1 and, therefore, could be safely 
interpreted as the (null) probability that a match between the two proteins occurred by 
chance. ACC: Agenesis of Corpus Callosum; ACTH: Adrenocorticotrophic Hormone; 
AP: Anterior Pituitary; APH: Anterior Pituitary Hypoplasia; CPHD: Combined Pituitary 
Hormone Deficiency; EPP: Ectopic Posterior Pituitary; FSH: Follicle-Stimulating 
Hormone; GH: Growth Hormone; IGHD: Isolated Growth Hormone Deficiency; LH: 
Luteinizing Hormone; SOD: Septo-Optic Dysplasia; TSH: Thyroid-Stimulating 
Hormone. D: Dominant; R: Recessive. 
 
The role of BARX2 in the pathogenesis of the clinical phenotype of 11q deletion 
syndrome had been investigated previously in a small cohort of 9 patients affected by a 
specific symptom of the disease, isolated trigonocephaly, and no changes to the 
sequence of the gene had been identified. [242] Similarly, no etiologic mutations of 
BARX2 coding sequence had been detected in 139 DNA samples from patients with 
ocular anomalies. [243] BARX2 had not been previously studied by genomic sequencing 
in individuals with pathology of the pituitary gland. 
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5.2. OTX2 
 
OTX2 is a member of the homeobox gene family and encodes a 289 amino acid protein, 
transcribed from a 5 kb genomic region that encompasses 3 coding exons, that acts as a 
transcription factor. The protein has a homeodomain, responsible for DNA binding, and 
C- and N-terminal transactivation domains, the activity of which relies on an intact 
homeodomain. The expression pattern of OTX2 studied in early human embryos 
highlighted its prime role in eye morphogenesis, as well as demonstrating a role in 
hypothalamo-pituitary development. [103, 104] PCR-based human cDNA library 
screening identified OTX2 expression in the pituitary gland and the hypothalamus, as 
well as in the whole foetal and adult brain, and the thalamus. [101-103] The expression 
of OTX2 in the hypothalamus was associated with a transactivation function for the 
promoter of interstitial retinoid-binding protein (IRBP), involved in ocular function, as 
well as for the promoters of GnRH1, POU1F1 and HESX1. [101, 102, 104] 
Mutations of OTX2 were first found to cause syndromic ano- microphthalmia and other 
ocular malformations by screening patients with a wide spectrum of eye defects, which 
ranged from bilateral anophthalmia to retinal dystrophy. [37] Heterozygous mutations in 
OTX2 were identified in 11 affected individuals from 8 unrelated families. Eye defects 
were associated with intracranial and brain malformations (i.e. ACC, malformations of 
the hippocampus and septum pellucidum), DD (including severe), microcephaly, 
seizures, hearing loss, hypotonia and joint laxity. A normal-sized pituitary gland was 
documented in 4 patients, but no formal endocrinological investigations were 
performed. Heterozygous loss-of-function mutations occurred de novo in severely 
affected offspring in two families, while in two other families they were inherited from 
a gonosomal mosaic parent. In 4 additional families, reduced penetrance and variable 
expression were suggested. [37] 
 
 
 
5.3. BMP4 
 
The transcriptional unit of the human BMP4 gene is encoded by 5 exons (of which 2 are 
coding exons) and spans approximately 7 kb. The gene encodes a 408 amino acid 
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protein that is a member of the bone morphogenetic protein family, which is part of the 
transforming growth factor-beta superfamily. In situ hybridisation in human embryos 
demonstrated expression of BMP4 protein in the optic vesicle, the developing retina, the 
pituitary region and digits, and haploinsufficiency of BMP4 was deemed a major 
candidate mechanism for abnormalities of the eyes (mainly ano- microphthalmia and 
retinal dystrophy), digits and brain, and for pathology of the pituitary gland. [247] 
Genomic sequencing of BMP4 first led to the identification of two familial 
heterozygous point mutations. In a family, where members of three generations suffered 
from anophthalmia-microphthalmia, iris and chorioretinal coloboma, retinal dystrophy 
of both rods and cones, mild DD, hypoplastic corpus callosum and polysyndactyly, a 
frameshift mutation, leading to a premature stop codon, was found. In a second family, 
a missense mutation in a highly conserved base of BMP4 was associated with 
microphthalmia, sclerocornea, coloboma, DD, seizures, bilateral cryptorchidism, and 
brain and digital anomalies. In addition to the two pathogenic mutations, several low-
penetrant variants were also identified in BMP4. [247] 
 
 
 
5.4. Ethical Approval and Informed 
Consent 
 
The personal and clinical data of the patients included in the study are stored in 
compliance with the Data Protection Act 1998. The project has received full research 
ethical approval (revised in 2009). 
A signed assent/consent form was obtained from each patient (and/or their legal 
guardians) included in the study. All participants received a patient/parents information 
sheet, detailing the aim of the study and the use of the participants’ DNA sample to 
study changes associated with the development and pathology of the pituitary gland. A 
copy of the information sheet is enclosed as Appendix B. 
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5.5. Selection Criteria of Patients for 
Mutation Analysis 
 
The pituitary stalk carries the neural and vascular connections between the 
hypothalamus and the pituitary gland, and damage to the pituitary stalk results in both 
anterior and posterior pituitary dysfunction, although to a significantly variable extent. 
The presence or absence of an intact stalk or ectopic localisation of the posterior lobe on 
imaging is considered to be an important part of the description of the phenotype in 
pituitary dysfunction syndromes. Patients 6089 and 18905640, who carried a 
chromosome rearrangement of region 11q24 where BARX2 is mapped, were both 
diagnosed with GHD and anterior pituitary hypoplasia; patient 6089 also presented with 
ectopic posterior pituitary, while absent pituitary stalk was diagnosed in patient 
18905640. Therefore, a highly homogeneous cohort of 71 patients with isolated 
pituitary pathology were selected from the database of 1,168 index endocrinological 
patients, according to the following criteria: presence of GHD and MRI evidence of a 
small pituitary gland and infundibulum and an ectopic posterior pituitary gland. 
Genomic sequencing of BARX2 was carried out in all 71 patients and in patient 
18905640. 
 
A list of 35 patients presenting with the association of hypopituitarism and/or 
anatomical defects of the pituitary gland with eye pathology, ranging from 
anophthalmia-microphthalmia to retinal dystrophy, were chosen to undertake mutation 
analysis in the candidate genes BMP4 and OTX2. The pituitary phenotype varied greatly 
in severity and manifestations, from short stature, IGHD, HH (with cryptorchidism and 
small/micro penis) to CPHD, small anterior pituitary, ectopic posterior pituitary, and 
SOD. Five patients (5238, 5328, 5984, 6222, JD98) included in the cohort selected for 
genomic sequencing of BMP4 and OTX2 had been identified during the review of the 
1,168 clinical records included in the database of endocrinological patients, as they 
presented with the recurrent association between hypopituitarism and pathology of the 
retina. During the selection process, other aspects of the clinical phenotype were taken 
into consideration. DD and behavioural problems, congenital malformations of the brain 
(e.g. cortical atrophy), kidneys (e.g. renal hypoplasia) and digits (i.e. polydactyly) were 
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considered risk factors for the presence of mutations in BMP4, in particular. Sporadic 
instances of hearing loss and CHD were also recorded amongst the selected patients. 
Three patients, who were included in the mutation analysis of BMP4 and OTX2, were 
also included in the high resolution genome-wide CN change screening with the 250K 
SNP array platform. Patients 4997 and 6110 had complex and partly overlapping 
clinical phenotypes, including microphthalmia, growth deficiency, bilateral 
cryptorchidism (patient 4997 only, patient 6110 is female), DD and renal dysplasia; the 
third patient, JD98, had hypoplasia of the optic chiasm and left optic nerve, retinal rod-
cone dystrophy, short stature, IGHD and hypoplastic anterior pituitary gland. 
 
 
 
5.6. BARX2 Sequence Variants 
 
In patient 5907, a novel heterozygous missense mutation, c.280G>A, p.Ala-94-Thr 
(A94T), in exon 2 of BARX2 was identified. Patient 5907 was a female born in 2000, 
from non-consanguineous parents, who suffered from panhypopituitarism (GH, TSH, 
ACTH deficiency and flat gonadotropin response) associated with an ectopic posterior 
pituitary gland and growth deficiency. She was receiving treatment with GH, thyroxine 
and hydrocortisone. 
A DNA sample was obtained from both parents, and tested by direct sequencing for 
mutations in exon 2 of BARX2. The base substitution c.280G>A (p.A94T) was found, in 
the heterozygous state, in the father of the proband (sample number 6334); the mother 
(6335) showed a homozygous wild-type sequence. No information regarding the 
medical history of the proband’s father were available. The mutation identified in 
patient 5907 and the results of the sequencing of the parental samples (6334, 6335) are 
shown in Figure 21. 
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Figure 21. Heterozygous mutation in exon 2 of BARX2 in patient 5907 and her 
father (6334). Detection of a heterozygous substitution (N) in exon 2 of BARX2 in 
patient 5907 and her father (6334, left chromatogram). The mother (6335) has a 
homozygous wild-type sequence. In the picture, the reverse sequence is shown, and the 
mutant allele is represented as c.280C>T. For sample 6334, the sequence is also shown 
excluding allele ‘C’ to better visualise the presence of the mutant allele ‘T’ (right 
chromatogram). 
 
The amino acid change A94T falls outside the conserved functional homeodomain 
(amino acids 108-167) of the protein encoded by BARX2. However, the substitution of 
the amino acid alanine with the bigger and polar amino acid threonine could potentially 
alter stoichiometry relationships. Figure 22 shows the conservation of the amino acid 
sequence including the one involved in the missense substitution. 
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Figure 22. Conservation of the amino acid residue affected by the BARX2 mutation 
in patient 5907. The multiple sequence alignment was generated by MUSCLE 
(multiple sequence comparison by log-expectation) version 3.6 from NCBI, showing 
gene conservation in Eutelostomi. The amino acid residue 94, affected by the mutation, 
is marked by an asterisk. 
 
The amino acid residue 94 is conserved in 50% of the species, and the conservation 
appears to extend to a longer amino acid motif. The human 11 amino acid motif 
ATPGIAQALSC (containing at the centre the residue 94) is almost fully conserved in 
50% of the species, while it is substituted by the motif TGxGLTPVxTR in 25% of the 
species. This pattern could reinforce the notion of a conserved stoichiometric 
relationship between the amino acid residues. 
The mutation c.280G>A (A94T) had not been previously reported in the literature, nor 
in the public databases of the NCBI and of 1000 Genomes. The mutation had not been 
found in any of the 148 patients, affected by either trigonocephaly or eye pathology, 
included in previous mutation screenings of BARX2, nor it was found in any other one 
of the 71 patients included in the present screening. 
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Apart from the A94T mutation in exon 2, no other sequence changes were detected in 
the first three exons of BARX2. In exon 4, three different SNPs were detected, two of 
which had been reported before in the NCBI website, [213] while one was reported for 
the first time in this study. A fourth SNP was found in intron 3, five bases from the first 
coding nucleotide of exon 4. This intronic polymorphism had also been previously 
reported by NCBI. [213] Two of the SNPs were present in multiple patients, both in the 
heterozygous and homozygous state. The SNP newly identified in this study was 
detected in five patients. One SNP, in the coding region of exon 4, was present in one 
patient only. A summary of the identified SNPs, with the relevant numbers of 
occurrences in either the heterozygous or homozygous state, and allelic frequencies are 
presented in Table 31. 
 
DNA change Protein change Number of patients Allelic frequency 
  Het. Hom. Present cohort NCBI 
c.574-5C>T - 25 7 0.271 0.428 
c.609C>T P203P 25 8 0.285 0.416 
c.690T>G G230G 5 - 0.035 - 
c.755G>A R252H 1 - 0.007 0.027 
Table 31. SNPs detected in intron 3 and exon 4 of BARX2. All allelic frequencies 
refer to the non wild-type allele. The allelic frequencies calculated in the present cohort 
are approximated to three decimal places. Het.: heterozygous; Hom.: homozygous; -: 
not present. 
 
The synonymous nucleotide change c.690T>G (G230G) had not been reported 
previously, and was found, in the heterozygous state, in five patients in the cohort under 
study. The missense amino acid change R252H had been reported previously in the 
NCBI website with an allelic frequency of 0.027 in the HapMap YRI population. One 
patient of probable African descent in the cohort under study presented the same 
missense SNP in the heterozygous state. A total of 24 patients carried both the c.574-
5C>T SNP in intron 3 and the P203P synonymous change in exon 4 in the heterozygous 
state, and 7 patients carried both SNPs in the homozygous state. The concomitant 
presence and concordant state of these two polymorphisms in a total of 31 individuals 
indicated a linkage disequilibrium. Only two exceptions were recorded: in one instance, 
heterozygosity for the P203P SNP was accompanied by a homozygous wild-type 
sequence of the polymorphic position of intron 3; in the second case, the sequence of 
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patient 18905640 revealed the presence of the intronic polymorphism in the 
heterozygous state and the P203P SNP in the homozygous state. 
The genomic sequencing of all exons and intron-exon boundaries of BARX2 in patient 
18905640 did not identify any other change, apart from the SNPs of intron 3 and exon 4 
described above. The occurrence of a heterozygous polymorphism indicated the 
presence of two copies of BARX2 at that genomic position. The results of the genomic 
sequencing did not suggest a disruption of a copy of BARX2 in patient 18905640. 
 
 
5.6.1. Conclusions regarding BARX2 Mutation 
Analysis 
 
The substitution c.280G>A is the only mutation leading to a non-synonymous amino 
acid change identified in the coding region of BARX2 outside of exon 4. The relative 
positions of the identified mutation and SNPs are shown in Figure 23. 
 
 
Figure 23. Structure and sequence variants of BARX2. The schematic representation 
highlights the relative positions of the identified mutation and SNPs. 
 
The lack of clinical data regarding the father of patient 5907 complicated the 
interpretation of the results of the mutation analysis. Controls were not screened for the 
A94T mutation during the course of this study. However, this decision was justified by 
the availability of information from the whole cohort of 71 patients in the present study, 
148 patients previously reported in the literature, and the NCBI and 1000 Genomes 
databases. According to these sources, the mutation A94T has been reported for the first 
time in this study, and, although its causal role in determining the endocrinological 
phenotype of patient 5907 could not be determined with certainty, the mutation’s 
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frequency would fall below 1%. Functional studies of the variant protein would have 
helped in clarifying the role of the mutation and of BARX2 in pituitary pathology. The 
lack of such contribution represents a limitation of this study. 
 
The CNAT 4.0 batch analysis of the Affymetrix GeneChip 250K Sty1 SNP Mapping 
Array run with GS = 0 Mb allowed to verify the CN status of all SNPs covering BARX2 
in patient 18905640. The results were compared with the ones obtained, applying the 
same procedure, for patient 6089. A total of ten SNPs covered BARX2. The gene is 76 
kb in size, which corresponded to an average of one SNP per ~8 kb, although the ten 
SNPs were not evenly distributed along the length of the gene. All SNPs were present in 
CN 1 in patient 6089, while they were present in CN 2 in patient 18905640, as shown in 
Figure 24. 
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Figure 24. Results of the CNAT 4.0 batch analysis of BARX2 in patients 6089 and 
18905640. The numerical analysis of the SNP log2 Ratio and CN State was carried out 
by exporting the CNAT 4.0 output to a Microsoft Excel spreadsheet. The ten SNPs that 
covered BARX2 are highlighted in green. The chromosome bands have been condensed 
for purpose of visualisation and to show also the fine definition of the breakpoint of the 
11q deletion in patient 6089 by using SNP positions (red arrow). Ch: Chromosome; 
CNState: Copy Number State. 
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5.7. OTX2 Mutation and 
Polymorphisms 
 
In patient 5976 a novel heterozygous nonsense mutation, c.235G>T, p.E79X, in exon 4 
of OTX2 was identified. Patient 5976 was a female, born from non-consanguineous 
parents, who suffered from a bilateral severe eye defect in the spectrum of 
anophthalmia-microphthalmia and structural abnormalities of the pituitary gland 
demonstrated at the MRI. 
A DNA sample was obtained from both parents, and tested by direct sequencing for 
mutations in exon 4 of OTX2. Both the father (sample number 6604) and the mother 
(sample number 6605) of the patient were found to be homozygous for the wild-type 
sequence. The mutation identified in patient 5976 and the results of the sequencing of 
the parental samples (6604, 6605) are shown in Figure 25. 
 
 
Figure 25. Heterozygous mutation in exon 4 of OTX2 in patient 5976. Detection of a 
heterozygous c.235G>T substitution (N) in patient 5976; the patient’s father (6604) and 
mother (6605) both showed homozygous wild-type sequences. 
 
The E79X mutation had not been reported previously, it was not found in any other one 
of the 34 patients included in the screening, nor in 60 controls (120 chromosomes). 
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Figure 26 shows the results of the restriction enzyme digestion of patient 5976, both of 
her parents, and a sample of the controls. 
 
 
Figure 26. Restriction digestion with the enzyme BfaI of mutation c.235G>T, 
p.E79X. Patient 5976 carries the heterozygous mutation, and both alleles can be 
identified: the wild-type sequence is identified by the 208 bp product and the mutated 
allele is identified by the 86 bp band. Both parents of the patient (6604 and 6605) and 
seven controls (B1-B7) show the wild-type allele (restriction digestion products of 208 
bp and 117 bp) only. An undigested PCR product of exon 4 of OTX2 (size of 325 bp), 
from a control DNA sample, was loaded onto the gel as a negative control for restriction 
enzyme activity. The virtual run of the products of the restriction digestion of both the 
wild-type (wt) and the mutated (mt) alleles, performed by the REBsites tool, is shown 
on the left of the image. 
 
The genomic sequencing of all exons and intron-exon boundaries of OTX2 in all other 
patients did not identify any other mutation in the coding regions. One SNP located in 
intron 3 and one SNP in the 3’ untranslated region (UTR), that had both been reported 
before in the NCBI database, were detected in 1 and 5 patients, respectively. The 
substitution c.97+12C>T in intron 3 was fond in 1 patient in the heterozygous state, 
corresponding to an allelic frequency in the present cohort of 0.028. The allelic 
frequency listed by NCBI was 0.036. [213] The c.870+10G>A SNP in the 3’ UTR of 
the gene was detected in 4 patients in the heterozygous state and in 1 patient in the 
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homozygous state. This SNP was present in the NCBI database with an allelic 
frequency of 0.052, [213] while the allelic frequency calculated in the cohort under 
study was 0.171. All allelic frequencies refer to the non wild-type allele. 
 
The mutation c.235G>T, leading to the insertion of a stop codon at the position of the 
amino acid residue 79 of OTX2 in patient 5976, truncates the functional homeodomain 
of the protein and is, therefore, expected to abolish the DNA-binding ability and, 
consequently, the transactivation properties of the N- and C-terminal domains. 
The pituitary pathology and the phenotype of patient 5976 are consistent with 
haploinsufficiency of the OTX2 protein, as observed in other patients with severe 
mutations of OTX2 and patients with deletions of the chromosome region 14q22-q23 
(where OTX2 is located), as discussed in chapter 6.7. 
 
 
 
5.8. BMP4 Mutation Analysis 
 
The whole coding sequence (including intron-exon boundaries) of BMP4 was screened 
for mutations in the 35 selected patients who presented with a complex clinical 
phenotype with the association of pituitary gland and eye pathology, and including 
brain, kidney and digit malformations. Genomic sequence analysis did not identify any 
pathogenic mutation in any of the patients. 
A SNP in exon 4 of BMP4, previously reported by the NCBI with an allelic frequency 
of 0.461, [213] was found in the cohort under study. The nucleotide change c.455T>C, 
leading to the amino acid substitution p.V152A, was present in the heterozygous state in 
13 patients, and in the homozygous state in 4 patients. The allelic frequency of the ‘C’ 
allele in the cohort under study was 0.6, while the frequency of the contig reference 
allele ‘T’ was 0.4. 
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6. DISCUSSION 
 
 
 
 
6.1. CNVs and Candidate Genes 
Associated with Pituitary Pathology 
 
Mutations in known genes involved in the development and function of the pituitary 
gland have been found to account for up to 10% of cases of congenital hypopituitarism. 
A list of these genes, the relevant clinical phenotypes and mode of inheritance is 
presented in Table 1. A non-sense mutation, not previously described, has been 
identified in the course of this project in one of these genes, OTX2. 
In the search for novel genes for pituitary pathology, BARX2 was considered a candidate 
because of its genomic position within the critical region for 11q deletion syndrome, 
and because of its protein homology and domain similarity with genes already known to 
be involved in pathology of the pituitary gland. BARX2 had not been screened before for 
mutations in patients with isolated pathology of the pituitary gland. A large cohort of 
patients with a homogeneous clinical phenotype were selected from the database of 
endocrinological patients of the Great Ormond Street Hospital, and a nucleotide 
substitution, leading to a novel missense amino acid change, was detected in 1/72 
patients. The sequence variation is not present in public databases nor in the literature. 
In the same candidate genomic region, chromosome band 11q24.2, a submicroscopic 
genomic rearrangement was identified involving one gene only, KIRREL3, in one 
patient affected by panhypopituitarism and carrying an apparently balanced 
chromosome translocation 46,XY,t(11;22)(q24;q13). 
A decisional workflow was designed to screen the CNVs identified in the cohort of 10 
patients under study, and allowed to filter the total of 3857 CNVs initially detected, in 
order to reduce the mean of CNVs, that warranted further assessment, from 386 to 37 
per patient. Two genomic imbalances, a terminal deletion of chromosome 11q and an 
interstitial deletion of chromosome 22q, were identified as the genetic cause of 
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pathology in two patients. 
 
 
6.1.1. 11q Deletion Syndrome 
 
The partial deletion of the long arm of chromosome 11 is a clinically recognised 
syndrome characterised by: DD in virtually 100% of patients (only two patients, with 
very small terminal deletions, did not show any sign of cognitive development 
impairment [Grossfeld, personal communication]), transient megakaryocytic 
thrombocytopenia (Paris-Trousseau syndrome), that tends to resolve spontaneously, 
with an age-dependent penetrance of 95-100%, growth deficiency with length or height 
below the 5th percentile in 68% of patients, unilateral or bilateral cryptorchidism in 
58% of males (one instance of hypospadias was also reported), clinically significant 
heart malformations in at least 50% of patients, trigonocephaly (~30% of patients), 
pyloric stenosis (~15% of patients), hearing loss, and characteristic facial dysmorphic 
features. [220] In 8 (6 male and 2 female) patients with del11q syndrome and height 
<5th percentile, the levels of IGF1 were assessed, and found to be low in 4 out of the 8 
patients; four male patients also showed cryptorchidism. These results implied that the 
cryptorchidism could represent a sign of underlying HH, and were interpreted as 
indicative of an overall pituitary gland dysfunction in del11q syndrome, with a critical 
region within the chromosome bands 11q24.2qter. [220, 248] Only one case was 
described in the literature of a female patient who underwent a full endocrinological 
investigation. The patient had a 11q terminal deletion with breakpoint within band 
11q23.3, and presented with severe growth deficiency with growth velocity at -9 SD, 
DD, CHD, and bilateral hearing loss. It was demonstrated that she suffered from both 
partial GHD and central hypothyroidism, and an MRI of the brain showed a small 
pituitary gland and infundibulum. Replacement therapy with GH and thyroxine restored 
her growth velocity to normal, but unfortunately the patient died of septic meningitis at 
the age of 2 years. [249, 250] 
The clinical information on 108 Italian patients with del11q syndrome were reviewed 
by us during the course of the project, and revealed that at least 14 individuals had signs 
indicative of pituitary function impairment. The breakpoint of a terminal 11q deletion 
was finely mapped within a 26 kb interval between genomic positions 124,370,133-
124,396,305 in patient 6089, who suffered from severe GHD, signs of HH, and 
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anatomical anomalies of the pituitary gland. Patient 18905640, affected by 
panhypopituitarism and severe structural abnormalities of the pituitary gland, carried an 
apparently balanced translocation involving chromosome band 11q24. Evidence has, 
therefore, been collected that supports the existence of an impaired function of the 
hypothalamo-pituitary axis in patients with 11q deletion syndrome, and the presence of 
a novel gene responsible for pituitary pathology. 
 
Both BARX2 and KIRREL3 map within the 11q24.2qter critical region for the 
endocrinological phenotype. 
BARX2 was investigated in patient 18905640 both by means of genomic sequencing of 
all exons and intron-exon boundaries and for CN changes on the Affymetrix 250K Sty1 
SNP array platform with CNAT 4.0 batch analysis run with GS = 0 Mb. All 10 SNPs 
covering BARX2 were detected in CN 2, no mutations of its coding sequence were 
found, while one heterozygous SNP in intron 3 was detected that confirmed the 
presence of two copies of BARX2 at that genomic position. However, a novel missense 
mutation of BARX2 was identified in another patient, 5907, with isolated 
hypopituitarism, as further discussed in chapter 6.9. 
 
In patient 18905640, two submicroscopic CNVs were identified in the genomic regions 
11q24.2 and 22q12.3, respectively, corresponding to the sites of the patient’s 
translocation breakpoints as defined by low resolution routine karyotyping. [216] The 
genomic imbalance in the region 11q24.2 was considered of particular interest, as it 
could have disrupted the gene involved in the etiopathogenesis of hypopituitarism in 
del11q syndrome. The 52 kb complex rearrangement in 11q24.2, comprising of both a 
deletion and a duplication, involved only one gene, KIRREL3. 
KIRREL3 is expressed in the human foetal and adult brain, with variable levels of 
expression in different regions. [226, 251] Three different heterozygous missense 
mutations have been identified in five patients in highly conserved residues of the gene. 
All patients, four females and one male, suffered from MR varying in degrees from 
mild to severe. [226] Moreover, in a female patient with severe DD and an apparently 
balanced chromosome translocation t(11;16)(q24.2;q24), the chromosome 11 
breakpoint junction sequence was demonstrated to map to intron 1 of KIRREL3, and the 
expression of KIRREL3 was 45% lower in the patient than in two controls. The patient 
also showed a few additional clinical features: alternating exotropia, and minor 
dysmorphic features of the face, fingers and toes. [226] No additional chromosomal 
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rearrangements at or near the chromosomal breakpoints or unrelated to the translocation 
were detected by whole genome 250K Nsp1 array analysis. [226] Overall, alterations in 
KIRREL3, either alone or potentially in combination with other factors, are considered 
likely to play a role in DD. However, a definitive genotype-phenotype correlation has 
not yet been established. [226] 
Genomic sequencing of KIRREL3 has never been carried out in a cohort of patients with 
pathology of the pituitary gland, either isolated or in association with DD. The lack of 
such a pilot screening poses limits to the interpretation of the significance of the 
rearrangement detected within KIRREL3 in patient 18905640, and, therefore, in del11q 
syndrome. 
 
 
 
6.2. Genetic Basis for Complex 
Pituitary Diseases 
 
The diagnosis of a pathogenic chromosomal imbalance or gene defect provides an 
explanation for the clinical symptoms of the patient, and potentially allows a more 
detailed prognosis and follow-up, as well as improved genetic counselling and 
definition of recurrence risks, benefiting the patients and their families. 
The high resolution 250K SNP array allows a high resolution screening of CN changes 
of the whole genome, and more precise breakpoint mapping by using the SNP positions, 
which has the potential to detect submicroscopic CNVs and distinguish subtle 
phenotypic heterogeneity at a molecular level. [184] However, the uneven SNP 
coverage leads to variability in the scale of accuracy of breakpoint definition. In the 
author’s experience breakpoint intervals, mapped by SNP position, have been found to 
be as large as 100-200 kb. Defining the size of a CNV by taking into consideration only 
the adjacent SNPs present in CN state different from 2 could increase specificity, while, 
on the contrary, including the flanking SNPs in CN state 2 as part of the CNV would 
increase sensitivity. In the current study, the first approach was generally preferred, in 
order to avoid the potential inclusion in a CNV of genes not covered by SNPs in the 
250K Sty1 SNP array (e.g. chromosome 1p36.33 interstitial deletion in patient 5608; 
data presented in paragraph 4.8.3.) However, it is acknowledged that this approach 
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might have led to the loss of information pertaining an individual CNV, and exceptions 
were applied when the inclusion of the first flanking SNPs in CN 2 in the definition of 
the CNV did not influence the definition of the gene content (e.g. chromosome 22q12.3 
interstitial deletion in patient 18905640; data presented in paragraph 4.8.1.). 
In the course of this study, the assessment of the content of each CNV has been limited 
to coding genes, while the presence of regulatory sequences, within the region of 
genomic imbalance, was not specifically investigated. This approach poses limitations 
to the identification of pathologic genomic imbalances. However, complex pathology of 
the pituitary gland was investigated in this study under the hypothesis that genomic 
imbalances of multiple genes, in a contiguous gene syndrome, are likely to underlie 
complex clinical phenotypes. [181, 207] 
A submicroscopic CNV in the chromosome region 1p36.33 was finely mapped and 
investigated as a potential candidate region for pathology in one patient, 5608, affetced 
by hypopituitarism and ToF. 
 
 
6.2.1. Assessment of CNV Genomic Loci in Patients 
with Hypopituitarism and Tetralogy of Fallot 
 
The revision of the database of endocrinological patients of the Great Ormond Street 
Hospital highlighted the recurrent association of hypopituitarism and ToF in six 
patients. Patient 5859, who unfortunately died at the age of 10 years, carried a large 
inverted duplication of chromosome 5q11.2-q22, patient 5066, on the basis of the 
revision of his clinical record, was referred for further molecular cytogenetic 
investigations with a suggested diagnosis of Kallmann syndrome. It could be argued 
that ToF represents the highest end of a spectrum of severity of CHD associated with 
pathology of the pituitary gland. However, ToF is a clinically and embryologically 
distinct cardiac malformation, [252, 253] and its incidence in the database of 
endocrinological patients was 1/292 versus 1/2500 in the general population. On these 
bases, the remaining four patients, presenting with this recurrent association, were 
included in the genome-wide copy number screening with the 250K SNP array 
platform. One pathogenic deletion of chromosome 22q11.21, and one genomic 
imbalance of chromosome 1p36.33 were identified. Although seemingly clinically 
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homogeneous this small group of six patients appeared to be genetically highly 
heterogeneous. 
 
By means of high resolution CN change screening, patient 5135 was found to carry a 3 
Mb deletion of the genomic region 22q11.21, with breakpoints that coincided with the 
LCR22s that flank and facilitate the recurrent 22q11.2 microdeletion. 
Variable degrees of impairment of the function of the pituitary gland are a known 
feature of del22q11.21 syndrome. Amongst children between the ages of 1 and 15 
years, with del22q11.2 syndrome, 41% showed a stature below the 5th percentile. Of 
them, 4 had a height significantly below the 5th percentile and low levels of IGF1 and 
IGFBP3. In three patients, GHD was confirmed and pituitary gland hypoplasia was 
documented at the MRI; two patients responded well to GH replacement therapy. [254] 
Hypoplastic pituitary gland was also observed amongst the CNS abnormalities in a 
cohort of 250 individuals (48% male and 52% female) with 22q11.2 deletion syndrome. 
[255] In a separate study, hypothyroidism was reported in 20% of adult patients with 
22q11.2 deletion. [256] 
Point mutations, leading to haploinsufficiency, of the gene TBX1 (chromosome band 
22q11.21) have been detected in individuals with a clinical phenotype overlapping the 
one of del22q11.21 syndrome, but without a chromosome deletion. Mutations in TBX1 
were aetiologically correlated to the physical anomalies in 22q11.21 deletion syndrome, 
while they did not seem to account for the CNS manifestations. [257, 258] According to 
the DGV, the 22q11.21 chromosome region is highly polymorphic, and a high number 
of CNVs overlapping the 22q11.21 deletion in patient 5135 was recorded. This 
observation could provide further evidence that only a few other genes, apart from 
TBX1, are involved in the pathogenesis of del22q11.21 syndrome. No candidate gene 
for the pathology of the pituitary gland has yet been identified in the chromosome 
region 22q11.21. Equally, there are no known genes involved in DI, or in the pathology 
of the anterior pituitary gland, in the whole of chromosome 22. The only instance of the 
association between DI and a genomic imbalance of chromosome 22q was the clinical 
report of a two-year-old female patient with 22q13.31 deletion syndrome, who 
presented with a complex phenotype including central DI, that was diagnosed at the age 
of 2 days and resolved at the age of 27 months. [259] 
It has been demonstrated that the size of the 22q11.2 deletion remains unchanged during 
parent-to-child transmission, even though a great inter- and intrafamilial clinical 
variability is observed, making the genotype-phenotype correlation difficult. [260] 
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Patient 5135 harbours the common ~3 Mb deletion of 22q11.21; while hypothyroidism 
has been described in ~20% of patients with a similar genotype, the occurrence of DI 
had never been reported before. These findings contribute to the notion that a novel 
gene, potentially responsible for pathology of both the anterior and posterior pituitary 
gland, is localised in the genomic region 22q11.21. 
 
Greenway et al. (2009) identified 10 genomic loci holding CNVs in subjects with non-
syndromic ToF; the genomic positions in their study were based on the NCBI build 
36.1. Recurrent CNVs were found at four loci: 1q21.1, 3p25.1, 7p21.3 and 22q11.2. 
CNVs at chromosome 1q21.1 were the most frequent, with a total of 4 duplications and 
1 deletion, accounting for 1% of non-syndromic cases of ToF investigated. At six 
further loci, individual CNVs were detected, including one duplication in the 
chromosome region 4q22.1 that was absent in 2,265 controls. [261] 
In patient 4997, in the present screening with 250K Sty1 SNP array, an unique genomic 
gain (CN 3) in chromosome 4q22.1 was identified that overlapped with the one detected 
by Greenway et al. (2009), and that was deemed to be pathogenic in their patient with 
isolated ToF. Greenway et al. (2009) identified a candidate gene for the ToF phenotype 
within the chromosome region 4q22.1: protein phosphatase, PP2C domain-containing, 
1K (PPM1K), that encodes a phosphatase expressed in human right ventricular outflow 
tract tissues. [261] The same gene fell inside the region of genomic imbalance, and was 
therefore found to be duplicated, in patient 4997. Patient 4997 presented with a complex 
clinical phenotype of growth deficiency and bilateral cryptorchidism, severe DD, 
microphthalmia, bilateral cleft lip and palate, multiple hemi- and butterfly vertebrae, 
bilateral renal dysplasia and urethral multiplication, while echocardiography excluded 
the presence of CHD. 
Although the findings from both studies derive from one patient only and do not 
provide conclusive evidence on the role of 4q22.1 microduplication in abnormal 
phenotypes, the severity of the clinical phenotype presented by patient 4997, and, at the 
same time, the lack of cardiac pathology, question the interpretation of the CNV in 
chromosome 4q22.1 as pathogenic in isolated ToF. These results caution against relying 
strictly on evidence of disease-derived CNVs and underscore the importance of 
genotype-phenotype correlation. An alternative explanation to the one proposed by 
Greenway et al. (2009) is that the microduplication of 4q22.1 constitutes a very rare 
genomic polymorphism. 
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6.2.2. SNP Mapping Array Assay in Monosomy 1p36 
 
An interstitial deletion of chromosome region 1p36.33 was identified, by high 
resolution CN screening on 250K SNP array platform, in a patient who presented with 
features of monosomy 1p36 syndrome. Patient 5608 had SOD with midline clefting, 
coloboma of the optic nerve, associated with aplasia of the retina and ensuing severe 
visual impairment including myopia and visual inattentiveness. Instances have been 
reported in the literature of patients with 1p36 deletions and intracranial midline defects, 
including a 3-year-old girl in whom the MRI of the brain revealed periventricular 
nodular heterotopia and truncation of the rostrum of the corpus callosum, [262] and an 
8-month-old girl with microcephaly in whom a brain MRI showed the presence of a 
midline malformation consisting of agenesis of the anterior commissure and rostral 
corpus callosum and partial agenesis of the septum pellucidum. [263] Coloboma of the 
optic nerve has also been reported in a minority of patients. [230] Interestingly, these 
structural defects of the CNS overlap with the ones observed in patient 5608 and are 
part of the SOD spectrum. Patient 5608 was diagnosed with CPHD, including TSH 
deficiency, and precocious puberty. In a cohort of patients with 1p36 deletion 
syndrome, 20% of patients were found to be affected by hypothyroidism. However, 
high levels of TSH were detected, implying a different nature (primary) of the 
hypothyroidism compared to patient 5608 (central). [231] Only a few patients reported 
in the literature were assessed for signs of precocious puberty. In a very small group of 
three patients, 2/3 (67%) cases of precocious puberty were identified. [228] Finally, 
patient 5608 presented with a complex and severe CHD, fulfilling the diagnosis of ToF. 
CHD are commonly observed in 1p36 deletion syndrome (66-71% of patients), and vary 
greatly in degrees of severity and manifestations. ToF has been estimated to represent 
the fourth most common CHD in 1p36 deletion syndrome. [230] 
 
The size of 1p36 deletions giving rise to symptoms of the 1p36 deletion syndrome has 
been found to vary widely from <0.5 Mb to >10 Mb, and there is no single common 
breakpoint location. Of all deletions, 40% have breakpoints that occur 3.0-5.0 Mb from 
the telomere, and 67% are true terminal deletions. A much lower percentage (~7%) are 
interstitial deletion, retaining the 1p subtelomeric region, or a derivative chromosome 1 
in which the 1p telomere has been replaced by another chromosome end. In fact, 33% of 
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genomic imbalances in 1p36 deletion syndrome result from complex rearrangements. 
[228-230] A review of the molecular basis of monosomy 1p36 identified four classes of 
rearrangements with no single common breakpoint: apparently simple terminal 
truncations, derivative unbalanced translocations, interstitial deletions, and complex 
rearrangements. Complex rearrangements included deletions with interrupted inverted 
duplications, large duplications and triplications with small terminal deletions, or more 
than one interstitial deletion on a single chromosome with normal intervening sequence. 
[228-230] Moreover, D1Z2 probe, estimated to map within 300 kb of the end of the 
chromosome on 1pterp36.33 (manufacturer’s data) and that binds to a distal 1p 
hypervariable repeated sequence, was found not to be deleted in all del1p36 patients. 
Patients not deleted for the D1Z2 probe were assumed to have an interstitial deletion, 
within 1p36.3, that preserved the more telomeric region of the chromosome. [228] 
The monosomy of 1p36 chromosome region is considered to be a contiguous gene 
deletion disorder, deriving from haploinsufficiency of multiple genes. However, it has 
been observed that individuals with the smaller deletions of chromosome 1p36 can 
present with most of the features associated with the 1p36 deletion syndrome, and no 
clear genotype-phenotype correlation has been identified. [230] In an attempt to 
establish genotype-phenotype correlations in monosomy 1p36, Redon et al. (2005) 
applied array CGH, using an overlapping clone microarray covering 99.5% of the 
euchromatic portion of chromosome 1, to six patients with clinical features 
characteristic of monosomy 1p36. They identified two patients who displayed very 
similar clinical findings (DD and facial dysmorphic features), but who had non-
overlapping 1p36 deletions. [264] The authors suggested that monosomy 1p36 
syndrome might be due to a positional effect of the 1p36 rearrangement, rather than 
haploinsufficiency of contiguous genes in the deleted region, and stressed the 
importance of correlating the clinical phenotype to FISH and molecular results, in order 
to draw conclusions. [264] 
 
Patient 5608 presented with most of the physical features characteristic of monosomy 
1p36 (Table 29), and a deletion with a minimal size of 410 kb in the chromosome 
region 1p36.33 was detected on the 250K SNP array platform. FISH with standard 
probes showed hybridisation of probe p58 (CDC2L1/CDC2L2) on both chromosomes 1 
in patient 5608. Probe p58 appeared to be deleted in all patients with monosomy 1p36 
syndrome. [228] However, both duplications and deletions of the genomic locus where 
probe p58 (CDC2L1/CDC2L2) hybridises have been entered into the DGV as genomic 
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variants (Figure 17), and the observation that the genomic region 1p36.33 appears to be 
highly polymorphic might support the notion that rearrangements of the subtelomeric 
region of the short arm of chromosome 1 are indeed complex in a significant proportion 
of patients. 
Rosenfeld et al. (2010) reported five individuals with 200-823 kb overlapping deletions 
of proximal 1p36.33. The genomic imbalances were ascertained with oligonucleotide-
based microarray analysis in four patients, and by BAC-based array CGH in patient 5. 
Metaphase FISH confirmed a deletion in patients 1-4, while FISH experiments were not 
performed in patient 5. All patients presented with features consistent with the 
monosomy 1p36 phenotype, namely, DD, behavioural problems, seizures, hypotonia 
and facial dysmorphic features. [265] The details of the genomic imbalances detected in 
this cohort of 5 patients with monosomy 1p36 are reported in Table 32, and compared 
with the findings in patient 5608 from the present study. 
 
 Rosenfeld et al. (2010) [265] Present 
study 
Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 Patient 
5608 
Telomeric 
breakpoint 
physical 
position 
    1,419,309  
1,468,016 
1,656,080 
1,713,510 1,713,510 
Chromosome 
1p36 
Critical 
Region 
   1,737,827   
      
     1,878,229 
1,912,154      
Centromeric 
breakpoint 
physical 
position 
 1,924,811  
2,171,157 
  
   
  2,242,269 
2,336,237  
Deletion size 
(kb) 
199 269 623 433 823 410 
Table 32. Comparison of genomic imbalances detected in patients with monosomy 
1p36 and patient 5608. The coordinates of the genomic positions defining the 
imbalances were given according to the NCBI build 36.1. The smallest region of 
deletion overlap amongst the 5 patients reported by Rosenfeld et al. (2010) is framed in 
grey. [265] 
 
The smallest region of deletion overlap amongst the 5 patients reported by Rosenfeld et 
al. (2010) was 174 kb, and contained five genes. [265] Characterisation of small 
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deletions is important in contiguous gene deletion syndromes for narrowing critical 
intervals, and for the identification of causative or candidate genes for a feature or 
features of the phenotype. The deletion in patient 5608 significantly overlapped with the 
critical region identified by Rosenfeld et al. (2010). The discrepancy between the results 
of 250K SNP array and standard FISH analysis in patient 5608 opens different possible 
scenarios for interpretation. The findings of a deletion in chromosome 1p36 in patient 
5608 could represent a false positive, or indeed the lack of SNP coverage on the 250K 
Sty1 array platform could have prevented the recognition of a complex rearrangement 
of chromosome region 1p36.33 in patient 5608, reflected in the hybridisation of the 
FISH probe in the region not covered by SNPs. Detection of smaller CNVs increases 
the interpretational challenge of distinguishing pathogenic CNVs from polymorphic 
ones, the incidence of which is ubiquitous and inversely proportional to size. [266] 
In patients with clinical features of monosomy 1p36 and no genomic imbalances 
detected by FISH with standard probes, a targeted FISH approach with additional 
probes might be necessary to characterise interstitial deletions and/or complex 
rearrangements of the 1p36 genomic region. [228, 229] It is acknowledged that such 
approach could have been valuable also in understanding the nature and impact of the 
1p36.33 genomic imbalance in patient 5608. Equally, the complexity in interpreting the 
results warrants the testing of parental samples and controls on the same, or comparable, 
SNP array platform. 
 
 
 
6.3. Availability of Clinical and 
Genetic Data and Clinical Pre-Selection 
of Patients 
 
In the database of endocrinological patients, the majority of records (1,168 index cases) 
carried sufficient clinical and genetic information to achieve a subdivision in primary 
diagnostic categories, and to allow a separation between patients who presented with a 
complex clinical phenotype and patients with an isolated pathology of the pituitary 
gland. The first group of patients included the candidates for the high resolution 
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genome-wide copy number change screening, the second group included the patients 
chosen for mutation analysis in the genes BARX2. 
However, the quantity and quality of information available in the database for each 
patient varied significantly. The patient pro-forma was designed by the author with the 
aim of resolving this issue, and collecting a standardised and detailed description of the 
phenotype of each patient included in the screening. The availability of anamnestic and 
clinical data is crucial to the interpretation of the genetic findings, and will increase the 
diagnostic and analytical power of molecular genetic testing, and can be pivotal in 
addressing further screening and testing, as well as the clinical management and follow-
up of patients. Similarly, the lack of clinical and anamnestic data can prevent high 
throughput techniques from reaching their full potential. The patient pro-forma has 
proven to be a valid instrument to link the clinical and genetic data when, logistically 
(e.g. geographic distance), a direct assessment of the patient/s was not possible. 
In two instances, in the course of this project, the lack of availability of a medical 
history and/or of a follow-up have impacted on the efficacy of a genotype-phenotype 
correlation study. Both patient 5907 and her father (6334) carry the same sequence 
variant of BARX2; the absence of clinical information regarding individual 6334 
prevented from establishing the segregation of the mutation with the clinical phenotype. 
In patient 4754, an interstitial deletion of chromosome 9q34.11 was detected that 
encompassed the whole of ENG gene. The patient was lost at follow-up and it was not 
possible to ascertain whether, at the age of 22 years, he showed signs of HHT1, and 
therefore to gain further insights into the potential role of the genomic imbalance into 
the etiopathogenesis of his complex clinical phenotype. 
 
De Vries et al. (2005) observed that submicroscopic chromosome imbalances could be 
identified in 20% of patients with MR-MCA in a screening by array CGH, and stated 
that this detection rate reflected the improvement obtained by a pre-selection of patients, 
based on a careful clinical assessment of the MR-MCA phenotype, as well as additional 
symptoms, such as facial dysmorphic features and/or growth abnormalities. [178] On 
the contrary, the use of genome-wide array CGH in an unselected sample of patients 
was deemed likely to have a lower yield of micro-deletions/duplications. [178] 
Clinically pre-selected patients were include in the present genome-wide copy number 
change screening with high resolution 250K Sty1 SNP mapping array. The choice of 
patients was based on the evaluation of the clinical records in the database of 
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endocrinological patients, organised into diagnostic categories, and the application of a 
selection criteria checklist designed by the author for this project. 
A criteria checklist for the clinical pre-selection of patients was first proposed to 
improve the study of the subtelomeric regions of the chromosomes with FISH probes. 
[171] It was constructed as a five item checklist comprising of: pre- and/or postnatal 
onset growth abnormalities, presence of at least two facial dysmorphic features, one or 
more non-facial dysmorphic feature and/or congenital abnormality, and family history 
of MR. [171] Subsequently, screenings carried out with array CGH were targeted at 
patients clinically pre-selected on the basis of similar and/or additional inclusion 
criteria, namely, behavioural problems, seizures, and clinical or radiological evidence of 
brain, trunk or limb anomalies. [206, 207] The checklist developed for the present study 
widened the spectrum of risk factors associated with the patient’s family history (i.e. 
multiple miscarriages, similar or different congenital malformation/s in a close relative) 
that suggest the presence of a chromosome rearrangement, and took into consideration 
both inclusion and exclusion (i.e. parental consanguinity) criteria. Differently from 
previously proposed checklists, the list of selection criteria utilised in the current project 
included the presence of either a known apparently balanced chromosome translocation, 
that could be associated with cryptic rearrangements, [145, 147] or a recognised 
monogenic disease that, when present within a more complex clinical phenotype and 
associated with an endocrinological disorder, could potentially lead to the identification 
of a novel genomic locus for pathology of the pituitary gland. 
 
 
 
6.4. Multiple CNVs Interpretational 
Challenge 
 
Because of its high coverage of the human genome, the 250K Sty1 SNP array platform 
detected multiple CNVs across the whole genome of all patients investigated; in the 
great majority of cases these CNVs would represent genomic polymorphisms. The large 
extent of CNVs represents a background noise in the output of high resolution genome-
wide genotyping arrays, and arguably it constitutes its major technical and 
interpretational challenge. [132, 176] Structural variants of DNA defined as CNVs 
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range in size between 1 kb and, usually, ~3 Mb. Typically, large-size CNVs (e.g. single 
BAC clone) were uncovered by array CGH, while smaller ones have been detected 
through SNP genotyping. [109, 132, 267] In the present study, 3857 CNVs were 
identified in the target cohort of 10 patients; one CNV with size of 3 Mb and two CNVs 
with a size of 10 Mb were demonstrated to be causal of the pathological phenotype of 
the patient. 
 
Redon et al. (2006) released the first map of CNVs with size equal or larger than 1 kb in 
the human genome. They investigated genome-wide characteristics of CNVs in samples 
from four HapMap populations, utilising two platforms: Affymetrix GeneChip 500K 
Mapping array, and CGH with a whole genome tilepath (WGTP) array that comprised 
26,574 large-insert clones representing 93.7% of the euchromatic portion of the human 
genome; two distinct relevant algorithms were applied. [109] The WGTP platform 
showed overestimation of CNV boundaries, as a CNV encompassing only a fraction of 
a clone would be reported as if the whole clone was involved. The average number of 
CNVs detected per sample was 24 for the 500K platform, and the mean size was 206 
kb. Forty-three percent of all CNVs identified on one platform were replicated on the 
other, and approximately half of the CNVs were called in more than one individual. 
[109] Approximately equal numbers of deletions and duplications were identified on the 
WGTP platform, whereas deletions outnumbered duplications by approximately 2:1 on 
the 500K platform. Over half (58%) of the detected CNVs overlapped known genes, 
including known disease-related loci, but a significantly lower proportion of deletions 
than duplications (identified on the 500K platform) overlapped with the OMIM 
database. Thus, deletions appeared to be biased away from genes with respect to 
duplications. [109] When only CNVs that were recognised independently by at least 
two different methods to extract CNV information from Affymetrix SNP array data 
were taken into consideration, the frequency of copy number gains was 2.3-fold greater 
than the one of deletions. [130] Moreover, clinical experience has suggested that 
deletions have a higher likelihood of being pathogenic than duplications. [111, 199] 
Gene content appears a more reliable indicator for clinical significance compared with 
CNV size, such that small, gene-rich CNVs are more likely to be pathogenic than larger, 
gene-poor CNVs. [111] The analytical workflow applied in the present study 
progressively and consistently reduced, in each phase, the ratio of genomic gains to 
genomic losses. At the same time, the cumulative percentages of unique CNVs per CN 
state demonstrated that CNVs in CN 1 tended to hold less genes than CNVs in CN 3. 
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Shaikh et al. (2009) identified and assessed the CNVs in 2026 individuals: 1320 
Caucasians (65.2%), 694 African-Americans (34.2%), and 12 Asian-Americans (0.6%). 
Overall, they detected a total of 54,462 CNVs, with an average of 27 CNVs per 
individual (range 4-79). Collectively, these CNVs spanned ~19.4% of the human 
genome. A majority of the CNVs detected (77.8%) were observed in more than one 
unrelated individual. The authors attributed the high rate of non-unique CNVs at least in 
part to the large study cohort. In fact, the relationship between non-unique CNV 
detection rate and sample size approaches a plateau as more samples are surveyed. [268] 
Moreover, it has been suggested that using local reference samples conveys the lowest 
noise in the test-over-reference intensity ratios for all SNPs used to identify CNVs. 
[269] The results presented in this study have been obtained on a cohort of 10 patients 
only assessed by genome-wide CN change screening of unpaired DNA samples, 
utilising a reference set built from data available from the HapMap collection. 
Increasing the number of tested DNA samples and introducing a group of controls 
would improve the extrapolation and inference of data regarding the pathogenic versus 
polymorphic nature of detected CNVs, allow to expand the local database of 
polymorphic CNVs, and, therefore, diminish the number of unique CNVs with gene 
content requiring individual risk assessment. 
 
The challenge of interpreting vast amounts of information delivered by high resolution 
genome-wide CN screening techniques is particularly demanding in clinical diagnostic 
settings. It has been suggested that CNVs should be categorised into: clearly or likely to 
be pathogenic, likely to be benign, and of unknown clinical significance. [111] For 
CNVs that are initially catalogued as ‘of unknown clinical significance’, the availability 
of parental DNA samples can determine the origin, inherited versus de novo, of the 
CNV. A CNV that has been inherited from an unaffected parent is considered unlikely 
to be pathogenic, whereas a CNV that occurred de novo is considered more likely to be 
causally related to the patient’s phenotype. However, exceptions could be found to this 
model, e.g. unmasked recessive mutations, imprinted genes and X-linked inheritance. 
[197] It has been argued that genome-wide testing is unwarranted when it is foreknown 
that parental samples will not be available for follow-up studies. [111] However, during 
the course of the presented project, the chromosome deletion 22q11.21 was identified in 
patient 5135, that represents an instance of a well characterised genomic microdeletion 
syndrome. The genomic imbalance was independently confirmed by FISH. Therefore, 
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genome-wide CN change screening on SNP array platform would retain the potential 
for identifying imbalances, that overlap critical regions of well-defined genomic 
disorders, for patients whose biological parents’ DNA samples might not be available. 
The diagnosis would be beneficial to the clinical management and follow-up of the 
patient, and the replacement of sequential locus-specific testing for microdeletion and 
microduplication syndromes with genome-wide SNP array analysis has been proposed. 
[266] Moreover, even the knowledge that a CNV is inherited should be tempered with 
consideration of issues such as mosaicism, incomplete penetrance and variable 
expression. Also, apparently inherited CNVs may have different breakpoints, that would 
result in different functions or phenotypes in an affected child and healthy parents. [111] 
 
Unique CNVs in one individual can be further assessed by cross-reference to catalogues 
of CNVs found in healthy (e.g. DGV) as well as affected (e.g. DECIPHER) individuals. 
However, the information related to a number of entries in the DGV are derived from 
CNV screening projects that used a single platform and were not validated, and lack 
precise breakpoint information. This raises issues regarding the reproducibility of those 
data. Moreover, considering age-dependent and incomplete penetrance disorders, it is 
possible that the lack of a clinical phenotype does not mirror the lack of presence of 
risk-alleles. [111] Similarly, the significance of a cross-reference to the catalogue of 
CNVs included in the database DECIPHER can be affected by the use of lower 
resolution platforms (like BAC-based array CGH) to generate the data, and, crucially, 
by the quantity and quality of clinical information available. [268] In the course of the 
presented study, in particular, the specificity of matches to phenotypes entered into the 
DECIPHER database needed to be thoroughly scrutinised, as information regarding the 
anatomy and function of the hypothalamus-pituitary gland axis are very rarely available 
or commented on. Therefore, the reference to the database DECIPHER was only 
utilised to evaluate supporting evidence of the pathogenicity of CNVs that had already 
been assessed within the decisional workflow. 
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6.5. Comparison of Analytical 
Workflow for Interpretation of CNV 
Significance 
 
The workflow designed for the present study is compared to the ones proposed in three 
studies published in the literature. Gijsbers et al. (2009) suggested a novel diagnostic 
workflow for all (unselected) MR-MCA patients by first analysing every patient with 
high-density SNP array instead of conventional karyotyping. The SNP array approach 
should make targeted FISH and multiplex ligation-dependent probe amplification 
(MLPA) analysis redundant, and therefore the patient assessment workflow less time-
consuming and more cost-effective. [181] Similarly, Bruno et al. (2009), presenting the 
first study describing the use of Affymetrix 250K Nsp1 SNP array for detection of 
pathogenic CNVs, aimed at investigating replacement of time-consuming, sequential 
locus-specific targeted testing for specific microdeletion and microduplication 
syndromes, using FISH or quantitative DNA tests, with genome screening using SNP 
array analysis, thus also improving the diagnostic yield in clinically pre-selected 
patients with DD-MCA. [266] Greenway et al. (2009) assessed the performance of 
high-resolution Affymetrix 6.0 array in detecting pathogenic CNVs in a cohort of 
patients affected by non-syndromic ToF. The results defined a minimum estimate of 
10% of sporadic non-syndromic ToF cases resulting from de novo CNVs, however, this 
frequency was lower than the 25%-30% rate of de novo genomic imbalances observed 
in individuals with syndromic CHD. [261] A summary of the layout of each study is 
presented in Table 33, and compared with the one of the current project. 
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Affymetrix 
mapping 
array 
platform 
Software Number 
of 
patients 
Phenotype CNV 
exclusion 
criteria 
Mean 
CNVs 
/sample 
Ref. 
250K Sty1 CNAT 4.0 
Microsoft 
Excel 
10 Pathology of 
pituitary 
gland 
<2 adjacent 
SNPs 
386 Present 
Study 
250K Nsp1 
250K Sty1^ 
CNAG 2.0 124 MR-MCA CN 1: 5 
adjacent SNPs 
or 150 kb; 
CN 3: 7 
adjacent SNPs 
or 200 kb 
3 [181] 
250K Nsp1 CNAG 3.0 
Microsoft 
Excel 
117 MR-MCA <7-10 
adjacent SNPs 
with log2 ratio 
<-0.3 (CN 1) 
or >+0.3 (CN 
3)* 
4 [266] 
6.0 Birdseye 
[270] 
121 Non-
syndromic 
ToF 
CNV <20 kb 14# [261] 
Table 33. Comparison of the layout of screenings of CNVs with SNP array. ^Two 
different SNP array platforms were used in this study, only results relevant to the 
Affymetrix GeneChip 250K Nsp1 and 250K Sty1 arrays are taken into account; *7 
SNPs for experiments with SD up to 0.20 and 10 SNPs for experiments with SD 
>0.20<0.26; #Chromosome X was excluded from the analysis. CN: Copy Number; 
MCA: Multiple Congenital Anomalies; MR: Mental Retardation; ToF: Tetralogy of 
Fallot; Ref.: Reference. CNAG: Copy Number Analyser for GeneChip. [271] 
 
In all three referenced studies, exclusion criteria were applied in the phase of 
determining the operational definition of CNV. This conservative approach was adopted 
in order to minimise the number of false positive findings, and increase specificity. In 
the present study, no exclusion criteria were selected, in order to favour the sensitivity 
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of the test and minimise the risk of losing viable information about potentially clinically 
relevant CNVs, allowing the maximum flexibility in the further stages of the decisional 
process workflow. 
 
The decisional processes for the screening of multiple CNVs, applied in the present and 
previous studies, are summarised in their 3 basic steps in Table 34. Each step 
corresponds to the removal of a number of CNVs from the total pool, based on the 
relevant criteria applied within each workflow. 
 
 Present study [181] [266] [261] 
STEP 1 CNVs non-
unique in the 
cohort of 
patients under 
study 
CNVs present in 
the DGV and/or in-
house reference set 
of 60 controls 
CNVs present in 
the DGV and/or 
UCSC genome 
browser 
Inherited CNVs 
STEP 2 CNVs with no 
gene content 
CNVs with no gene 
content 
CNVs with no 
gene content 
CNVs found in 
2,265 control 
samples and/or 
reported in the 
literature [114] 
STEP 3 CNVs with low 
pathogenic-risk 
Inherited CNVs CNVs with low 
pathogenic-risk 
CNVs in 
individuals with 
CNV excess 
compared to the 
mean of the whole 
cohort 
Table 34. Three basic steps of the decisional process for the screening of multiple 
CNVs. Each step indicates what class of CNVs were removed from the total pool, based 
on the relevant criteria applied at the corresponding stage within each decisional 
workflow. 
 
Gijsbers et al. (2009) removed CNVs entered in the DGV and in their in-house 
reference set of 60 controls, when present in at least 3 individuals. [181] However, they 
did not define the criteria to establish an overlap between CNVs. Greenway et al. (2009) 
removed from the pool of potentially pathogenic CNVs, CNVs that shared at least 50% 
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overlap with 0.1% or more of control samples, as well as CNVs that matched previous 
reports in the literature. [261] The removal of CNVs shared across the cohort of 10 
patients in the present study constituted the first step in the decisional workflow, and a 
CNV was defined as shared when it fulfilled stringent criteria. 
The choice of utilising the presence in the DGV (and/or other genomic structural variant 
databases) as the sole criteria to catalogue CNVs as polymorphic can also be argued 
against. The information included in the DGV and similar databases need to be 
tempered with the knowledge and consideration of the following issues. The 
polymorphic genomic structural variants, and ensuing precision of breakpoint 
definition, can originate from lower resolution array platforms, such as array CGH 
platforms that contain large-insert BAC clones, which are on the order of 150 kb in size. 
Empirically, a significant copy number ratio change can be noted when a clone has 
gained or lost a copy of 25%-30% of its unique DNA sequences. This can lead to the 
potentially erroneous assumption that a CNV identified by a given clone on an array 
platform is the same CNV in another individual when identified by overlapping 
genomic sequence/s on another platform. [111] The population frequency of a 
previously reported CNV entered into databases and online catalogues can often be 
related to one individual only, and, crucially, the phenotypic characteristics of the 
comparison population often remain uncertain or unknown. [199] Therefore, it has been 
suggested that caution should be exercised when relying heavily on such databases like 
DGV to interpret the clinical significance of a CNV. This holds true especially for 
CNVs that have been reported only in a single individual. [111] Bruno et al. (2009) 
documented that polymorphisms described in the DGV accounted for 73% of the CNVs 
identified in their cohort, and they ruled out all the relevant CNVs in the first stage of 
the workflow. [266] The comparison with the DGV was used only in phase 3 of the 
workflow proposed in this study, during the risk assessment of CNVs, and did not 
represent an exclusion criteria alone. About 34% of unique CNVs with gene content 
overlapped with documented polymorphisms described in the DGV, and more than half 
(~57%) of unique CNVs with gene content overlapped at least partly (or fully) with 
genomic imbalances reported in the DGV. In the third and last phase of the decisional 
workflow, this criteria, if utilised alone, would have removed from further investigation 
only 3% of the total of CNVs initially identified, compared to the figure of 73% of 
CNVs excluded by Bruno et al. (2009) in the first stage of their workflow. [266] 
The approach chosen for the present study was, instead, the creation in the first phase of 
the decisional workflow of a database of all non-unique CNVs detected, by 
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comparative analysis, in the cohort of patients derived from the database of 
endocrinological patients. This approach had the advantages of allowing to set stringent 
criteria for the definition of shared CNVs, and controlling the anamnestic and clinical 
data of all the individuals in whom the CNVs were detected. This method has been 
validated by subsequent observations that it minimises the potential of false positives 
due to platform-specific artefacts. [111, 268] 
 
 
 
6.6. Genotype-Phenotype Correlation 
of BARX2 Mutations 
 
BARX2 was identified as a potential candidate gene for pathology of the pituitary gland 
following a bioinformatic prediction. Although the output of a bioinformatic prediction 
using Gene Sorter can be biased by the amount of information entered in the relevant 
databases, the calculation returned BARX2 as the only gene fulfilling the input criteria. 
A novel heterozygous A94T missense mutation was identified in exon 2 of BARX2 in 
one patient (5907) who presented with a clinical phenotype comprising of 
panhypopituitarism and ectopic posterior pituitary gland. The amino acid change was 
not found in any other patient in the cohort under study, nor in any patient or control 
tested in previous screenings, [242, 243] but was present in the father of the proband. 
 
In mice, the loss of Barx2 appeared to cause a defect in the initiation and progression of 
hair follicle remodelling. [272] The Barx2-null mouse pups showed a minimal 
phenotype, they could be distinguished from the wild type pups only by their short 
whiskers, and about half were born with open eyelids. Later in life, adult mice had 
shorter hair than wild type mice. The heterozygous pups and adults appeared identical to 
the wild type animals. [272] However, expression studies of Barx2 revealed a 
prominent activity throughout the development of the pituitary gland and associated 
structures. Early developmental expression of Barx2 has been reported for embryonic 
day 9.5 (E9.5) to E12.5. [273] Localisation studies showed that expression of Barx1 and 
Barx2 overlap in the nervous system, particularly in the telencephalon, spinal cord and 
dorsal root ganglia. Barx2 was also prominently expressed in the floor plate of the 
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midbrain. During craniofacial development Barx1 and Barx2 showed complementary 
patterns of expression whereas Barx1 appeared in the mesenchime of the mandibular 
and maxillary processes, Barx2 was observed in the ectodermal lining of the same 
tissues. [273] From E12.5, intense expression of Barx2 was documented in the 
developing anterior pituitary gland in a spatial distribution resembling that of Pit1 
(POU1F1). [273] High levels of Barx2 were confirmed in the Rathke’s pouch after 
E13.5 by in situ hybridisation. [272] Therefore, while expression data would support a 
role of Barx2 in pituitary gland development in mouse, the Barx2-null mice do not show 
an impairment of the pituitary function. Given the overlap between the expression 
patterns of Barx1 and Barx2, it is possible that a degree of functional redundancy plays 
a role in avoiding the development of a pathological phenotype in Barx2-null mice, 
demonstrating the difficulties in extrapolating information from one organism to 
another. 
 
Mutation analysis of BARX2 had not been carried out before in a cohort of patients with 
pathology of the pituitary gland, however, BARX2 was suggested as a potential 
candidate for the craniofacial features of 11q deletion syndrome. [242, 243] Although 
outside of the functional homeodomain of the BARX2 protein, the A94T change is the 
only mutation identified in the coding region of BARX2 outside of the C-terminal exon 
4. The A94T mutation is located in exon 2, proximal to the functional homeodomain, 
and within a relatively conserved amino acid sequence of the protein. Indeed, BARX2 
appears to be conserved amongst species. The genomic sequencing of the 72 patients 
under study identified two SNPs of BARX2, the nucleotide substitution c.574-5C>T in 
intron 3 and the P203P synonymous change in exon 4, in a total of 31 patients in 
concordant heterozygous or homozygous state, with allelic frequencies 0.271 and 0.285, 
respectively. These observations suggested linkage disequilibrium, and only two 
exceptions were recorded. The same observation was made in a separate study, where 
an allelic frequency of 0.280 was calculated for both the intronic and exonic SNP. [210] 
The frequency of one missense mutation of BARX2 detected in the whole cohort of 72 
screened patients would indicate that the gene does not play a prominent role in the 
etiopathogenesis of isolated hypopituitarism and defects of the anatomy of the pituitary 
gland. However, it remains possible that the mutation is causally related to the clinical 
phenotype of patient 5907. The lack of anamnestic and clinical information regarding 
the father of patient 5907 prevented a genotype-phenotype correlation, and, in the 
absence of these information, functional studies of the effects of the A94T variant 
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should be undertaken to clarify the potential etiopathogenic role of BARX2 mutation in 
pathology of the pituitary gland. 
 
 
 
6.7. Genotype-Phenotype Correlation 
of OTX2 Mutations 
 
Patients have been reported in the literature with deletions of the long arm of 
chromosome 14 overlapping the genomic loci of OTX2 and BMP4; a summary of the 
genotype-phenotype correlation of these genomic imbalances is presented in Table 35. 
 
Chromosome 
deletion 
Sex Age Endocrine/pituitary 
phenotype 
Other symptoms Ref. 
del(14)(q22q23) F 21 w 
(ga) 
hypoplastic pituitary 
gland and stalk 
bilateral 
anophthalmia, small 
cerebellum, 
hypoplastic kidneys 
[274] 
del(14)(q22.1q22.3) M 4 y growth deficiency, 
hypogonadism 
(bilateral 
cryptorchidism, 
micropenis), central 
hypothyroidism, 
suspected 
hypopituitarism 
bilateral 
anophthalmia, DD, 
facial dysmorphic 
features 
[275] 
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del(14)(q22.1q23.2) F 21 m small sella turcica, 
hypoplastic pituitary 
gland 
bilateral 
anophthalmia, 
craniosynostosis, 
cervical vertebral 
anomalies, absent left 
auditory canal, facial 
asymmetry, 
microretrognathia, 
DD, cortical atrophy, 
hypotonia 
[276] 
del(14)(q22q23) familial - (normal anatomy of 
the pituitary gland) 
uni- or bilateral 
anophthalmia, 
polydactyly 
[277] 
del(14)(q22q23) M 5 y hypoplastic pituitary 
gland, bilateral 
cryptorchidism 
anophthalmia, DD, 
hypotonia, hearing 
loss, facial 
dysmorphic features, 
syndactyly 
[278] 
del(14)(q22.3q23.2) F n.r. hypothyroidism bilateral 
anophthalmia, partial 
ACC, DD 
[247] 
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del(14)(q22.2q23.1) M 7 y APH, posterior 
pituitary not 
visualised, growth 
hormone deficiency, 
hypogonadism 
(bilateral 
cryptorchidism), 
neonatal 
hypoglycaemia 
bilateral 
anophthalmia, partial 
ACC, severe DD, 
epilepsy, sleep 
disturbances, 
cerebellar vermis 
hypoplasia, 
microcephaly, 
hypotonia, mixed 
(conductive and 
sensorineural) 
hearing loss, 
recurrent otitis media, 
gastro-oesophageal 
reflux, scoliosis, high 
palate, bifid uvula, 
minor facial 
dysmorphic features 
Patient 
6137 
and 
[247] 
del(14)(q22.1q22.3) F 1 y - (normal anatomy of 
the pituitary gland) 
bilateral congenital 
corneal opacity, DD, 
hypotonia, bilateral 
polysyndactyly 
[279] 
Table 35. Genotype-phenotype correlation of 14(q22q23) genomic imbalances. The 
endocrinological and/or pituitary phenotype and a summary of the other symptoms 
observed in each case are included. ACC: Agenesis of Corpus Callosum; APH: Anterior 
Pituitary Hypoplasia; DD: Developmental Delay; F: Female; M: Male; m: month/s; w: 
week/s; y: year/s; ga: gestational age (of foetus after premature termination of 
pregnancy); -: not present (the anatomy of the pituitary gland was investigated with 
brain MRI); n.r.: not reported. Ref.: Reference. Patient 6137 was included in the 
database of endocrinological patients under study. 
 
The clinical phenotype associated with deletions of the chromosome region 14q22-q23 
comprises of pathology of the eyes, CNS (particularly, DD, cerebellar hypoplasia, and 
hypotonia), digits, kidneys, as well as hearing loss and facial dysmorphic features. 
Hypopituitarism and anomalies of the anatomy of the pituitary gland have been 
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reported in most instances. Haploinsufficiency of genes, mapped within the 
chromosome region, was suggested as the likeliest mechanism of pathology. Four genes 
in particular were considered candidates, the hemizygous deletion of which could 
account for the clinical phenotype: BMP4, OTX2, SIX1 and SIX6. [247, 278] In the 
present study, genomic sequencing of BMP4 and OTX2 was carried out in the same 
cohort of 35 patients with variable degree and manifestations of pathology of the 
pituitary gland, associated with defects of eyes, brain, kidneys and digits. The choice of 
the clinical phenotypes reflected the complex array of symptoms detected in patients 
with deletions of the chromosome region 14q22q23. 
 
A novel heterozygous nonsense mutation, E79X, was identified in exon 4 of OTX2 in a 
patient, 5976, with a bilateral severe eye defect in the spectrum of anophthalmia-
microphthalmia, structural abnormalities of the pituitary gland and CPHD. The 
mutation lies within the homeodomain of the protein. 
Twenty-five different heterozygous mutations of OTX2 had been documented in 
previous studies, and are listed in Table 36, with a summary of the associated clinical 
phenotype and indication of their origin. [37, 38, 40, 280-286] 
 
DNA 
mutation 
Protein 
mutation 
Eye Pituitary Other Origin Ref. 
c.81delC p.S28PfsX52 Mp n.r.  p.m. [37] 
c.93C>G p.Y31X Mp n.r.  De novo [282] 
c.106dupC p.R36PfsX87 Mp -  n.r. [282] 
c.117delCC p.R39fsX86 Ap - DD Mat. 
(healthy) 
[37] 
c.136dupA p.T46NfsX84 Mp - Microcephaly, 
anteriorly 
placed anus 
Pat. [285] 
c.214_217 
delGCAC 
insCA 
p.A72fsX86 Mp -  n.r. [280] 
c.221_236 
del16 
p.K74fsX103 Mp/Ap IGHD, 
APH, 
EPP 
DD n.r. [280] 
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c.235G>T p.E79X Mp/Ap CPHD, 
structural 
defects 
 De novo 5976 
c.265C>G p.R89G Mp -  De novo [37] 
c.265C>T p.R89X Ap -  De novo [286] 
c.270A>T p.R90S Ap IGHD, 
APH, 
EPP 
DD Pat. [283] 
c.289C>T p.Q97X Mp n.r.  Pat. [282] 
c.295C>T p.Q99X Ap n.r.  Pat. 
(healthy) 
[37] 
c.313C>T p.Q105X Ap - DD De novo [285] 
c.371_372 
delAG 
p.E124EfsX135 Ap n.r. DD Mat. [282] 
c.397C>A p.P133T Ap n.r.  Pat. 
(healthy) 
[37] 
c.400C>G p.P134A Ap n.r. DD De novo [37] 
c.402insC p.L135fsX136 Ap IGHD DD, CP De novo [281] 
c.405_406 
insCT 
p.S136fsX178 Ap CPHD, 
APH, 
EPP 
DD, Chiari 
defect 
De novo [38] 
c.413C>G p.S138X RD IGHD  De novo [284] 
c.456_457 
delGAinsAT 
p.W152X Mp/Ap CPHD DD, 
microcephaly 
De novo [285] 
c.464insGC p.A155fsX177 Ap - DD, ACC De novo [37] 
c.537T>A p.Y179X Mp n.r. DD p.m. [37] 
c.553_556 
dupTATA 
p.S186IfsX187 Mp APH, 
absent 
posterior 
pituitary 
DD, 
microcephaly 
De novo [285] 
c.562G>T p.G188X Mp CPHD, 
APH, 
EPP 
DD, seizures n.r. [280] 
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c.674A>G p.N225S - CPHD, 
APH, 
EPP 
 n.r. [40] 
Table 36. Heterozygous mutations in the OTX2 gene. The novel mutation identified 
in this study is highlighted in grey. Mp: microphthalmia; Ap: anophthalmia; RD: 
Retinal Dystrophy. APH: Anterior Pituitary Hypoplasia; CPHD: Combined Pituitary 
Hormone Deficiency; EPP: Ectopic Posterior Pituitary; IGHD: Isolated Growth 
Hormone Deficiency. ACC: Agenesis of Corpus Callosum; CP: Cleft Palate; DD: 
Developmental Delay. Mat: Maternal; Pat: Paternal; p.m.: parental mosaicism; -: absent; 
n.r.: not reported. Ref: Reference. 
 
Together with point mutations, whole gene deletions of OTX2 and microdeletions 
involving its genomic locus have been reported that led to a similar phenotype with the 
association of pituitary and eye defects. [280, 282, 287] In the course of this study, no 
genomic imbalances in the chromosome region 14q23.1 were detected, by high 
resolution CN change profiling with the 250K SNP array platform, in patients who 
presented with the association of pituitary gland and eye pathology. In patient 6137, 
who presented with bilateral anophthalmia, pituitary hypoplasia and CPHD, within a 
more complex clinical phenotype, a de novo interstitial deletion of chromosome 
14(q22.2q23.1) was detected by array CGH, after specific loci MLPA 
deletion/duplication screening, MLPA and FISH screening with probes for the 
subtelomeric regions of the chromosomes, and genomic sequencing of the coding 
regions of SOX2 had failed to identify any genomic imbalance or mutation. 
The ocular phenotype of patients with mutations in OTX2 is variable in severity; 
microphthalmia-anophthalmia is the most common symptom, but at least one case of 
isolated early onset retinal dystrophy has been reported, [284] and familial studies have 
shown that the penetrance of OTX2 mutations is not complete. [37, 282, 283] An 
individual mutation in OTX2 was also reported in a patient with CPHD and no ocular 
phenotype. [40] Similarly, heterozygous mutations of OTX2 are associated with variable 
degrees and manifestations of pathology of the pituitary gland, although GHD, pituitary 
hypoplasia and ectopic posterior pituitary seem to occur with increased frequency. [280] 
Furthermore, a percentage of patients, carrying either a point mutation or a whole gene 
deletion, exhibit additional features, mainly brain anomalies, seizures and DD. 
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The c.235G>T mutation of OTX2 reported in this study inserts the third most premature 
truncation of the protein homeodomain described to date, p.E79X. All three amino acid 
residues (valine 84, lysine 87, and asparagine 88) belonging to the homeodomain, and 
that have been demonstrated to have a critical role in DNA binding, are ablated by the 
mutation. [39] Functional analysis showed that the p.G188X-OTX2 protein localised to 
the nucleus, as did the wild-type protein, whereas the p.K74fsX103-OTX2 and 
p.A72fsX86-OTX2 proteins were incapable of localising to the nucleus. Transactivation 
analysis demonstrated that the p.K74fsX103-OTX2 and p.A72fsX86-OTX2 proteins 
had virtually no transactivation function, while the p.G188X-OTX2 protein had reduced 
(~50%) transactivation activity. [280] These observations confirm the severity of the 
c.235G>T mutation, that leads to the truncation of the protein homeodomain as early as 
at the amino acid residue 79 and to a complete loss-of-function. [39, 280] 
Only one OTX2 mutation, the amino acid missense change N225S, has been reported to 
date to act via a dominant-negative effect. This mutation occurred in a patient with 
CPHD and no ocular phenotype. [40] Despite the severity of the E79X mutation, patient 
5976 did not present with any clinical symptom outside the eye and pituitary spectrum. 
At present, no genotype-phenotype correlation has been established between 
heterozygous mutations of OTX2 and variable pituitary and clinical phenotypes. [280] 
The lack of a genotype-phenotype correlation strengthens the need for continuous 
endocrine follow-up of affected patients, throughout childhood and adolescence, since 
the clinical course cannot be anticipated. [283] Finally, patients with IGHD or CPHD 
and ocular malformations, together with genetic analysis for classic transcription factor 
genes involved in pituitary development and pathology (e.g. PROP1, POU1F1, HESX1, 
SOX2) should be tested also for the presence of mutations in OTX2. 
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Patient Pro-forma 
 
Patient’s NAME:     SEX:  M  F 
DATE of BIRTH:     DATE of EXAMINATION: 
HOSPITAL/CONSULTANT: 
HOSPITAL No.: 
Mother’s NAME:      DATE of BIRTH: 
Father’s NAME:      DATE of BIRTH: 
 
1) Family history 
recurrent miscarriages:  No   Yes 
If Yes, details: 
 
 
mental retardation:   No   Yes 
If Yes, details: 
 
 
congenital malformations:  No   Yes 
If Yes, details: 
 
 
cancer:     No   Yes 
If Yes, details: 
 
 
known genetic conditions:  No   Yes 
If Yes, details: 
 
 
 
Parent consanguinity:   No   Yes 
If Yes, degree and relationship within the family tree: 
 
 
 
Family tree 
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2) Normal pregnancy and delivery? Yes   No 
If No, details: 
 
 
 
Week of gestation at birth: 
 
Delivery: 
 
maternal smoking:   No   Yes 
If Yes, details: 
 
 
maternal alcohol    No   Yes 
If Yes, details: 
  
 
 
APGAR score at 1’:  5’: 
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3) Normal psychomotor development?  Yes   No 
If No, details: 
 
 
Degree and profile of cognitive delay (including scale used for assessment, and 
age at assessment): 
 
 
 
 
 
Normal brain MRI?    Yes   No 
If No, details: 
 
 
 
Date of examination: 
 
 
Normal EEG?     Yes   No 
If No, details: 
 
 
Date of examination: 
 
 
Other neurological symptoms?   No   Yes 
If Yes, details: 
 
 
 
 
Other investigations?    No   Yes 
If Yes, details: 
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4) Clinical examination 
At birth  
 Current 
Length/height: 
Weight: 
Head circumference: 
 
 
Head and Neck 
 
Head shape: 
 
 
Hair/eyebrows/eyelashes: 
 
 
Eyes/palpebral fissures/eye distance: 
 
 
Ears: 
 
 
 
Nose: 
 
 
Philtrum: 
 
Mouth/lips/gums/palate/tongue: 
 
 
 
Teeth: 
 
 
Chin: 
 
 
Neck: 
 
 
 
Bones, joints and muscles 
 
Spine: 
 
 
 
Thorax shape/ribs/intermamillary distance: 
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X-ray skeletal survey/other skeletal anomalies: 
 
 
 
 
 
 
 
Bone age: 
 
 
Joints: 
 
 
 
 
 
Muscles: 
 
 
 
 
 
Hands and Feet 
 
Hand lenght:  cm   Middle finger lenght:  cm 
 
Fingers and toes: 
 syndactyly    No  Yes 
 If Yes, details: 
 
 
 camptodactyly   No  Yes 
 If Yes, details: 
 
 
 clinodactyly    No  Yes 
 If Yes, details: 
 
 
 broad thumb    No  Yes 
 
 broad hallux    No  Yes 
 
 sandal gap    No  Yes 
 
 
Palmar and plantar creases/other ridges/pads: 
 
 
 
Nails: 
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Skin 
 
Are extensibility, trophic properties and vascular pattern normal? Yes 
 No 
If No, details: 
 
 
 
 
Is body hair normally distributed?     Yes 
 No 
If No, details: 
 
 
 
Are skin spots (hyper- hypopigmented, etc) present?  No 
 Yes 
If Yes, details: 
 
 
 
 
Are keloids or other abnormal scar formation present?  No 
 Yes 
If Yes, details: 
 
 
 
 
 
Genital organs/perineal region 
 
MALE 
 Penis: 
 
 
 
 Testicles/volume: 
 
 
 
 Scrotum: 
 
 
 
FEMALE 
 External genitalia: 
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Anal orifice: 
 
 
 
 
Internal organs 
 
Normal echocardiography?   Yes  No 
If No, details: 
 
 
 
 
Date of examination: 
 
 
Normal abdominal echography?  Yes  No 
If No, details: 
 
 
 
 
Date of examination: 
 
 
Other investigations?    No  Yes 
If Yes, details: 
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5) Endocrinological examination 
 
Mid Parental Height: 
 
Spontaneous Puberty:     Yes  No 
 
 
VISUAL ACUITY 
Right Eye:      Left Eye: 
Right Optic Disc:     Left Optic Disc: 
 
 
ERG (date:    /   /    ): 
 
 
VER (date:    /   /    ): 
 
 
Other Ophthalmological Features: 
 
 
 
 
Free Thyroxine: 
 
Basal TSH:     TRH Test Peak TSH: 
 
Basal Prolactin:    TRH Test Peak Prolactin: 
 
 
 
GH Provocation Test Type: 
 
Peak GH: 
 
 
 
Basal Cortisol:    Peak Cortisol On Synacthen: 
 
 
 
Basal LH:     Peak LH On LHRH: 
 
Basal FSH:     Peak FSH On LHRH: 
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Diabetes Insipidus:      Yes  No 
 
Any Other Endocrine Results: 
 
 
 
 
Hydrocortisone Treatment (Age): 
 
Thyroxine Treatment (Age): 
 
GH Treatment (Age): 
 
DDAVP Treatment (Age): 
 
Sex Steroids (Age): 
 
Zoladex Treatment (Age): 
 
 
Type Of Neuroimaging: 
 
 
Results: 
 
 
 
 
 
 
 
Final Diagnosis: 
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6) Genetic testing 
 
Candidate Genes to be Tested for the Endocrinological Phenotype: 
 
 
 
 
 
 
ISCN +550 karyoptye: 
 
 
 
Subtelomeric FISH: 
 
 
 
Other tests: 
 
 
 
 
Patient DNA Sample No.: 
 
Source of DNA (fresh blood, cell culture, etc.): 
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Title of Project: GENETIC ANALYSIS OF CHILDREN WITH 
FOREBRAIN, EYE AND/OR PITUITARY DEFECTS 
 
Investigator: Professor M.T. DATTANI 
 
We would like to invite your child to take part in our research study. Before you decide 
we would like you to understand why the research is being done and what it would 
involve for you and your child. One of our team will go through the information sheet 
with you and answer any questions you have. We would suggest that this should take 
about 10 minutes Talk to others about the study if you wish. Ask us if there is anything 
that is not clear. Take time to decide whether or not you wish to take part. Thank you 
for reading this. 
 
Introduction 
The pituitary gland in the brain makes a number of chemicals called hormones that help 
children grow and develop normally. In some children who do not grow well, the 
pituitary gland may not make growth hormone (GH) and/or other hormones. The gland 
may be very small or even absent. These children would need to be treated with the 
hormones that are missing. Occasionally, the small pituitary gland may be associated 
with abnormalities affecting the eyes and the brain; this is called septo-optic dysplasia 
or SOD. 
 
We now know that the way your child’s body changes and grows depends on the 
genetic material (called DNA, which is made up of thousands of genes) that your child 
has inherited from their parents. Changes within genes are the reason why we are all 
very different to each other. Normally, your child has two copies of a gene, one that 
comes to them from their father and one that comes to them from their mother. 
Sometimes a change within a gene that your child gets from his/her parents can lead to a 
medical condition. So far, we only know some of the genes that are important for 
normal pituitary development. 
 
The aim of the study 
In this study, we aim to study the genes controlling the development of the brain and 
pituitary gland. We have recently found that changes in a number of genes are 
associated with a small pituitary gland and a lack of growth hormone (GH) in some of 
our patients. We now want to look at children with these conditions in more detail and 
to examine their DNA for abnormalities in these and other genes that are important for 
the normal development of the brain. We hope that this will help us to understand why 
children suffer from these particular conditions. 
 
 
Why is the study being done? 
This study will help us to understand why children develop abnormalities of the 
forebrain, eyes and pituitary gland. Additionally, we will gain further insights into the 
complex development of these structures. Knowledge of the exact genetic mechanism 
for the underlying disease will enable us to make an earlier diagnosis in further affected 
children from the same family, and also to offer ante-natal diagnosis in certain cases. 
This will reduce the complications that could potentially arise in children with these 
disorders. Finally, understanding these conditions will enable us to find the best ways of 
making the diagnosis ie using the best tests available so that the diagnosis can be made 
with minimal discomfort to the patient. 
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How is the study being done? 
We need to take a small blood sample (2 teaspoonfuls) from your child. To minimise 
discomfort, we will perform the blood test using local anaesthetic cream prior to 
collection of blood. Genetic material (DNA) will then be extracted from the blood, and 
full genetic analysis will be performed on these samples. The blood test will be 
performed by a member of the Paediatric Endocrinology team at Great Ormond Street 
Children’s Hospital during one of your child’s visits to the hospital. Only a single 
sample of blood is required for the study. Where possible, the blood sample will be 
taken at the same time as other tests of pituitary gland function which may need to be 
performed on your child from time to time in the out-patient clinic. If a change 
(mutation) is found within one of the genes that are important for pituitary development, 
then further blood samples may be required from your child and the rest of your family. 
However, the requirement for these samples will be discussed in detail with you and 
your family. 
 
What will happen to the blood sample after it is taken? 
The blood sample will be processed by members of Professor Dattani’s team and stored 
without your child’s name or details on it. Only Professor Dattani and the doctors who 
are directly involved in your child’s medical care will be able to identify the sample by 
using a password protected database. This study is ongoing and the sample will not 
therefore be destroyed unless you ask for it to be destroyed. Ethical approval for this 
study to be ongoing will be asked for at regular intervals. The blood sample will remain 
in the Institute of Child Health (attached to Great Ormond Street Hospital); it will not be 
sent anywhere else. 
 
What are the risks and discomfort? 
No risk to your child can be foreseen. There is discomfort from a single needle prick for 
blood sampling, but this will be minimised by using local anaesthetic cream. 
 
What are the potential benefits? 
This study may help us to understand why your child has developed their problems. 
Additionally, we may be able to make the diagnosis earlier in future children who may 
have the condition, and where one child in the family already has the disorder, we may 
be able to make a diagnosis before birth in future pregnancies. An improved 
understanding of these conditions will help us to find the best ways of making the 
diagnosis i.e. using the best tests available so that the diagnosis can be made with 
minimal discomfort to the child. Some of these genes are associated with a changing 
(evolving) picture, with more hormonal abnormalities appearing with time. If that is the 
case, then we will be in a better position to anticipate these abnormalities once we have 
the genetic information and hence we will be able to diagnose the problem more 
rapidly.  
 
Who will have access to the case/research records? 
Only the researchers and a representative of the Research Ethics Committee will have 
access to the data collected during the study. We will tell people what we have learned 
in the study in reports and publications, but nobody will learn anything personal about 
your child, or any other child, by reading these reports or publications. The use of some 
types of personal information is safeguarded by the Data Protection Act 1998 (DPA). 
The DPA places an obligation on those who record or use personal information, but also 
gives rights to people about whom information is held. If you have any questions about 
data protection, contact the Data Protection officer via the switchboard on 020 7405 
9200 extension 5217. We will also inform your general practitioner that you will be 
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taking part in this study. 
 
What are the arrangements for compensation? 
The project has been approved by an independent research ethics committee (Chelsea 
and Westminster) who believe that it is of minimal risk to you. However, research can 
carry unforeseen risks and we want you to be informed of your rights in the unlikely 
event that any harm should occur as a result of taking part in this study. 
 
This research is covered by a compensation scheme which may apply in the event of 
any significant harm resulting to your child from involvement in the study. Under this 
scheme, it would not be necessary for you to prove fault. You also have the right to 
claim damages in a court of law. This would require you to prove fault on the part of the 
Hospital/Institute and/or any manufacturer involved. 
 
Does my child have to take part in this study? 
No. If you decide, now or at a later stage, that your child does not wish to participate in 
this research project, that is entirely your right, and will not in any way prejudice any 
present or future treatment. 
 
Who is organizing and funding the study? 
The study is being funded by the Wellcome Trust and a number of other charities. 
 
Who do I speak to if problems arise? 
Please contact Professor Dattani directly with any problems relating to the study. 
If you have any complaints about the way in which this research project has been, or is 
being conducted, please, in the first instance, discuss them with the researcher. If the 
problems are not resolved, or you wish to comment in any other way, please contact the 
Chairman of the Research Ethics Committee, by post via the Research and 
Development Office, Institute of Child Health, 30 Guilford Street, London WC1N 1EH, 
or if urgent, by telephone on 0207 905.2620, and the Committee administration will put 
you in contact with him. 
 
Researcher who will have contact with the family 
Professor Mehul Dattani, Professor of Paediatric Endocrinology 
 
 
Address of Researcher 
Developmental Endocrinology Research Group, Clinical and Molecular Genetics Unit, 
UCL Institute of Child Health, 30 Guilford Street, London, WC1N 1EH. 
Telephone: 020 7905 2657 
Message Pager via GOSH switchboard. 
